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Abstract 
In this thesis, the role of platelets as potential drivers of both thrombotic and bleeding 
risk in patients with atherosclerosis and the influence of platelets on the immune 
system were investigated. The prevalence of high and low residual platelet reactivity 
phenotypes and the association of these phenotypes with thrombotic and bleeding 
risk in acute coronary syndrome (ACS) patients and patients with atherosclerotic 
vascular disease were examined. In ACS patients, the clinical factors that influence the 
residual platelet phenotype including the presence of genetic polymorphisms were 
tested. In addition to residual platelet reactivity, the utility of other cardiac biomarkers 
to predict perioperative and 1-year risk in vascular patients was also examined. To 
investigate the influence of platelets on the immune system, platelet-lymphocyte 
interactions in vascular patients and healthy volunteers were analysed.  
 
In ACS patients treated with aspirin and clopidogrel, the prevalence of high on 
treatment residual platelet reactivity (as identified with the Multiplate assay), was 
common in a New Zealand population and high residual platelet reactivity levels could 
be significantly reduced with prasugrel treatment. This phenotype was predicted by 
the presence of diabetes, high platelet count and a low clopidogrel dose. It was also 
demonstrated that although the prevalence of loss of function and gain of function 
CYP2C19 alleles were high in our population, genotype had little influence on residual 
platelet reactivity levels in ACS patients. Furthermore, both phenotype and diabetes 
were significantly and independently associated with major adverse cardiovascular 
events (MACE) at 1 year. Genotype was not found to be a significant driver of risk. The 
incidence of major bleeding in this cohort was low and not predicted by platelet 
reactivity phenotype or genotype. 
 
In stable vascular patients the study found the level of residual platelet reactivity on 
aspirin therapy was not significantly associated with MACE or bleeding following 
major elective surgery. However, baseline high sensitivity troponin T was the most 
predictive biomarker and an elevated preoperative level was significantly associated 
with an increased risk of MACE in both the short and long term. Bleeding was frequent 
 iv 
and occurred early following surgery in the majority of patients and open abdominal 
aortic aneurysm repair surgery was the only predictor of bleeding.  
 
Investigating the interactions between platelets and lymphocytes in atherosclerosis, 
the study found higher levels of platelet-T cell conjugates in patients with vascular 
disease compared to healthy controls. There was also interesting changes in the CD4 
T cell activation phenotype with a switch from a predominant memory phenotype in 
healthy controls to an effector activation phenotype in vascular patients. A follow on 
study investigated the impact of platelets on CD4 T cells in more depth and found that 
platelets had a potent stimulatory effect on CD4 T cell differentiation and cytokine 
production ex vivo in healthy volunteers. Furthermore, the CD4 T cell stimulation 
provided by platelets was eliminated with in vivo prasugrel treatment. The influence 
of platelets on the immune system demonstrated in these two studies suggests that 
antiplatelet therapy may modulate not only thrombosis but also inflammation.   
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1.1 Introduction Overview 
Cardiovascular disease is both the current and projected number one cause of 
mortality and morbidity in the developed world. The impact of this disease is even 
greater in New Zealand (NZ) with 6000 patients dying from an Acute Coronary 
Syndrome (ACS) or "heart attack' every year and a disproportionate number of 
patients represented by Maori or Pacific Island ethnicities. Atherosclerosis is the 
principle underlying pathophysiology for the majority of cardiovascular disease and 
the platelet plays a central role in the progression and destabilisation of 
atherosclerosis. This is highlighted by the frontline treatment of ACS with antiplatelet 
agents such as aspirin and clopidogrel. The use of these treatments has been shown 
to be highly effective in reducing rates of death, recurrent myocardial infarction (MI), 
ischaemic stroke and stent thrombosis following an ACS. However, it is now 
recognised that the response to aspirin and clopidogrel is highly variable with patients 
lying somewhere on a spectrum of on treatment platelet reactivity. High on treatment 
platelet reactivity (HOTPR) results in an inadequate inhibition of platelets, which has 
been associated with an increased risk of ischaemic events. Low on treatment platelet 
reactivity (LOWPR) at the other end of the spectrum, leads to a significant decrease in 
clotting ability which has been linked to an increased risk of major bleeding. This 
variability suggests the presence of a therapeutic window when treating patients with 
aspirin and clopidogrel where both ischaemic and bleeding risk is reduced. Identifying 
where a patient sits on this platelet reactivity spectrum has been made possible by 
platelet function assays that test a patients’ response to agonist stimulation. More 
potent new antiplatelet agents have the potential to decrease on treatment platelet 
reactivity and in the right patient population group guided by platelet function testing, 
reduce ischemic events.  
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1.2 Atherosclerosis 
1.2.1 Pathophysiology  
Atherosclerosis is an inflammatory disease and the main cause of coronary artery and 
vascular disease. Atherosclerotic lesions develop in the intima of arteries with an 
asymmetrical pattern of thickening and are characterised by the presence of lipids, 
immune cells, connective tissue elements, endothelial and smooth muscle cells (1). 
The progression of simple lesions or fatty streaks to complex vulnerable plaques is 
shown in Figure 1-1.  
 
Fatty streaks are comprised largely of lipid-laden macrophages and T cells 
accumulating beneath the endothelium (2) and preferentially distribute at areas in the 
vasculature where blood flow is low and oscillatory or “turbulent”(3). This turbulent 
flow limits the exposure of endothelial cells to nitric oxide in the blood, which leads to 
an increase in endothelial permeability, leukocyte adhesion and endothelial cell death 
supporting initiation and progression of atherosclerotic lesions (4). Oxidization of low-
density lipids (LDL) in the intima leads to the release of phospholipids that can also 
activate endothelial cells and cause dysfunction (5). Therefore both hemodynamic 
strain and lipid oxidisation contribute to initiating inflammation in the artery. Platelets 
are one of the first cells to arrive at the site of endothelial activation and have been 
shown to participate in recruitment and aiding infiltration of leukocytes at the site of 
injury (6). The prevalence of these fatty streaks is high in the general population and 
can be found in young patients. They are subclinical and never cause symptoms but 
can progress on to complex lesions or eventually disappear (7).  
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Figure 1-1 Progression of atherosclerotic plaques 
The schematic depicts the sequences involved in the progression of atherosclerosis. These 
include the main histology findings associated with progression of lesions, the onset of each 
stage according to a patients age, the main growth mechanism involved at each stage and the 
clinical manifestation of each stage. With progression of atherosclersosis there is also an 
increase in endothelial dysfunction and complexity of the lesion. Image reproduced with 
permission from Creative Commons Attribution-Share Alike 3.0 Unported.  
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As lesions develop, a core of foam cells and extracellular lipid droplets expands with a 
smooth muscle cell and collagen-rich matrix forming the surrounding cap. This process 
involves a mass infiltration of immune cells into the plaque including monocytes, T 
cells and dendritic cells creating a rich pro-inflammatory milieu of cytokines and 
growth factors (8, 9). These cells preferentially deposit at the shoulder of plaques with 
a necrotic core of debris, lipids and dead cells (8).  As these lesions develop and expand 
in size, the artery enlarges to compensate for the extra thickness of the atheroma and 
maintain flow in the lumen of the artery. However, if this enlargement of the artery 
progresses beyond the thickness of the atheroma, then an aneurysm is created (10). 
Stenosis is a relatively late event in the atherosclerotic process and is often a result of 
repeated plaque rupture and fibrous remodelling.  
1.2.2 Immune system 
The immune system is involved in both the initiation and progression of 
atherosclerotic plaques. Not only are immune cells present in large numbers at the 
early stages, their effector cells can accelerate or modulate progression and 
exacerbation of the local inflammatory environment can elicit an ACS or stroke. One 
of the critical elements for the development of atherosclerosis is the production of 
macrophage colony stimulating factor (M-CSF) in the inflamed intima that induces the 
differentiation of monocytes to macrophages as they enter the plaque (11). 
Differentiation induces the up-regulation of scavenger receptors and toll-like 
receptors on macrophages, which allows recognition and internalisation of oxidized 
LDL (12, 13). The scavenger receptors function to destroy internalised LDL but if 
accumulation is too great, macrophages can be transformed into the prototypical 
foam cell. In contrast, toll-like receptor internalisation of oxidised LDL can initiate 
signal cascades leading to cell activation (13). This activation of macrophages induces 
the release of pro-inflammatory cytokines, proteases and reactive oxygen species (7). 
These two processes promote cell death, further infiltration of immune cells and 
weakening of the surrounding collagenous structure.    
Large populations of CD4+ T cells take residence in atherosclerotic plaques. Their 
infiltration is in response to the presentation of oxidised LDL and heat shock protein 
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60 antigens by trafficking macrophages and dendritic cells in the blood (14-16).  The 
interaction between T cell and antigen causes an activation cascade in the T cell 
resulting in the expression of a set of cytokines, cell-surface molecules and enzymes. 
The type 1 helper (Th1) response is the predominant phenotype of CD4 T cells in the 
plaque resulting from the Th1 promoting cytokines (rather than a Th2) present during 
activation in plaques (17, 18). Th1 effector cells produce the macrophage activating 
cytokine interferon-γ (IFN-γ) that in turn improves the macrophages’ antigen 
presenting ability and augments synthesis of pro-inflammatory cytokines interleukin-
1 (IL-1) and tumour necrosis factor (TNF) (19).  The synergetic action of these cytokines 
instigates the production of many inflammatory and cytotoxic molecules in 
macrophages and vascular cells promoting atherosclerosis (16). 
 
The Th2 phenotype, classically an allergy response cell, has shown to be largely anti-
inflammatory but may also be pro-inflammatory in atherosclerosis. The Th17 
phenotype, characterised by the secretion of IL-17, has more recently been recognized 
to be present and play a role in atherosclerotic plaques. Similarly to Th2 CD4 T cells, 
the impact of Th17 cell response in atherogensis is controversial (20-22). T regulatory 
(Treg) cells produce the anti-inflammatory IL-10 and TGFβ and are found in low 
numbers in atherosclerotic plaques (23). Treg cell numbers and IL-10 levels are 
severely decreased in patients experiencing an ACS (24) and in mouse models, the 
deficiency of these cells is linked to increased atherogenesis and lesion inflammation 
(25). Furthermore, increased Treg presence and stimulation of this phenotype has 
shown to reduce lesion formation and attenuate atherosclerosis (26-28).  Natural 
Killer T cells and CD8+ T cells are also present in atherosclerotic plaques but tend to 
be found in early plaque development and in much smaller numbers (16, 29). Both cell 
types are pro-atherogenic in their activity (30). All major T cell lineages are present 
during atherogenesis and destabilisation of the balance between pro and anti-
inflammatory phenotypes drive the development of vulnerable plaques. 
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1.2.3 Acute Coronary Syndromes 
Despite the chronic nature of atherosclerosis, thrombotic complications or Acute 
Coronary Syndromes (ACS) occur suddenly and often without warning. The traditional 
view of infarction is the progressive luminal narrowing of a coronary artery from 
continued growth of smooth muscle cells in the plaque which a small platelet 
thrombus could occlude the vessel completely. However, angiographic studies have 
identified culprit lesions that do not cause marked stenosis (31), and often an ACS 
occurs without the preceding symptoms of angina which would be indicative of a high 
grade stenosis. 
 
Computed tomographic (CT) angiography, which showcases the arterial wall as well 
as the lumen, has revealed plaque characteristics associated with ACS events which 
include: low attenuation (i.e. little or no calcification) and an outward expansion of 
the artery wall which allows for very little encroachment on the lumen (32, 33). This 
expansion also accommodates the growth of the plaque for much of its development 
(34).  
 
Instead of progressive narrowing of the lumen, it is the activation of vulnerable 
plaques that precipitates ischaemia and infarction. Some studies have noted the role 
of coronary spasm causing restricted blood flow to the myocardium, but in most cases 
the formation of an occluding thrombus on the surface of the plaque is the driver of 
infarction (35). Thrombosis can occur due to plaque rupture, which is detectable in 60 
to 70% of cases, or less frequently due to endothelial erosion (36). Plaques vulnerable 
to rupturing, which most commonly cause a fatal ACS, often have a thin fibrous caps 
(37). This cap allows for a barrier between the immune and thrombogenic rich 
material of the necrotic core and the coagulation factors found in the blood. Thinning 
of this fibrous cap and degradation of collagen, which provides tensile strength, is 
caused by an excess of proteinases that break down collagen and an inhibition of 
smooth muscle cells to replenish it (38). These enzymes belong to the matrix-
metalloproteinase (MMP) family and macrophages have been found to over produce 
all three of the human MMP collagenases (MMP-1, 8 and 13) in atherosclerotic 
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plaques (39, 40). When the fibrous cap ruptures or is disrupted, blood is allowed to 
come in to contact with the thrombogenic core. Tissue factor, a potent pro-coagulant 
produced by macrophages, comes in to contact with the blood triggering thrombin 
generation and platelet activation and aggregation (40). 
 
Superficial erosion of coronary plaques causes approximately 20 – 25% of deaths from 
an ACS (40). These lesions usually lack prominent inflammatory infiltrates and exhibit 
a much richer proteoglycan accumulation compared to rupture prone plaques. The 
mechanisms of superficial erosion have received much less attention than those 
involved in the rupture of the fibrous cap. Apoptosis of endothelial cells could 
contribute to desquamation and production of tissue factor (41). Oxidative stress, in 
particular the production of myeloperoxidase by activated leukocytes, can initiate 
endothelial cells to undergo programmed cell death. Endothelial cell loss and tissue 
factor production could propagate local thrombosis found in the coronary arteries 
(42).    
 
Although it is noted in autopsy studies that frank rupture of plaques causes the 
majority of deaths (43), and superficial erosion making up the rest, there is growing 
evidence that not all plaque ruptures and thrombus formation cause coronary events 
(44). Rather, plaque rupture and thrombus formation occurs frequently at a subclinical 
level and is instrumental in plague progression, remodelling and later luminal 
narrowing (34, 45). Therefore, it is not only the act of plaque exposure to the blood, 
but also the combination of other factors and conditions with rupture or erosion that 
lead to the perfect storm resulting in an ACS (34).  Tabled below is a list of factors and 
conditions associated with increased risk of ACS (Table 1-1).   
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Table 1-1 Factors and conditions associated with increased risk for an Acute Coronary Syndrome  
Coronary Plaque 
characteristics  
Coronary Blood 
Flow Dynamics 
Intrinsic Hemostasis 
Factors 
Metabolic and 
Inflammatory Conditions 
Neurohormonal 
imbalance 
Environmental 
Factors and Drugs 
Plaque Burden 
Lumen Encroachment 
Lesion location 
Plaque composition 
Endothelial 
remodelling 
Blood viscosity 
Shear Stress 
Reduced blood 
flow/low cardiac 
output 
Vascular tone and 
reactivity 
Arterial 
Hypertension 
 
Platelet function/volume 
Circadian variation 
Factor V Leiden deficiency 
Von Willebrand factor 
deficiency 
Antiphospholipid syndrome 
 
Diabetes 
Obesity 
Dyslipidemia 
Connective tissue 
diseases 
Infections 
Renal disease 
Stress 
Catecholamine 
surges 
Depression 
Exertion 
Autonomic 
dysfunction 
Endocrine 
imbalance 
Smoking 
Pollution 
Climate 
Legal drugs 
Illegal drugs 
Diet 
Sedentary lifestyle 
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1.2.4 Treatment 
The management and treatment of ACS is dictated by where the patient falls on the 
ACS spectrum (Figure 1-2) and is intended to reduce myocardial necrosis and thus 
preserve left ventricular function and prevent major adverse cardiac events such as: 
ventricular fibrillation, decompensated heart failure and cardiogenic shock (46).  
 
 
Figure 1-2 Spectrum of Acute Coronary Syndromes (ACS) 
Adapted from C. Karras et al. Acute Coronary Syndromes. Disease-a-month (2013) 202-209 
with permission from Elsevier. 
Reperfusion of the ischaemic myocardium is the primary objective in the acute setting 
and restoring coronary flow to the muscle is time critical. Percutaneous coronary 
intervention (PCI) with balloons or stents are the treatment of choice and are able to 
achieve restored coronary artery flow in >90% of patients in optimal circumstances. 
Fibrinolytics are indicated in STEMI patients where a skilled facility and provider for 
primary PCI is not accessible within 90 minutes. Other adjunct therapies to manage 
the acute phase and chronic disease include: oxygen, nitroglycerin, analgesia, 
antiplatelet agents, hypertensive medications, anticoagulation and statin therapy.     
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1.2.5 Peripheral Vascular Disease 
Atherosclerosis as a systemic disease not only affects the coronary arteries but also 
the aorta, cerebral and lower arterial extremities. The manifestation of peripheral 
atherosclerotic disease has long been underestimated and under diagnosed, with 
large epidemiology studies showing a high prevalence of peripheral vascular disease 
(PVD) in the elderly, diabetics and patients with existing cardiovascular risk factors 
(47). Importantly, those with PVD have an increased risk of premature mortality and 
cardiovascular and cerebrovascular events (48-50).  Studies using stress testing or 
coronary angiography found 60 – 90% of patients with PVD also had coronary disease 
and was an independent risk factor for cardiovascular death (50).  
1.2.6 Carotid Artery Disease 
Carotid artery disease is the formation and progression of atherosclerotic plaques in 
the carotid artery usually at the branching of the artery into its internal and external 
counterparts. The risk of cerebrovascular stroke is increased as the carotid artery 
becomes more stenosed with plaque but also as the morphology of the plaque 
becomes more unstable leading to a higher risk of embolism (51). Embolism from the 
carotid bifurcation is the most frequent pathogenetic mechanism of cerebral 
ischaemia (52). This ischaemia can be temporary causing Transient Ischaemic Attacks 
(TIA) or blood flow can be blocked permanently causing a cerebrovascular stroke and 
tissue death. TIAs can act as a warning sign as a plaque is becoming unstable and the 
risk of stroke is greatly increased in the short term (53). Cerebral ischaemia can cause 
paralysis, loss of vision, slurring of speech, numbness and loss of power on the 
contralateral side to the infarct.  
 
Intervention with carotid endarterectomy surgery or carotid stenting in severe carotid 
stenosis (>75%) is recommended to reduce secondary stroke risk particularly if the 
patient is symptomatic (54). Primary stroke prevention with surgery or stenting in 
asymptomatic patients with a severe stenosis is not as heavily recommended (55). 
Furthermore, as a significant proportion of cerebrovascular events occur in patients 
with carotid stenosis <75% and as the embolic process is a significant driver of stroke, 
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therapies to reduce plaque progression and destabilistation such as antiplatelet, 
statins and anti-hypertensive drugs are also crucial (55).  
1.2.7 Lower Extremity Peripheral Vascular Disease 
 Lower extremity peripheral vascular disease (PVD) is the atherosclerotic plaque 
obstruction of the arteries in the legs and pelvis. At the time patients are diagnosed 
with lower extremity PVD, >50% present with asymptomatic disease or complain of 
atypical leg pain. A smaller percentage of patients who have lower extremity PVD also 
have intermittent claudication distinguished by cramping pain, discomfort, or a 
sensation of weakness in the legs that occurs with exertion and is relieved by rest. 
These symptoms are primarily attributed to the flow limiting stenosis or occlusion in 
the artery limiting oxygen supply to the muscle during exercise. Limb ischaemia also 
evokes an acute systemic and local response characterised by increased oxidative 
stress, inflammation and endothelial dysfunction (56-58). 
 
Although claudication symptoms remain stable in 70% to 80% of patients, 
approximately 10% to 20% worsen and 1% to 2% of patients will progress to critical 
limb ischemia (CLI) over a 10-year period (59). Some patients undergoing amputations 
for CLI did not experience claudication pain 6 months previously, which indicates that 
not all PVD advances through the traditional classification schemes (60). In addition 
to functional impairment, as mentioned previously, PVD is a strong marker for 
coronary artery disease and increased risk of cardiovascular death. Interestingly, 
although the risk of death is higher in patients with PVD compared to those without, 
the risk is equal in patients who are symptomatic or asymptomatic (61).   
 
Treatment of lower extremity PVD is intended to improve debilitating claudication 
symptoms and reduce cardiovascular morbidity and mortality. Along with 
revascularising the atherosclerotic arteries with surgery or percutaneous intervention 
where indicated, addressing risk factors such as smoking cessation, and proper 
diabetes and blood pressure management is also imperative for reducing symptom 
burden and cardiovascular risk. Studies have found the use of statins in lower 
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extremity PVD can increase walking distance and slow progression of disease (62). 
Furthermore, the use of antiplatelet drugs in PVD with and without known coronary 
artery disease reduces the risk of stroke, MI and cardiovascular death (63, 64). Clear 
indications for revascularisation include ischemic rest pain, ischemic ulceration, 
gangrene, or symptomatic disabling claudication.  
1.2.8 Abdominal Aortic Aneurysm 
Patients with an abdominal aortic aneurysm (AAA) remain asymptomatic in most 
cases until rupture, which leads to death in 65% of patients (65). This highly fatal 
outcome is caused from the dilatation of the aortic wall and a weakening of the 
connective tissue to a point of rupture. As atherosclerotic lesions and thrombus are 
always present at the site of abdominal aneurysms, traditionally these aneurysms 
have been regarded as the same pathological consequence as coronary artery disease. 
However, this conventional view has been challenged by more recent studies showing 
a divergence from the athero-occlusive process with a more significant role of 
proteases pushing atherosclerotic plaques down an aneurysm path (66, 67). In 
particular the decreased expression of protease inhibitors such as, TIMP-2 and PAI-1, 
and increased production of MMPs, allow the imbalanced degradation of elastin and 
collagen in the aneurysm, which cross link with other connective molecules to provide 
strength and stability (68). The formation of a AAA is associated with a mural 
thrombus, which undergoes continual remodelling due to the constant blood flow in 
the aneurysm, unlike the turbulent flow in athero-occlusive disease (69). This mural 
thrombus has been implicated in reducing aneurysmal wall stress, but it’s increasing 
thickness rich in platelets and thrombin can also lead to a local hypoxic environment 
in the aneurysm, exacerbating inflammation, apoptosis of smooth muscle cells and 
promoting remodelling of the arterial wall (70, 71).  
 
The treatment of AAA with open surgery or endovascular stenting is based on the risk 
of rupture and is essentially prophylactic in nature, with the most benefit and risk 
reduction resulting from operating on aneurysms >5cm in diameter (69). As well as 
surgery, the proper management of cardiovascular risk factors is suggested, in 
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particular smoking. There is a strong association between tobacco smoking and 
aneurysm development, with the prevalence of AAAs four times greater in smokers 
compared to non-smokers (72, 73). When relative risks were assessed in chronic 
smokers, the risk of developing a AAA is three-fold greater than developing coronary 
artery disease and five-fold higher than cerebrovascular disease (74). Therefore, 
smoking cessation is even more imperative in patients with AAA.    
1.3 Platelets 
1.3.1 Function in Hemostasis 
Platelets are anuceleated cells in the blood, produced by megakaryocytes in the bone 
marrow and have been acknowledged for over 150 years for their important role in 
hemostasis and thrombosis (75). Platelets circulate at high shear rates and the primary 
physiological role is to sense damage to the endothelial wall and plug any circulatory 
leak. Platelets are activated by exposed collagen binding to the glycoprotein VI (GPVI) 
on the platelet at the site of injury, allowing the platelet to adhere to the substratum. 
Firm adhesion promotes the release of intracellular stores from granules, including 
adenosine diphosphate (ADP) and thromboxane A2 (TXA2), which triggers the 
recruitment and activation of more platelets. During activation platelets undergo 
dramatic shape change which is calcium dependent and form into spiny spheres with 
finger like projections using their extensive actin cytoskeleton (76). In addition to 
shape change and granule release, activation leads to the important conformational 
change of the integrin glycoprotein IIb/IIIa (GPIIb/IIIa) increasing its affinity for 
fibrinogen, von Willebrand factor (VWF) and fibronectin to promote firm platelet-
platelet adhesions (77).  Activated platelets produce thrombin, which triggers the 
coagulation cascade resulting in the formation of a fibrin mesh encapsulating cross-
linked platelets, red blood cells and leukocytes that effectively plugs the hemostatic 
leak.  
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1.3.2 Platelets in Atherosclerosis 
In addition to hemostasis, platelets also contribute to pathological processes such as 
host defence from microbial infection, sepsis, autoimmune diseases, tumour growth 
and metastases and atherosclerotic plaque progression, rupture and thrombosis (75).  
1.3.3 Plaque initiation and development 
Platelets are not only activated by collagen, but by an array of extra cellular matrix 
proteins and soluble factors in the blood such as ox-LDL, thrombin, ADP, serotonin and 
shear stress (78). Endothelial dysfunction and injury exposing pro-coagulant proteins 
to the circulation, as well as pro-inflammatory states such as diabetes; results in the 
increase of activated circulating platelets. Upon activation, platelets up-regulate 
several ligands that allow the cell to interact with the endothelium and leukocytes, 
promoting the initial inflammatory infiltration in atherosclerosis and progression of 
plaques. The platelet glycoproteins GPIbα, GPIIb/IIIa and GPVI have important roles in 
platelet-endothelial interactions (79-81) and GPIbα and GPVI have shown to mediate 
platelet-leukocyte interactions (82, 83). Platelets are able to tether to atherosclerotic 
endothelium and bind to leukocytes under high vascular shear to aid in leukocyte 
infiltration (84). Inhibition or knock out of these ligands in animal models has resulted 
in the reduction of plaque progression (83, 85) and interestingly, GPVI has been 
proposed as a novel diagnostic marker for ACS in clinical studies (86).  
 
P-selectin is one of the primary ligands for platelets’ involvement in atherosclerosis, 
highlighted from P-selectin-deficient animal studies showing protection from the 
disease (87). It is expressed on platelets and is also stored and released in a soluble 
form from α-granules. Platelets bind to the endothelium through P-selectin, but also 
to leukocytes via P-selectin glycoprotein ligand 1 (PSGL-1). Through this 
communication, multicellular aggregates can form which promotes the release of 
chemokines CCL2, CCL5 and cytokines like interleukin (IL)-1β to further activate and 
recruit leukocytes and promote atherosclerosis (88, 89). Platelet-Leukocyte 
aggregates are able to tether and roll on endothelial cells with a higher avidity than 
unconjugated leukocytes, enhancing endothelial activation and leukocyte 
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transmigration (90). Soluble (s)P-Selectin has shown to be a good biomarker of 
platelet and/or endothelial cell activation and high levels indicate an elevated risk for 
future cardiovascular events independent of traditional risk factors (91). Beyond a 
biomarker function, sP-Selectin is also considered an active player in inflammation 
during atherosclerosis, potentially through binding to PSGL-1 on leukocytes and 
promoting pro-coagulant microparticle generation via the Mac-1 pathway (92). 
 
CD40 ligand (CD40L), a member of the TNF-family, is one of the best characterised co-
stimulatory molecules that enhances immune responses and inflammation through 
binding to CD40 and inducing cell activation and differentiation (93, 94). Platelets 
express CD40L on activation and can also shed the ligand, contributing to the soluble 
CD40L in the circulation. The presence of platelet bound and soluble CD40L enable 
binding of CD40 on the endothelium and different leukocyte subsets. Atherosclerotic 
lesions are abundant in CD40L expressing cells and platelet expressed CD40L 
represents the majority of circulating CD40L (95). Studies investigating the inhibiton 
of the CD40-CD40L stimulation found a reduction in atherosclerotic plaque size and 
an increase in stable fibrous lesions (95). Through CD40L, platelets can bind to 
lymphocytes, particularly T cells and promote pro-inflammatory effector cell 
generation and reduce Treg populations (96, 97). Soluble CD40L has been 
demonstrated to be a potential biomarker for atherosclerotic instability, with higher 
levels found in patients experiencing acute atherosclerotic infarctions and patients 
with atherosclerotic disease compared to healthy controls (98). Additionally, platelets 
express scavenger, chemokine and toll-like receptors that also have key roles in 
atherosclerosis development and have been reviewed by several groups (98-100) 
 
Platelets also release a multitude of chemokines, cytokines and other immune 
modulatory proteins that drive atherosclerosis. The chemokines Platelet Factor 4 (PF4 
or CXCL4), RANTES (CCL5), CDCL7 and stromal-cell derived factor-1 (SDF-1 or CXCL12) 
are stored in α-granules and released on activation.  In particular RANTES and PF4 
have been studied extensively and are both pro-atherogenic and act to selectively 
recruit monocytes, neutrophils and T cells to injured endothelium (101-104). The 
cytokine IL-1β is recognized as a main driver of platelet-induced endothelial cell 
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activation (105). Release of this cytokine causes endothelial secretion of IL-6, IL-8, 
CCL2 and expression of adhesion molecules ICAM-1 and αvβ3 (106, 107). 
Transforming growth factor β (TGF-β) is a potent modulator of the immune system 
and promotes anti-inflammatory and wound healing responses. Interestingly, 
platelets are the largest containers of TGF-β in the body and release it in abundance 
on activation/degranulation (75). The role of platelet released TGF-β remains unclear, 
with potential roles in promoting Treg development to counter pro-inflammatory 
responses in the plaque but also proatherogenic functions in promoting calcification 
and apoptosis (108). Platelet derived TGF-β may also provide key signals during 
thrombosis to induce matrix production (109).      
 
There are multiple other expressed receptors and secreted mediators that platelets 
produce to influence plaque initiation and development as reviewed by Lievens and 
von Hundelshausen (78). Overall the platelet has a big impact on determining the 
inflammatory milieu of the plaque and the progression from stable to unstable 
potentially resulting in a thrombotic event as summarised in Figure 1-3. 
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Figure 1-3 Role of platelets in the vascular inflammatory response associated 
with atherosclerosis 
Platelets interact with immune cells via both cell to cell contact and platelet derived soluble 
mediators. These interactions can lead to increased levels of chemotaxis and adhesion in 
immune cells as well as differentiation and infiltration. This heightened inflammation can lead 
to the phenotype of plaque to change from stable to and unstable phenotype. CCR1, 
Chemokine (CC motif) receptor 1; JAM-3, Junctional adhesion molecule 3; TXA2, Thromboxane 
A2; TP, Thromboxane A2 receptor; TLRs, Toll-like receptors; IL-1_, Interleukin-1 beta; SDF-1, 
Stroma-cell derived factor-1; GPIb_, glycoprotein Ib_; PSGL-1, P-Selectin Glycoprotein Ligand 
1; and Mac-1, Macrophage 1 antigen. Lievens D and Von Hudelshausen P. Platelets in 
atherosclerosis. Thrombosis Haemostasis 2011; 106: 827 – 838. Permission for reproduction 
sough from Elsevier.  
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1.3.4 Platelets in thrombosis 
The main role of platelets in the body is thought to be clot formation and therefore it 
is not surprising that in atherosclerosis, platelets drive the late events of thrombus 
formation during plaque rupture, microembolism, or spasm within the 
microcirculation. The mechanisms involved in hemostasis and thrombosis are similar 
with early key roles for exposed collagen coupled with VWF and GPIV to initiate 
adhesion of platelets to injured endothelium and exposed plaque (111).  
 
The propagation of thrombus is reliant on soluble agonists such as ADP, thromboxane 
and α-thrombin, as only the first layer of platelets are in direct contact with 
thrombogenic proteins. These soluble agonists induce a broad range of biochemical 
and functional platelet responses—including intracellular Ca2+ flux, platelet shape 
change, and the secretion of granule contents—coincident with the formation of 
platelet aggregates (112). However, recent studies have shown discoid shaped 
platelets adhering to growing thrombi in the early stages that do not undergo shape 
change, Ca2+ or α granule release, indicating that additional platelet aggregation 
mechanisms could be involved (112, 113). One of these is the biomechanical 
mechanism of activation via shear stress due to arterial blood flow promoting 
thrombus growth (114).   
 
After platelets activate and aggregate at the sites of vascular lesions, the thrombus 
undergoes stabilisation to maintain its location against opposing blood flow. Newly 
recruited platelets to a growing thrombus send feedback signals to platelets in the 
deeper layers of the thrombus to prevent disaggregation. This leads to strengthening 
of the interactions between adhesive ligands (VWF, fibrinogen, fibronectin) and 
receptors (GPIbα and GPIIb/IIIa). In particular, ADP signaling through the P2Y1 and 
P2Y12 receptors causing cyclic Ca2+ oscillations is vital to maintain GPIIb/IIIa activation, 
which provides the thrombus stability in flowing blood. Brass et al present an 
exhaustive review on this feedback system in thrombus stabilization (116).   
Thrombosis is also a potentially life threatening complication after the implantation 
of stents or grafts in atherosclerotic lesions. Stent thrombosis (ST) is a relatively 
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uncommon complication but it’s mortality and morbidity is high with 20-40% of cases 
causing death and 50-70% causing myocardial infarction and the need for 
revascularisation (116, 117). The occurrence of stent thrombosis is directly related to 
the acuity of the clinical syndrome before stenting. A patient presenting with an ACS 
has a several fold increase risk of stent thrombosis independent of stent type 
compared to a patient with stable coronary symptoms (118, 119). This risk is related 
to underlying inflammation and unstable plaque at the time of implantation leading 
to incomplete endothelialisation, less neointima formation allowing for continued 
exposure of circulating platelets to the injured vessel (120). Patients with critical limb 
ischaemia undergoing femoral bypass surgery and endovascular procedures are at 
high risks of graft occlusion and limb amputation (122). The risk of limb amputation 
and death, also increases significantly with every revascularisation procedure (123). 
 
1.4 Antiplatelet agents and Non-Response 
Platelets are the drivers of thrombotic events in atherosclerosis and are central to 
disease progression. Therefore, antiplatelet therapy is a cornerstone of the 
pharmacologic treatment strategy in patients with cardiovascular disease. As platelet 
activation and aggregation is controlled by complex and overlapping pathways, there 
are many targets for antiplatelet drugs to prevent ischaemic events as displayed in 
Figure 1-4. 
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Figure 1-4 Antiplatelet agent targets to prevent ischaemic events  
The process of PCI or plaque rupture leads to an increase in the release of TF, initiating the 
coagulation cascade and the release of collagen, activating platelets. Platelet activation is a 
complex process involving many receptors and signalling pathways highlighted in blue. Platelet 
activation leads to several secondary pathways including granule secretion and GPIIb/IIIa as 
highlighted in green. Therefore, antiplatelet drugs highlighted in black, target multiple pathways 
to inhibit platelet activation and aggregation to prevent ischaemic events. Gurbel PA and Tantry 
US, Monitoring of antiplatelet therapy, Platelet Third Edition, 2013; 603-633. Reproduced with 
permission from Elsevier. ACS, acute coronary syndromes; ADP, adenosine diphosphate; 
PAR-1, pro-tease activated receptor1; GPIIb/IIIa, glycoproteinIIb/IIIa; PCI, percutaneous 
coronary intervention; TF, tissue factor; TP, thromboxane receptor; TxA2, thromboxaneA2; 
vWF, von Willebrand factor. 
The use of dual antiplatelet therapy (DAPT) comprising of aspirin and a P2Y12 
inhibitor, commonly clopidogrel, is the most widely used combination for prevention 
of ischaemic events in ACS patients (123). A summary of the current European and 
American guidelines for antiplatelet therapies is shown in Table 1-2. The widespread 
use of these agents, coupled with more evidence-based interventions and therapies, 
has led to a significant reduction in adverse events following an ACS, including death, 
over the last decade (125). However, adverse events still occur in these patients who 
are on DAPT and recent studies have observed that there is a wide inter-individual 
variability in the response to therapy. A proposed therapeutic window exists where a 
patient with high on treatment platelet reactivity (HOTPR) is at risk of ischaemic 
events and a patient with low on treatment platelet reactivity (LOWPR) is at risk of 
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bleeding complications. The use of aspirin and clopidogrel in atherosclerosis as well as 
the prevalence of HOTPR and LOWPR and their contributing risk factors are 
summarized below. 
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Table 1-2 Guidelines for Antiplatelet therapy in patients with CAD 
 Preclinical 
CAD 
ESC (125) 
Stable 
CAD 
ESC (125) 
Elective PCI 
 
UA/NSTEMI STEMI 
ESC (123, 125) AHA/ACC (126) ESC (125) AHA/ACC (128) 
Aspirin II-A I-A I-A (125) I-A I-A I-A I-A 
Clopidogrel _ I-A I-A (125) I-B a I-B b, I-A c I-C I-C 
Prasugrel _ _ _ IIa-B, I-B d I-B I-B I-B 
Ticagrelor _ _ _ I-B _ f I-B _ f 
 
aOnly if prasugrel or ticagrelor are not an option. b Before PCI, cAt the time of PCI. dIn case of known coronary anatomy, intent to PCI and no pretreatment with 
P2Y12-inhibitiors, eAt the time of PCI, if not pretreated with thienopyridines, f Not approved at the time of guidelines compliation. 
ACC, American College of Cardiology; AHA, American Heart Association; CAD, coronary artery disease; ESC, European Society of Cardiology; NSTEMI non-
ST segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST elevation myocardial infarction 
Classes of Recommendation: 
Class I: Benefits >>> Risk: Procedure/ treatment SHOULD be performed/administered. 
Class IIa: Benefits >> Risk: Additional studies with focused objectives needed; it is REASONABLE to perform procedure/administer treatment. 
Levels of Evidence: 
Level A: Multiple populations evaluated; data derived from multiple randomized clinical trials or meta-analyses 
Level B: Limited populations evaluated; data derived from a single randomized trial or nonrandomized studies 
Level C: Very limited populations evaluated; only consensus opinion of experts, case studies, or standard of care 
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Clinical trials investigating the use of DAPT in patients with PVD is limited. The only 
available evidence comes from a substudy of the large DAPT trial CHARISMA, which 
evaluated the effect of aspirin plus clopidogrel versus aspirin alone in patients with 
established and at risk for cardiovascular disease (128). In a subgroup analysis of PVD 
patients, there was no observed benefit in the DAPT arm at reducing cardiovascular 
events compared to aspirin monotherapy (130). Further trials in larger PVD 
populations are needed to investigate whether DAPT therapy can reduce risk over 
standard aspirin therapy. 
1.4.1 Aspirin therapy 
Aspirin blocks thromboxane A2 (TXA2) mediated platelet aggregation through the 
acetylation of the COX-1 enzyme (Figure 1-5) and this process is irreversible as 
platelets are enucleate and are unable to resynthesize COX-1 (130). However, as 
aspirin is not a direct inhibitor of thromboxane, it has been demonstrated that even a 
10% residual thromboxane synthase activity is sufficient to cause aggregation (132). 
Furthermore, it is believed a 95% inhibition of thromboxane is needed to observe 
clinical efficacy from aspirin therapy (133).  COX-2, even at low levels is also able to 
induce platelet aggregation via thromboxane A2 and aspirin inhibits COX-2 but 166 
times less effective than COX-1. Additionally, endothelial cells and 
monocytes/macrophages can rapidly (2-4 hours) recover from the aspirin effect by 
resynthesizing the COX-2 enzyme and may contribute prostaglandin H2 to platelets 
that synthesize TXA2 by thromboxane synthase (transcellular TXA2 synthesis), as 
detailed in Figure 1-5.  As atherosclerotic plaques have an abundance of 
monocytets/macrophages, this local provider of COX-2 may be an important 
mechanism that platelets use to overcome the antithrombotic effect of aspirin 
therapy. Under normal conditions, COX-2 only comprises 10% of platelet COX activity. 
However, in environments such as post coronary artery bypass (CABG) surgery or 
diabetes, where there is high turnover and a higher proportion of young platelets, 
COX-2 activity can be as high as 60% and may contribute to thromboxane production 
despite COX-1 inhibition (133).    
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Figure 1-5 Aspirin effects via the inhibition of COX activity. 
Aspirin has inhibitory effects on both COX-1 and COX-2 activity. Aspirin prevents the access 
of arachidonic acid to the catalytic site of COX-1. In platelets (highlighted in pink) this leads to 
a reduction thromboxane A2 production, which promotes aggregation and this inhibition is 
irreversible. However, in endothelial cells and monocytes (highlighted in yellow), the aspirin 
effect can be overcome by resynthesising the COX-2 enzyme and may contribute PGH2 to 
platelets by Transcellular TxA2 synthase. COX, cyclooxygenase; TX, thromboxane; PG, 
prostaglandin; NSAIDs, nonsteroidal antiinflammatory drugs Gurbel PA and Tantry US, 
Monitoring of antiplatelet therapy, Platelet Third Edition, 2013; 603-633. Reproduced with 
permission from Elsevier.  
Aspirin remains the drug of choice for secondary prevention of recurrent ischaemic 
events in ACS patients (130). Conversely, aspirins’ role in primary prevention of ACS 
remains unclear and somewhat controversial (134, 135). In the setting of established 
preclinical vascular disease without the presence of other risk factors, aspirin has a 
Class II-A indication for use but the risk of bleeding must be taken in to consideration 
(134). There is also no apparent benefit of daily doses above 100mg from meta-
analyses and a negative dose-dependant effect on gastrointestinal complications with 
increasing doses (136, 137). It is hoped that continuing studies such as ASCEND 
(NCT00135226) and ACCEPT-D (ISRCTN48110081), both investigating aspirin for 
primary cardiovascular event protection will provide clarifying information.  
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Early administration of aspirin in ACS has consistently been shown to be beneficial 
over all factions of ACS including: unstable angina/NSTEMI (138, 139) and STEMI (140). 
Aspirin HOTPR has been extensively reviewed and several studies have linked the 
presence of HOTPR to a higher risk of recurrent ischaemic events (141, 142). A 
systematic review and meta-analysis of various studies linking aspirin HOTPR to clinical 
outcomes utilising different methods, an odds ratio of all cardiovascular outcomes of 
3.8 (95% CI; 2.3–6.1) for aspirin HOTPR was observed (143). Additionally, the 
important role of aspirin in ACS is underlined by the nearly two-fold (OR 1.82, 1.52-
2.18, p< 0.00001) increased risk of adverse events in patients with an ACS or history 
of CAD who discontinued or were not compliant with their aspirin therapy (145). 
 
Despite the abundance of data demonstrating the efficacy of aspirin therapy in 
patients with CAD, the data in PVD is less compelling. Aspirin therapy has been 
demonstrated to decrease cardiovascular events in patients with PVD, but has little or 
no effect on symptomatic improvement in subjects with intermittent claudication 
(146). In a recent meta-analysis of 18 prospective randomised studies including 5269 
patients with PVD, aspirin resulted in 12% reduction of the combined end point of 
nonfatal MI, nonfatal CVA and cardiovascular death but failed to reach statistical 
significance (64). Whether studies with a larger number of vascular patients would 
provide more convincing benefit is unknown. Because a large majority of PVD patients 
also have symptomatic CAD or cerebrovascular disease, aspirin is an acceptable 
antiplatelet agent in this setting and the ACCF/AHA endorse aspirin with class I, level 
of evidence B recommendation (146). Further studies are needed to elucidate the 
relationship between aspirin HOTPR and risk in PVD patients.  
1.4.2 Aspirin HOTPR 
Estimates of the prevalence of aspirin HOTPR vary dramatically (from 5.5% to 56.8%), 
depending on the method of platelet function testing, cut-point used and the 
population (148). Aspirin HOTPR has also been linked to high platelet reactivity in the 
response to other agonists such as ADP and collagen and may reflect a global hyper-
reactivity (148). The concomitant use of particular NSAIDs may influence the response 
INTRODUCTION 
 
 27 
to aspirin by interfering with aspirins ability to bind COX-1 (150) and the use of these 
drugs has been associated with an increased risk of cardiovascular events (150). 
Genetic polymorphisms in the genes encoding COX-1, COX-2, GPIIIa, P2Y12, and P2Y1 
have been suggested and studied for their potential influence on aspirin response. A 
systematic review looking at 50 studies investigating 9 genes in more than 11,000 
people only found a significant relationship between the PLA1/A2 polymorphism in 
the GPIIIa receptor and an increased rate of aspirin HOTPR in healthy subjects but not 
CAD patients (151). The relationship between gene polymorphisms and aspirin 
responsiveness remains unclear. 
 
When aspirin HOTPR is identified in patients, the treatment to correct this is still 
unknown. Currently, there is no published study that has investigated the clinical 
efficacy of changing therapy based on aspirin response and therefore guidelines do 
not recommend routine testing of aspirin response or tailoring of therapy based on 
these tests (152). Furthermore, there are only a handful of studies that have 
investigated aspirin HOTPR in a strictly PVD population and have found mixed findings 
between HOTPR and adverse events (153, 154).  
1.4.3 P2Y12 Inhibitors  
P2Y12 inhibitors are used in conjunction with aspirin to prevent secondary ischaemic 
events in patients with ACS. The drugs work by blocking the ADP platelet amplification 
pathway by antagonising P2Y12 receptors on platelets and inhibiting GPIIb/IIIa 
formation. The first P2Y12 inhibitor Ticlodopine, belonging to the Thienopyridine 
family of drugs, was discovered after antiplatelet/aggregation screening studies in the 
1970s. Ticlodopine was found to have greater antithrombotic efficacy than aspirin in 
many clinical settings including; secondary protection against ischaemic events 
following stroke, TIAs and unstable angina, leading to FDA approval in 1991 (156). A 
further 5 years later, a study published in the New England Journal of Medicine found 
DAPT therapy of aspirin plus ticlodopine decreased the risk of MI and repeat 
revascularisation after PCI by 82% compared to aspirin alone (156). However, 
ticlodopine had unfavourable side effects such as diarrhoea, nausea and vomiting in 
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up to 50% of treated patients (157). But some patients also suffered from rare but 
serious side effects including neutropenia and thrombotic thrombocytopenic purpura, 
which lead to the recommendation of regular full blood count tests in the first 3 
months of treatment (158). The development of clopidogrel, another theinopyradine 
with a similar efficacy for preventing vascular events, but a much more favourable 
safety profile (160), lead to clopidogrel becoming the most commonly prescribed drug 
in the world (160).  
1.4.4 Clopidogrel 
Clopidogrel is a pro-drug that requires hepatic biotransformation into its active 
metabolite to exert its antiplatelet response. Only 10-15% of the absorbed drug 
undergoes biotransformation, the remaining 85-90% is hydrolysed by hepatic 
carboxylase to an inactive carboxylic acid metabolite. The metabolism of clopidogrel 
is a two-step process controlled by hepatic cytochrome (CYP) P450 isoenzymes (Figure 
1-6). The first step involves the oxidation of the thienol ring to 2-oxo-clopidogrel and 
studies have indicated the CYP isoenzymes CYP2C19, CYP1A2, and CYP2B6 as the main 
enzymes involved. The second metabolism step produces the highly unstable active 
metabolite (R-130964) through hydrolysis and similarly to the first step, CYP2C19 is 
actively involved in the metabolism along with CYP2C9, CYP2B6, and CYP3A (161). The 
active metabolite of clopidogrel covalently and specifically binds to the P2Y12 
receptor on platelets trafficking through the hepatic circulation. This interaction is 
non-reversible and blocks ADP induced platelet aggregation for the platelets lifetime. 
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Figure 1-6 Metabolism of clopidogrel  
Cattaneo M, ADP Receptor Antagonists, Platelet Third Edition, 2013; 1117–1138. Reproduced 
with permission from Elsevier.    
Clopidogrel has shown to be very effective in secondary prevention of ischaemic 
events in patients with established cardiovascular disease (63). However, clopidogrel 
as a single or dual antiplatelet therapy is not indicated for primary prevention of 
ischaemic events in patients with preclinical cardiovascular disease or multiple risk 
factors. In the primary prevention cohort of the CHARISMA trial, there was no clear 
benefit of DAPT with clopidogrel over aspirin alone and subgroup analysis revealed a 
higher mortality and bleeding risk in patients on DAPT who were asymptomatic (162, 
163). This cohort also comprised a large proportion (42%) of diabetics and currently 
there is no evidence to support DAPT in this high-risk group for primary prevention.  
 
The CAPRIE study investigated the risk of recurrent ischaemic events in a larger cohort 
(19,185) of high-risk patients due to a previous ACS, ischaemic stroke or peripheral 
vascular disease (63). The study found clopidogrel single therapy (75mg) to be 
superior to aspirin therapy (325mg) at preventing major cardiovascular adverse 
events with an 8.7% relative risk reduction of MI, ischaemic stroke and vascular death 
in those treated with clopidogrel. The use of DAPT (aspirin and clopidogrel) in stable 
cardiovascular disease has not been directly tested in a prospective randomised trial. 
However, post-hoc analysis from the CHARISMA study in patients with a history of 
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cardiovascular events (similar to CAPRIE) showed an improvement in prognosis 
without excess bleeding in those who were on DAPT compared to aspirin alone (128). 
Interestingly, the reduced risk of MI, stroke and cardiovascular death seen in stable 
coronary disease patients on DAPT was also found in the peripheral vascular disease 
subgroup (164). In the context of cerebrovascular ischaemia and secondary 
prevention of TIAs or addition strokes, clopidogrel has some data to support its use 
over aspirin although the size of the additional benefit is controversial (165). The use 
of DAPT in preventing recurrent stroke and TIAs is not favoured over aspirin or 
clopidogrel alone. The MATCH trial, a study of high-risk patients with recent ischaemic 
stroke or TIA and at least one risk factor, found DAPT compared to clopidogrel alone 
resulted in a non-significant reduction in major vascular events but a doubled relative 
risk in life threatening hemorrhages (166). Although analyses of predefined subgroups 
in the MATCH trial did not identify patient groups where DAPT therapy was 
advantageous and bleeding risk was relative to single clopidogrel therapy.   
 
In contrast to preclinical and stable cardiovascular disease, there is a wealth of trial 
data supporting the use of DAPT in patients following an ACS or PCI. The sustained and 
incremental benefit of clopidogrel on top of standard therapy, including aspirin, was 
demonstrated in the CURE trial in unstable angina (UA), non-ST elevation MI (NSTEMI) 
(167) and acute ST-elevation MI patients (STEMI) (168). The UA and NSTEMI patient 
cohort received clopidogrel (300mg) within 24 hours of symptom onset and 
chronically (75mg) on top of standard therapy for 3 – 12 months following the event. 
This lead to a 20% risk reduction of MACE in patients receiving clopidogrel compared 
to the placebo group. With a more potent antiplatelet added on top of standard 
therapy, not surprisingly the rate of major bleeding was greater in the clopidogrel 
group compared to placebo (3.7% vs 2.7%, p< 0.001), although the rates of life 
threatening bleeds and hemorrhagic stokes were similar (2.1% vs 1.8% p=0.3) (167).  
In the STEMI patient group a loading dose of clopidogrel (300mg) was given within 12 
hours of ACS onset and compared to standard therapy. Patients who received 
clopidogrel had a 20% risk reduction in MACE at 30 days. Furthermore, the addition 
of clopidogrel in the acute setting lead to 36% reduced risk of an occluded infarct-
related artery on angiography, which reduces reperfusion and increases complication 
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risk, and decreased rates of recurrent MI and death before angiography could occur 
(168). The COMMIT trial randomly allocated clopidogrel (75mg) or placebo to a large 
cohort of patients (45,852) with suspected MI on top of daily aspirin. Although 
treatment was of a short duration (average 15 days); clopidogrel treatment was again 
associated with a statistically significant reduction in the incidence of death, re-
infarction and stroke, and was consistent over a wide range of patients and 
independent of other therapies used (169). 
 
Coronary revascularisation with the use of coronary balloons or stents in both elective 
and acute settings is associated with an increase in thrombosis risk and therefore 
adequate antiplatelet therapy is even more critical after PCI. Within the CURE trial, a 
pre-specified subset who underwent PCI (PCI-CURE) were assessed to investigate the 
benefit of a pre-procedural loading dose of clopidogrel (300mg) followed by long term 
daily doses (75mg). A 31% reduction in cardiovascular death and MI risk was observed 
in the patients receiving clopidogrel and a 30% risk reduction in target-vessel 
revascularisation at 30 days compared to aspirin alone (171). In addition, the CREDO 
trial showed that DAPT should be continued beyond the usual 30 days, as one year 
outcomes revealed a 27% risk reduction in death, MI and stroke in patients on DAPT 
compared to patients on aspirin alone past 30 days of DAPT (172).  In the high-risk 
STEMI population, the use of DAPT before or after PCI in the CLARITY study resulted 
in significantly lower rates of cardiovascular death or ischaemic complications without 
an increase in major or minor bleeding (172). The doubling of clopidgorel dose to 
600mg before PCI in the ARMYDA-2 study, significantly reduced periprocedural MI 
compared to patients receiving the conventional 300mg. These studies in total show 
the superior efficacy of DAPT to prevent MACE in patients undergoing PCI compared 
to aspirin alone. Current guidelines advocate DAPT with aspirin and clopidogrel for up 
to 12 months depending on type of stent and favour continuation beyond this time 
period according to individual risk assessment (174).  
 
There is also evidence to support clopidogrel monotherapy in PVD patients. In a 
subgroup analysis from CAPRIE, clopidogrel had its greatest effect on reducing 
cardiovascular events in patients with PVD (63). Clopidogrel has been approved for 
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use in PVD, particularly in patients with adverse reactions or intolerance to aspirin 
(146).   
1.4.5 Clopidogrel HOTPR 
Despite remarkable improvements in patient outcomes following the implementation 
of DAPT, 8-10% of patients suffer a recurrent cardiovascular event during the first year 
following an ACS (175). It was first reported in 2002 by Jaremo et al. and then Gurbel 
et al. that recommended doses of clopidogrel produced very variable antiplatelet 
effects when given to different patients (175, 176). Then the following year, Matetzky 
et al. observed that this variability in response to clopidogrel correlated with clinical 
outcomes following PCI (178). In Gurbel et al’s. early study in patients undergoing 
elective PCI, platelet reactivity in response to ADP was measured at several time 
points, pre and post loading (clopidogrel 300mg), 5 days and 30 days post PCI (176). 
HOTPR was classified as a <10% fall from baseline and 31% of patients post loading 
and at day 5, fell in to this category. The prevalence of HOTPR dropped to 15% at day 
30 post-PCI, but there remained a wide inter-individual variability in the response to 
clopidogrel (176). The prevalence of clopidogrel HOTPR in coronary artery disease 
patients has since been the focus of a number of studies and rates vary between 25-
40% depending on the assay used, the population tested and the timing of 
measurement post clopidogrel therapy (178, 179).  
 
Several studies have linked clopidogrel HOTPR to increased risk of thrombotic events 
following PCI as summarised in Table 1-3. Early studies by Matetzky et al. using light 
transmission aggregometry (LTA) in STEMI patients undergoing PCI, found patients in 
the lowest quintile of clopidogrel responsiveness had the highest rates of ischaemic 
events during follow up (178). Subsequently, it was suggested that high on treatment 
platelet reactivity to ADP would be a superior marker of ischaemic risk instead of the 
difference from baseline to on treatment, as platelet reactivity to ADP on aspirin alone 
was highly variable (181). The relationship between HOTPR and risk of ischaemic 
events was first prospectively investigated in the PREPARE POST-STENTING study 
(181). The presence of HOTPR was associated with a 2.6 increased risk of ischaemic 
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events and the occurrence of MACE in patients without HOTPR was relatively rare, 
postulating a potential therapeutic target to protect patients against thrombotic 
complications post PCI. In 2008, Price et al. demonstrated patients with HOTPR (>235 
PRU as measured by VerifyNow) had significantly higher rates of cardiovascular death 
(2.8% vs. 0%, p=0.04) and stent thrombosis (4.6% vs. 0%,p=0.004) (182). Additionally, 
Sibbing et al. demonstrated a similar risk of ischaemic events associated with HOTPR 
as measured by the Multiplate analyser (184). Patients with HOTPR had a dramatic 
increased risk of stent thrombosis, OR 9.4 and cardiovascular death, OR 3.2 compared 
to normal responders at 30 days post PCI. Many other studies have consistently 
demonstrated HOTPR to be an independent risk factor for ischaemic events post PCI 
(Table 1-3). The wealth of data on this subject also suggests that patients could 
potentially be protected from thrombotic/ischemic complications if low to moderate 
on treatment platelet reactivity were achieved. 
 
There is limited data on the frequency of clopidogrel HOTPR in PVD patients. A small 
study looking at the incidence of HOTPR in 54 stable PVD patients found 32% had 
HOTPR on clopidogrel monotherapy and that this phenotype was not stable in all 
patients over time (184). The relationship between clopidogrel HOTPR and MACE had 
not been examined in a PVD population to our knowledge. 
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Table 1-3 Studies linking HOTPR to adverse clinical events in CAD 
Study Patient group 
(n) 
Methods Definition of 
HOTPR 
Clinical Relevance 
Barragan et 
al. 
(185) 
PCI (46) VASP-PRI >50% VASP  Stent thrombosis 
Gurbel et al. 
(181)  
Elective PCI 
(192) 
5 μM ADP – 
LTA 
75th percentile 
post PCI 
platelet 
reactivity 
 post PCI events 
at 6 months, OR 2.1 
Matetzky et 
al.(186) 
STEMI-PCI 
(60) 
5 μM ADP – 
LTA 
75th percentile 
platelet 
reactivity 
 cardiac events at 
6 months post PCI 
Bliden et al. 
(187) 
Elective PCI 
(150) 
5 μM ADP – 
LTA 
≥50% platelet 
aggregation 
 1 year post PCI 
events 
Blindt et al. 
(188) 
High risk for 
ST – PCI (99) 
VASP-PRI 
(72-96 hrs 
after 
stenting) 
>48% PRI  6 month ST 
Cuisset et al. 
(190) 
NSTEMI –PCI 
(190) 
10 μM ADP-
LTA 
>70% LTA  periprocedural 
ischaemia 
Frere et al. 
(190) 
NSTEMI – 
PCI (195) 
10 μM ADP-
LTA 
>70% LTA  30 days post PCI 
events MACE + 
Stroke 
Geisler et al. 
(191) 
CAD-PCI 
(802) 
20 μM ADP-
LTA 
Upper quartile  30 days MACE 
and death OR = 4.9 
Price et al. 
(182) 
PCI (380) VerifyNow 
P2Y12  
≥ 235 PRU  6 months post 
PCI events 
including ST 
Gurbel et al. 
(192) 
Elective PCI 
(297) 
5 & 20 μM 
ADP-LTA 
>46% 5 μM 
ADP 
>59% 20 μM 
ADP 
 2 year ischaemia 
events 5 μM OR = 
3.9, 20 μM OR = 
3.8 
Bonello et al. 
(193) 
PCI (144) VASP-PRI >50% PRI  6 months post 
PCI MACE 
Marcucci et 
al. (194) 
PCI-ACS 
(683) 
VerifyNow 
P2Y12 
≥ 240 PRU  12 month 
ischaemic event, 
CV death OR = 
2.55, nonfatal MI 
OR = 3.36 
Patti et al. 
(195) 
PCI (160) VerifyNow 
P2Y12 
≥ 240 PRU  1 month MACE 
Sibbing et al. PCI-DES 
(1608) 
Multiplate 
Analyser (6.4 
μM ADP) 
Upper quintile 
(>47 AU) 
 1 month definite 
ST, OR =9.4 
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1.4.6 Clopidogrel LOWPR    
The prevalence and significance of low on treatment platelet reactivity (LOWPR) to 
ADP has not been as extensively studied as HOTPR. Early observations of higher 
bleeding rates in studies where more potent antiplatelet treatments were being 
administered suggested a negative trade-off of a poorer safety profile with improved 
clinical efficacy. In the CURE trial, DAPT was associated with a 38% increased relative 
risk of major bleeding compared to aspirin single therapy (196). Recent studies have 
investigated the relationship between LOWPR and bleeding risk following PCI. An 
enhanced response or hypersensitivity to clopidogrel as measured by the Multiplate 
in Sibbing et al. study, was associated with a 3.5 fold increased risk of procedure 
related major bleeding following PCI (197). In the Sibbing study, the investigators also 
found an association between HOTPR and ischaemic events, unveiling a spectrum of 
response to clopidogrel. In a study utilising the VerifyNow P2Y12 assay, the presence 
of LOWPR (PRU ≤86) was associated with an increase in 1 month bleeding events in 
507 patients tested undergoing PCI (198).  
1.4.7 Prasugrel 
Prasugrel is a second-generation thienopyridine pro-drug similar to clopidogrel.  It is 
also metabolised by hepatic CYP isoenzymes into its active form, although prasugrel’s 
chemical structure allows for a more efficient metabolism that is not as reliant on the 
CYP2C19 or CYP2C9 enzymes as clopidogrel (Figure 1-7) (199). This efficient 
metabolism results in a faster onset of action at doses’ 10-100 fold lower than 
clopidogrel. A loading dose of 60mg reaches 80% inhibition of platelets 30 minutes 
after dosing, whereas clopidogrel even at a 600mg-loading dose exerts minimal 
inhibition at the same time point (200). The anti-aggregatory effects of prasugrel lasts 
the lifespan of the platelet due to irreversible binding of the active metabolite to the 
P2Y12 receptor, similar to clopidogrel. Studies comparing prasugrel (60mg loading, 
10mg maintenance) and clopidogrel (300mg loading, 75mg maintenance) in healthy 
subjects and patients with coronary artery disease consistently find a faster and higher 
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mean platelet inhibition in participants receiving prasugrel (201-203). Although there 
exists a degree of variability in on-treatment platelet reactivity to prasugrel therapy, 
the prevalence of HOTPR on prasugrel is much lower than clopidogrel treatment (204). 
This is thought to be due to CYP2C19’s limited role in the biotransformation process 
leading to a more consistent level of active metabolite between individuals rather 
than a greater potency of the active metabolite to inhibit the P2Y12 receptor (201) 
(202). In pharmacokinetic studies, low body weight and increasing age (≥75) resulted 
in significantly greater platelet inhibition levels (205). 
Figure 1-7 Metabolism of Prasugrel 
Cattaneo M, ADP Receptor Antagonists, Platelet Third Edition, 2013; 1117–1138. Reproduced 
with permission from Elsevier.   
The more potent efficacy of prasugrel compared to clopidogrel, was demonstrated in 
the TRITON-TIMI-38 trial, a phase III trial that evaluated 13,608 high-risk ACS patients 
undergoing PCI (206). Patients were randomised to receive either prasugrel (60mg 
loading, 10mg maintenance) or clopidogrel (300mg loading, 75mg maintenance) for 6 
– 15 months. Prasugrel was associated with a 19% risk reduction in ischaemic events 
(HR 0.81, p < 0.001) but a higher incidence of major and fatal bleeding complications 
(HR 1.32, p = 0.03). Landmark analysis revealed a significant protection from ischaemic 
events particularly in the perioprocedural time period, but decreased ischaemic rates 
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also extended out to the end of the study (207). There was a notable increase in the 
incidence of major bleeding in patients undergoing CABG surgery on prasugrel 
compared to clopidogrel and post hoc analysis indicated when prasugrel was withheld 
7 days before surgery, the rates of major bleeding were substantially reduced (207). 
Other post-hoc analyses also identified subgroups that either received more benefit 
or more harm from prasugrel therapy. Patients with previous cerebrovascular 
accidents, patients over 75 years of age or weighing less than 60kg appeared to have 
less of a net clinical benefit and/or greater harm than the same subgroups receiving 
clopidogrel. Consequently, adjustment of the maintenance dose to 5mg is 
recommended in these populations and validity of this approach is the subject of 
ongoing studies (208). Patients with diabetes, STEMI, coronary stents, or recurrent 
cardiovascular events on treatment all had significantly more favourable outcomes 
compared to the same subgroups on clopidogrel (209) (210, 211). Based on the results 
of the TRITON TIMI-38 trial, prasugrel was FDA approved and is recommended in high-
risk patients for a short time period (213).  
1.4.8 Ticagrelor   
Ticagrelor is a direct and reversible P2Y12 antagonist and belongs to the new chemical 
class cyclopentyl-triazolo-pyrimidines. Interestingly, ticagrelor binds to the P2Y12 
receptor via a mechanism that is non-competitive to ADP, suggesting the existence of 
an independent alternative-binding site on the receptor (213). Ticagrelor also has a 
rapid onset of action, achieving maximal platelet inhibition in about 2 hours and the 
achieved platelet inhibition levels are less variable compared to clopidogrel (214, 215). 
Unlike clopidogrel and prasugrel, ticagrelor does not undergo hepatic metabolism and 
is ingested in its active form resulting in the observed fast onset and consistent 
platelet inhibition.  
 
The DISPERSE-2 study compared the safety of ticagrelor with that of clopidogrel in 990 
NSTEMI patients on top of aspirin therapy for up to 12 weeks (217). There was no 
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difference in major bleeding observed between the two groups. The study did confirm 
that dyspnea occurred more frequently with ticagrelor and in this study the impact on 
discontinuation of treatment was low. The mechanism of this side effect remains 
unclear and some have hypothesised that it is mediated by the induced increase in 
adenosine release. Whether this side effect will impact more in a real world setting of 
ticagrelor administration is unknown. Ticagrelor was shown to decrease the incidence 
of cardiovascular death, MI or stroke by 16% compared to clopidogrel (9.8% vs. 11.7%) 
in NSTEMI and STEMI patients in the PLATO study (217). This was a high-risk 
population and two thirds were undergoing PCI. The more potent ticagrelor also 
reduced the secondary endpoints of MI (5.8% vs. 6.9%) and unexpectedly, 
cardiovascular death (4.0% vs. 5.1%). Whilst in the overall study there was no 
difference in bleeding between the two treatment groups, the incidence of major non-
CABG related bleeding was significantly higher in the ticagrelor treated patients (219). 
In patients undergoing CABG the incidence of both cardiovascular and total mortality 
was lower in the ticagrelor treated patients, while the incidence of major CABG-
bleeding was similar, potentially due to the quicker regain of platelet function after 
discontinuation of ticagrelor (219). Therefore, similar to the TRITON-TIMI 38 trial, the 
PLATO trial demonstrated that more potent and consistent P2Y12 inhibition of 
platelet function than clopidogrel is associated with greater antithrombotic protection 
but a higher risk of non-CABG major bleeding. Based on the results of the PLATO trial, 
ticagrelor is now FDA-approved.  
1.4.9 Novel P2Y12 inhibitors  
Several other novel antiplatelet agents are in development for the use in ACS, some 
of these are outlined in Table 1-4. Cangrelor and elinogrel are both new P2Y12 
receptor antagonists. Cangrelor has undergone two phase III trials, CHAMPION-PCI 
(220) and CHAMPION-PLATFORM (221) that have evaluated the intravenous and oral 
form of cangrelor. Both trials were terminated early, as there was insufficient 
evidence to show cangrelors efficacy. Another phase III trial, CHAMPION-PHOENIX is 
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currently under way to evaluate cangrelors efficacy with outcomes. Elinogrel has 
shown promising results in the phase II INNOVATE-PCI trial with greater and more 
rapid antiplatelet action compared to clopidogrel and no excess bleeding, as is 
common with stronger platelet inhibition (222). The current targets of antiplatelet 
agents have either been COX-1 or P2Y12 platelet activation pathways. Patients 
continue to have events on these antiplatelet agents and this may be due to the 
known upregulation of other pathways that are left uninhibited.  
1.4.10 Other platelet inhibitors under clinical trial 
Several drugs including cilostazol, protease-activated-receptor-1 (PAR-1) antagonists 
and oral anticoagulants have been suggested as adjunct therapies to aspirin and a 
P2Y12 inhibitor. Cilostazol is a phosphodiesterase III inhibitior, that  effects platelet 
intracellular cAMP levels. It has shown some promise in diabetic patients (OPTIMUS-
2) with a significant decrease in measured P2Y12 activation levels compared to control. 
However, a multitude of side effects has inhibited its development (223). PAR-1 
antagonists, atopaxar and vorapaxar are at varying stages of development (225) and 
could be particularly relevant in ACS populations, as thrombin generation processes 
are enhanced in these patients (225). Early development of revacept, a soluble dimeric 
Glycoprotein VI-Fc fusion protein, that interferes with collagen induced platelet 
activation has been shown to inhibit platelet aggregation in a dose dependent manner 
without altering general homeostasis (226). 
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Table 1-4 Major novel antiplatelet agents in development 
 Key: PAR-1, Protease-activated receptor-1; GP, Glycoprotein.  
Drug Class Platelet inhibition target Administration Half life Development stage 
Cangrelor ADP P2Y12 
receptor 
antagonist 
Direct, reversible P2Y12 
inhibition 
Intravenous 3 – 5mins Phase III trial –CHAMPION-
PHOENIX 
 
Elinogrel ADP P2Y12 
receptor 
antagonist 
Competitive, direct and 
reversible P2Y12 inhibition 
Intravenous and oral 12 hrs Phase III trial  
Vorapaxar Thrombin PAR-1 
antagonist 
Direct, reversible Oral 165-311 hrs Phase III trial – TRACER and 
TRA-2P 
Atopaxar Thrombin PAR-1 
antagonist 
Direct, reversible Oral 22-26 hrs Phase II (LANCELOT-ACS 
and LANCELOT-CAD) 
complete 
Revacept GP V1 pathway 
blocker 
Interferes with collagen 
mediated platelet activation 
Intravenous 67-137 hrs Completed phase I trial 
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1.4.11  HOTPR and LOWPR risk factors 
The variability in response to clopidogrel is multi-factorial and complex, influenced by 
genetic factors, clinical variables and non-compliance. A schematic diagram of these 
factors is depicted in Figure 1-8. 
 
Figure 1-8 Factors influencing clopidogrel metabolism and ADP response. 
The pharmacodynamic response to clopidogrel is influenced by numerous factors such as 
single nucleotide polymorphisms of genes encoding p-glycoprotein transporter (ABCB1) and 
CYP2C19 and also by drugs that are metabolized by hepatic cytochrome enzymes along with 
clopidogrel (e.g., proton pump inhibitors, calcium channel blockers, St. John’s Wort, smoking). 
In addition, platelet response to ADP is also influenced by age, body mass index, diabetes, 
coronary artery disease state, and renal insufficiency. The variable response to ADP results in 
increased ischemic outcomes in the presence of high platelet reactivity and bleeding in the 
presence of low platelet reactivity. BMI, body mass index; CAD, coronary artery disease; CCB, 
calcium channel blockers; CYP, cytochrome; DDI, drug-drug interaction; HPR, high platelet 
reactivity; LPR, low platelet reactivity; PPI, proton pump inhibitor; SNP, single nucleotide 
polymorphism; SJW, St. John’s Wort. Gurbel PA and Tantry US, Monitoring of antiplatelet 
therapy, Platelet Third Edition, 2013; 603-633. Reproduced with permission from Elsevier 
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1.4.12 Genetic Factors  
Several genetic mutations or single nucleotide polymorphisms (SNPs) have been 
identified in genes that control clopidogrel absorption and metabolism and could 
affect the level of active metabolite that is produced. Several SNPs, at least 25, have 
been identified in the gene encoding the CYP2C19 isoenzyme, which influence the 
catalytic activity of the enzyme is a dose-dependent manner. Of the SNPs identified in 
the CYP2C19 gene, the most widely analysed and most frequent are *2, a G→A 
mutation in exon 5 producing an aberrant splice site, leading to the complete absence 
of CYP2C19 activity; and *17 (-806C→ T), a regulatory region variant that has 
been associated with increased expression and enzymatic activity. The *2 is the most 
common loss-of-function (LOF) allele whereas *3, and *4, *5, *6, *7, and *8 are less 
common LOF alleles (227).  
 
The prevalence of the *2 LOF allele differs between ethnic groups, occurring in 13% 
of Caucasians, 18% of African Americans and 29% of East Asians (228). Importantly, in 
a NZ population a single small study has identified a higher frequency of the *2 LOF 
Maori (24%) compared to NZ Europeans (15%) (230). On the other hand, the *17 GOF 
allele has found to be more prevalent in Caucasians (21%) compared to African 
Americans (16%) and Asians (4%) (228). Carriage of at least one CYP2C19 LOF allele 
was demonstrated to decrease both active metabolite levels of clopidogrel in the 
blood by 34% (relative reduction, p<0.001) and platelet inhibition (9% absolute 
reduction from baseline, p<0.001) compared to non-carriers in healthy participants 
(231). Homozygous LOF allele carriage has the greatest impact on ADP induced 
platelet reactivity resulting in a significant increase in on treatment platelet reactivity. 
Platelet function between heterozygous diplotypes is highly variable and therefore 
genotyping will fail to identify a large proportion of patients who have HOTPR (231).      
 
The impact of CYP2C19*2 carriage on MACE risk is debatable in the literature with 
some metanalyses reporting an increase in cardiovascular risk, particularly stent 
thrombosis in patients undergoing percutaneous coronary intervention (PCI) (232, 
233). However, other studies have directly challenged this link and report a marginal 
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increase in MACE for patients with the LOF allele (234, 235). The reported 
inconsistencies linking CYP2C19 and MACE are most likely due to the small influence 
(5-12%) that the LOF allele has on the variability in clopidogrel response (236). 
 
The gain of function allele CYP2C19*17 is associated with significantly lower levels of 
ADP-induced platelet aggregation and a higher risk for bleeding during clopidogrel 
treatment compared to wild-type carriers (237). However, in this study conducted by 
Sibbing et al, platelet function was not reported in those who had bleeding and 
whether the GOF allele affects cardiovascular events remains unclear.  
 
Genetic polymorphisms also affect other genes that are central to active clopidogrel 
metabolite production. Limited intestinal absorption and therefore decreased hepatic 
biotransformation of clopidogrel has been associated with the homozygous 3435C to 
T mutation of ATP binding cassette sub family B member 1 (ABCB1). The gene encodes 
the efflux pump P-glycoprotein and is central to clopidogrel absorption in the gut 
(238). It has more recently been proposed that paraoxonase-1 (PON-1) is the crucial 
enzyme involved in clopidogrel bioactivation and polymorphisms in this gene lead to 
higher rates of HOTPR (239), but this finding was not confirmed by several subsequent 
studies (240).  
1.4.13 Drug-Drug Interactions 
Several drug interactions with the P450 isoenzymes have shown to contribute to the 
variability in clopidogrel metabolite production. The coadministration of clopidogrel 
with proton pump inhibitors, calcium channel blockers, St. John’s wort, smoking and 
warfarin, which are metabolised by the CYP2C19, CYP3A4, CYP1A2 and CYP2C9 
isoenzymes may potentially influence clopidogrel response (242). 
 
Patients treated with clopidogrel for cardiovascular disease, are frequently also on 
proton pump inhibitors (PPIs) and both drugs are mainly metabolised by CYP3A4 and 
CYP2C19 isoenzymes. Consequently, recent studies have focused on the relation of 
PPI treatment to clopidogrel metabolism and cardiovascular outcomes. Platelet 
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function studies have found an association between omeprazole administration and 
reduced clopidogrel response, as measured by the VASP phosphorylation, but no 
change with pantoprazole or esomeprazole administration (242, 243). Several 
retrospective studies have observed higher rates of major adverse cardiovascular 
events in patients receiving both clopidogrel and a PPI suggesting a decrease in 
clopidogrel’s ability to prevent ischaemic events (245). However, this finding has not 
been consistent and other studies have found no association leaving a lack of 
conclusive evidence to support a clinically important interaction between clopidogrel 
and PPI use. 
1.4.14 Diabetes  
Diabetes Mellitus (DM) is a metabolic disorder that is accompanied by a 
prothrombotic state and cardiovascular disease is the leading cause of mortality in this 
patient group (246). Diabetic patients not only have a higher cardiac risk than non-
diabetics but also suffer from more cardiovascular complications and recurrent 
atherothrombosis events (245, 246). Multiple mechanisms have been suggested to 
contribute to the platelet dysfunction observed in DM patients and are caused by 
metabolic and cellular abnormalities (247-250). This dysfunction results in two 
important factors that negatively impact diabetic patients: a higher level of baseline 
platelet reactivity and higher levels of antiplatelet drug targets compared to non-
diabetics 
 
These include the enhanced production of thromboxane due to increased arachidonic 
acid metabolism and observed low intra cellular levels of glutathione and other 
antioxidants in diabetic platelets (251, 252). Calcium homeostasis is also disrupted 
leading to increased cytosolic calcium concentration and platelet hyperaggreability 
(254). Due to the hyperglycemic environment in diabetic patients, platelet function is 
augmented in many ways. There is enhanced expression of P-selectin (254) and 
glycation of certain platelet surface proteins such as GPIIb/IIIa, which may decrease 
membrane fluidity and increase platelet adhesion (255, 256). 
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Nitric oxide (NO) production by platelets inhibits interactions with the endothelium 
and promotes endothelium mediated vasodilation in normal conditions (258). NO 
synthase levels are significantly decreased in diabetic patients (259) although 
interestingly, levels can be improved by the presence of insulin (259). Furthermore, 
this deficiency of insulin and/or its response on tissues that is central to diabetes, 
contributes to platelet dysfunction from the abolishment of insulin’s platelet-
inhibitory effects (260, 261).  Recent research has shown a striking upregulation of the 
ADP P2Y12 receptor on platelets from diabetic patients compared to non-diabetic 
controls, leading to increased adhesion, aggregation and procoagulant activity (262, 
263). Lastly, diabetic patients have a higher turnover of platelets, with the presence 
of larger, sensitive reticulated platelets, resulting in platelet hyperactivity and lower 
response to antiplatelet agents (264-266).  
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Table 1-5 Mechanisms contributing to platelet dysfunction in diabetes 
Increased production of thromboxane A2 
Increased expression of platelet surface adhesion molecules, including; CD31, 
CD4ab, CD62P and CD63. Leads to an increase in platelet activation.  
Increase in platelet-dependent thrombin generation 
Increased expression of platelet surface receptors P-selectin, GPIb and GPIIIb/IIa. 
GPIa binds to Von Willibrand Factor            
GPIIb/IIIa binds fibrinogen            
Important step in thrombogenesis 
Decrease vascular synthesis of NO and PGl2 – pushing balance towards 
aggregation opposed to vasoconstriction. 
Disorded calcium homeostasis – effect shape change, secretion, aggregation and 
thromboxane formation. 
Decrease platelet insulin receptor number and affinity.  
Insulin is thought to decrease platelet response to ADP, collagen, thrombin, 
arachidonate and PAF 
Key: GP = glycoprotein; vWf = von Willebrand factor; PGI2 = prostacyclin; NO = nitric oxide; 
ADP = adenosine diphosphate; PAF = platelet-activating factor 
1.4.15 Obesity 
Increased BMI has also been associated with an increase in HOTPR rates. Furthermore, 
there appears to be a linear relationship, with increasing BMI leading to higher levels 
of platelet reactivity in obese patients (267). A contributing factor to the high rates of 
HOTPR in obese patients is the underdosing of clopidogrel in relation to body weight. 
However, studies have found even triple doses of 600mg of clopidogrel in some obese 
patients has not been sufficient to overcome HOTPR suggesting additional factors 
contributing to the observed high platelet reactivity (268). These include an increased 
inflammatory state and enhanced PAR-1 medicated platelet activation and impaired 
hepatic metabolism of clopidogrel due to fatty liver disease (268).    
1.4.16 Renal Insufficiency  
Renal insufficiency is associated with increased rates of HOTPR on clopidogrel therapy 
(269). A confounding factor is the high rate of diabetes in renal failure patients, which 
is the key risk factor for nearly half of end stage renal failure patients and as previously 
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described is a known contributor to HOTPR (270). However, a recent study observed 
a significant association between renal insufficiency, as measured by estimated 
glomerular filtration rate (eGFR) and residual platelet reacitivty with the highest rates 
of HOTPR in patients with a eGFR of <15 ml/min/1.73m2. This finding was independent 
of diabetes as a significant predictor of HOTPR but only in patients with an eGFR below 
15 (271). The mechanism to which renal insufficiency fosters HOTPR is still unknown.  
 
Other variables that influence the response to clopidogrel include: advanced age, CAD 
state and non-compliance (238). More recently the role of microRNAs which are 
involved in regulating gene expression, was investigated in platelet reactivity in a 
study by Rui Shi et al (273). The microRNA miR-223 expression in this study was found 
to negatively correlate with platelet reactivity in patients on clopidogrel. The 
expression of miR-233 in platelets, correlated with higher levels of P2Y12 expression 
and consequently with high levels of HOTPR and was a significant predictor of HOTPR 
in 33 PCI patients. Future studies with larger populations are needed to test the impact 
of this miRNA on clopidogrel response.   
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1.5 Platelet Function Testing  
The diverse response to antiplatelet drugs and its link with clinical outcomes has 
driven the development and implementation of platelet function testing in an effort 
to improve clinical outcomes. There are several tests available (outlined in Table 1-6 
and Figure 1-9) that differ significantly in predictive value of clinical outcome (238), 
consumable and testing costs and their appropriateness as a point of care assay for 
real time platelet function monitoring (274). 
 
Figure 1-9 Laboratory measurement of on treatment platelet reactivity. 
Laboratory methods to assess clopidogrel responsiveness are conducted by either measuring 
the response to ADP or specifically measuring the amount of P2Y12 inhibition. Genetic analysis 
of polymorphisms in the genes associated with metabolism of clopidogrel can also be 
performed. The ADP and P2Y12 specific methods can also be used to measure the response 
to other antiplatelet agents such as: prasugrel, ticagrelor, cangrelor and elinogrel which are all 
P2Y12 receptor antagonists. ADP, adenosine diphosphate; cAMP, cyclic adenosine 
monophosphate; CYP, cytochrome; PRP, platelet-rich plasma; LTA, light transmittance 
aggregometry; PI3K, phosphatidylinositol 3-kinase; TEG, throm- belastography; VASP, 
vasodilator-stimulated phosphoprotein; VASP-P, phosphorylated vasodilator-stimulated 
phosphoprotein. Gurbel PA and Tantry US, Monitoring of antiplatelet therapy, Platelet Third 
Edition, 2013; 603-633. Reproduced with permission from Elsevier. 
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Table 1-6 Platelet Function Assays 
 
Abbreviations: ADP, adenosine diphosphate; PGE1, prostaglandin E1. AU indicates aggregation units; LTA, light transmittance aggregometry; ROC, receiver 
operator characteristic curve analysis; PRI, platelet reactivity index; PRU, P2Y12 reaction units; VASP, vasodilator-stimulated phosphoprotein phosphorylation 
analysis
Assay Methodology Platelet  
stimulation 
Advantages Disadvantages Diagnostic cutoff  
point for ADP (ROC) 
LTA Reduction of optical density 
 after stimulation in PRP 
ADP, collagen, 
 AA, TRAP 
Good predictivity,  
historical measure 
Complex sample prep,  
time consuming 
n/a 
VASP Flow cytometric detection  
of VASP phosphorylation 
ADP and 
ADP + PGE1  
in parallel 
Whole blood assay,  
P2Y12 receptor specific 
Technically complex method, 
need flow cytometer,  
weak sensitivity and  
predictivity 
PRI > 50% 
VerifyNow Platelet mediated aggregation  
of fibrinogen-coated  
polystyrene beads 
ADP + PGE1  
(P2Y12 assay)  
AA (Aspirin assay) TRAP-6 
(IIb/IIa assay) 
Whole blood assay,  
true point of care,  
standardized procedure 
No room for assay  
adjustment, expensive  
cartridges 
PRU > 235-240 
Multiplate 
Analyser 
Impedance aggregometry  
coating of 2 electrode pairs  
by platelets 
ADP, ADP + PGE1, 
 AA, TRAP-6 
Whole blood assay, 
simple and rapid,  
standardized procedure,  
good predictivity for  
bleeding and stent  
thrombosis 
Requires pipetting,  
samples time sensitive 
>47 AU 
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1.5.1 Platelet function assays  
Laboratory based methods require specialised facilities, skilled personnel and can be 
time consuming. Examples of these include, Light transmission aggregometry (LTA) 
(274), which measures the optical density after preparation of platelet rich plasma 
and stimulated with an agonist. Historically, it has been viewed as the ‘gold standard’ 
of platelet function testing, and although it has good predictivity of clinical outcomes, 
the assay remains complex with no standardisation between testing (276). Another 
laboratory-based method, VASP phosphorylation measured by flow cytometry, is a 
whole blood assay that specifically measures P2Y12 receptor antagonism. Similarly to 
LTA, this assay is complex with the requirement of specialised equipment and time 
consuming. Unlike, LTA the VASP assay has weak sensitivity and predictivity (276). 
 
On the other hand, point-of-care assays are rapid and less complex, which are more 
desirable features when integrating these assays into clinical practice. The two most 
commonly used point-of-care assays are the VerifyNow Assay and the Multiplate 
analyser. The VerifyNow assay is a turbidimetric assay that measures aggregation of 
platelets to fibrinogen-coated beads in whole blood (182). The Multiplate analyser is 
an impedance aggregometer that assesses platelet function in whole blood (277). 
Both these assays are rapid and simple, with results obtained in less than 10 minutes 
and can be used to test residual platelet reactivity to a range of agonists. Testing 
procedures are completely standardised allowing comparable results between 
operators and institutions. The Multiplate is semi-automated, requiring pipetting and 
has been found to strongly predict bleeding and stent thrombosis risk (277), with a 
recent study displaying it was more predictive of ischaemic events than the VASP 
assays (278). On the other hand, VerifyNow is completely automated but 
consequently requires expensive testing cartridges. It is becoming more apparent that 
while laboratory-based assays are valuable for platelet function research purposes, 
only the rapid, standardised and easy to use methods will be appropriate for wide 
spread clinical use.  
Diagnostic cut-point values for high on treatment platelet reactivity have been 
determined for the reviewed platelet function assays using receiver operating 
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characteristic curve analysis (Table 1-3) and these are recommended by the Working 
Group on High On-Treatment Platelet Reactivity (238). Irrespective of the assay used, 
these cutoffs are a strong predictor of recurrent ischaemic events such as myocardial 
infarction or stent thrombosis. Furthermore, according to a recent meta-analysis of 
20 studies utilising the described platelet function tests, a patient identified with 
HOTPR has a 3.4 fold higher risk of cardiovascular death compared to a patient with 
an adequate ADP response (279). As with recurrent ischaemic risk, bleeding risk has 
also been linked with low platelet reactivity or hypersensitivity in patients on 
clopidogrel (192). The TRITON TIMI 38 trial (280) and recent Sibbing et al. (282) study 
suggest there is a therapeutic window for antiplatelet therapy in general and 
specifically P2Y12 receptor inhibition with “normal platelet reactivity” showing the 
lowest risk of either bleeding or stent thrombosis as measured by the Multiplate 
(Figure 1-10).  
 
 
Figure 1-10 Therapeutic window of P2Y12 blockade 
Sibbing et al. study suggest there is a therapeutic window for antiplatelet therapy in general 
and specifically P2Y12 receptor inhibition with “normal platelet reactivity” showing the lowest 
risk of either bleeding or stent thrombosis as measured by the Multiplate Sibbing et al. Platelet 
Aggregation and Its Association With Stent Thrombosis and Bleeding in Clopidogrel-Treated 
Patients. Initial Evidence of a Therapeutic Window. Journal of the American College of 
Cardiology. (2010) Vol 56: 4:317-318. Reproduced with permission   
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1.5.2 Personalised antiplatelet therapy 
Following the observed link between HOTPR and increased adverse outcomes, several 
studies have aimed to improve patient outcome by modifying antiplatelet therapy and 
lowering platelet reactivity. Treatment of HOTPR on maintenance clopidogrel therapy 
has been attempted by using higher loading or maintenance doses of clopidogrel, 
adding cilostazol, switching to more potent alternative P2Y12 receptor blockers such 
as prasugrel or ticagrelor, or by adding elinogrel or GPIIb/IIIa antagonists (283). Two 
small studies by Bonelle et al. randomised patients undergoing PCI to a guided 
antiplatelet therapy using the VASP assay or unguided therapy. Those who were found 
to have HOTPR in the guided arm were given an additional 600mg loading of 
clopidogrel. This treatment was successful in reducing on treatment platelet reactivity 
and decreased the rate of early stent thrombosis without an increase in major 
bleeding compared to a non-guided approach (283, 284). The selective addition of 
GPIIb/IIIa antagonists on top of DAPT in PCI patients with HOTPR has also been shown 
to improve patient outcomes without increasing bleeding (285). These early studies 
suggested that a platelet reactivity threshold of increased thrombotic and ischaemic 
risk could be used to target therapy and improve clinical outcomes. 
 
However, this outcome was not observed in the three largest randomised trials using 
platelet function testing to tailor antiplatelet therapy. The GRAVITAS trial was the first 
large scale trial (n = 2214) that utilised the VerifyNow P2Y12 assay to identify patients 
with HOTPR and subsequently doubled clopidogrel dosing(287). High-dose clopidogrel 
treatment was ineffective in reducing the 6-month composite ischemic event 
occurrence (cardiovascular death, nonfatal MI, and stent thrombosis); both treatment 
groups had an unexpectedly low event rate (2.3%). Similarly, the ARCTIC study 
enrolled 2440 patients undergoing PCI to receive guided therapy with the VerifyNow 
or non-guided therapy. Several different treatments were available to clinicians in the 
guided arm including reloading with clopidogrel (600mg), switching to prasugrel or 
administration of a GPIIb/IIIa inhibitor during PCI. The study was also neutral with no 
improvement in clinical outcomes for patients receiving guided therapy compared to 
standard clopidogrel therapy without monitoring (287). The TRIGGER-PCI trial, which 
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compared prasugrel versus clopiodgrel in patients with HOTPR as identified by the 
VerifyNow, was stopped by the steering committee prematurely after randomisation 
of 423 patients (out of the planned 2150) due to an interim analysis indicating a lower 
than expected incidence in the primary endpoint. Given the low rate of ischemic 
events, the clinical utility of this strategy could not be demonstrated (288). 
 
Many have taken the results of these trials and concluded the platelet reactivity is not 
a modifiable risk factor that can be treated to improve patient outcome. However, 
there are several issues with the study design of these trials that may have contributed 
to the negative results. These include, recruiting a study population with a low risk of 
thrombotic complications, the assay used to determine tailored therapy may not have 
been sensitive enough and the use of antiplatelet treatment that provided inadequate 
therapy to overcome HOTPR. Therefore, it remains a fundamental issue to 
characterise patient populations using the right platelet function assay and cut-point, 
to identify a population that may benefit from the use of proper protocols of 
personalised antiplatelet therapy. 
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1.6 Overall aims and objectives 
This thesis explores the presence and prevalence of high and low residual platelet 
reactivity in patients with atherosclerotic disease and the different clinical, 
demographic and genetic factors that influence this phenotype. Furthermore, which 
factors are predictive of a patient’s outcome and could be used to inform a patient’s 
risk or tailor antiplatelet therapy. In addition to assessing the extent to which platelet 
function testing is useful as a risk-marker in patients, the wider interactions between 
platelets and lymphocytes contributing to the inflammatory state of a patient with 
atherosclerosis could also influence risk. Therefore, interactions between platelets 
and T cells were examined.  
 
The overall aims of the thesis are: 
1. To understand the reproducibility of the Multiplate assay and the 
different methodological factors that add variance when measuring 
residual platelet reactivity 
2.  To examine the incidence of HOTPR in a NZ ACS population and the 
impact of prasugrel to reduce high on treatment residual platelet 
reactivity.  
3. To investigate the independent clinical predictors of high residual 
platelet reactivity as well as the prevalence and impact of genetic 
variants in the CYP2C19 gene on platelet reactivity. 
4. To examine the relationship between phenotype, genotype and 
predictors of phenotype with MACE and bleeding events in an ACS 
population. 
5.  To investigate the relationship between residual platelet reactivity on 
aspirin as well as the cardiac biomarkers hs-TnT, NT-proBNP and CRP 
with cardiovascular and bleeding outcomes in patients undergoing 
major vascular surgery. 
6. To discern differences in platelet–T cell interactions in patients with 
atherosclerotic vascular disease compared to healthy controls. 
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7. To study the impact of platelet interactions on CD4 T cell differentiation 
and the effect of antiplatelet therapy on platelet – T cell interactions 
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2 Chapter 2 – Measurement of platelet 
reactivity  
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2.1 Introduction 
Several assays are available to measure platelet reactivity that differ in their 
complexity, price and time to deliver results as reviewed in section 1.5.1. We have 
chosen to use the Multiplate in a series of clinical studies to investigate platelet 
reactivity within this thesis. To use this assay clinically we need to understand the 
reproducibility of the measurement and the impact of methodological factors on the 
precision of the assay. There is substantial variation in the Multiplate methodology of 
reported studies to date, and the effect of these methodological variations on the 
reported results is unknown.  
 
Thus, the aims of the study were:  
1. To assess how reproducible the assay is in ADP and Arachadonic Acid 
(AA) stimulated platelets. 
2.  To determine the effect of time delay from sample collection to testing 
on platelet reactivity.  
3. How the choice of anticoagulant effects the measurement of platelet 
reactivity. 
4.  If the use of a manual pipette can improve the analytical precision of 
the assay.  
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2.2 Methods 
2.2.1 Study Population  
Patients presenting to our institution were eligible for inclusion in the study if they 
presented with an ACS, there was an invasive approach (coronary angiography +/- PCI) 
planned and they were adequately pretreated with aspirin and clopidogrel. ACS was 
defined as symptoms suggestive of ischaemia lasting > 10min in duration coupled with 
either a troponin elevation or new 1mm ST segment deviation or T wave inversion in 
at least 2 contiguous leads (289). Adequate pretreatment was defined as chronic 
therapy with aspirin (75mg) and clopidogrel (75mg) or loading with clopidogrel  
300 mg at least 6 hours before or aspirin 300 mg at least 2 hours before enrolment. 
 
Exclusion criteria included a platelet count less than 100 x 109/L, known platelet 
function disorder, administration of a fibrinolytic agent within 24 hours of enrolment 
and administration of a glycoprotein IIb/IIIa receptor antagonist within a week prior 
to enrolment. The study was reviewed and approved by the Upper South A Regional 
Ethics Committee and all patients provided written informed consent 
(URA/11/05/016).  
2.2.2 Blood sampling and platelet function testing 
Blood for platelet function testing was collected from a peripheral vein using a 21-
gauge needle before angiography or collected in the cardiac catheterization 
laboratory from the arterial sheath immediately after insertion and before 
administration of heparin. All samples were collected in tubes containing huridin (25 
μg/ml, Dynabyte, Munich, Germany) and were tested 30 min post collection unless 
otherwise stated. 
 
Residual platelet aggregation in whole blood was assessed with multiple electrode 
impedance aggregometry using the Multiplate analyser (Figure 2-1), following the 
manufacturer’s instructions.  
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Figure 2-1 Multiplate Analyser System 
Images recreated from Multiplate educational material 
http://www.multiplate.net/en/detection.php. 
Whole blood was added directly to the test cuvette (Figure 2.2A) and diluted 1:1 with 
0.9% NaCl solution to give a final volume of 600μL. Inside each test cell is a Teflon 
coated magnetic stirring bar (Figure 2-2A) and samples were stirred for 3 minutes at 
37°C. After stirring 20 μL of 0.2mM ADP (Dynabyte, Munich, Germany) was added to 
the test cell with a final concentration of 6.4mM. The Multiplate automatic pipette, 
which delivers 20-300μL volumes, was used for reagent delivery unless stated 
otherwise. Addition of an agonist stimulates platelets to aggregate to the paired 
electrodes in the test cells and impede the current across them (Figure 2-2B & C).  
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Figure 2-2 Multiplate electrode impedance aggregometry 
Whole blood and saline are added to test cuvette using the automated pipette (A). Paired 
electrodes are present in each test cell and with the addition of platelet agonists, platelets are 
activated and aggregates form on electrodes and impede the current (B). Electron Scanning 
Microscopy image of platelet aggregates on electrode surface (C). Images recreated from 
Multiplate educational material http://www.multiplate.net/en/detection.php.  
The increase of impedance due to the attachment of platelets to the electrodes is 
detected for each sensor unit separately and was continuously recorded for 6 minutes 
(Figure 2-3). The change in impedance is measured over time and the area under the 
curve (AUC) is transformed to arbitrary units and platelet reactivity is expressed in AU. 
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Both pairs of electrodes (Test 1 and 2) are measured and the difference in these tests 
acts as an internal quality check. 
 
Figure 2-3 Aggregation over time in Multiplate test 
Impedance is measured from each electrode pair (Test 1 and Test 2) and aggregation is plotted 
over time. The area under the curve is then converted in to arbitrary units and platelet reactivity 
is expressed as AU.  
2.2.3 Experimental Design 
Using the above platelet function testing protocol and the following changes, we 
tested reproducibility of measurement, effect of different anticoagulants, time 
sensitivity and the use of a manual pipette on variance in the following 4 studies.  
2.2.3.1 Protocol 1 – Analytical Precision 
Blood was drawn from 30 patients and tested using the above Multiplate protocol. In 
addition to ADP stimulation, the reproducibility of Arachidonic acid (AA) stimulation 
was also tested by the addition of 20μL of 15mM stock AA (Dynabyte, Munich, 
Germany) in addition to the standard Multiplate protocol with a final concentration 
of 0.5mM. The coefficient of variation (CV) between each pair of measurements was 
then calculated. 
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2.2.3.2 Protocol 2 – Choice of anticoagulated blood tube 
To determine the effect of different anticoagulants on platelet aggregation, blood 
from 20 patients was collected into tubes containing 3 different anticoagulants; 
hirudin (25 μg/ml, Dynabyte, Munich, Germany), lithium heparin (15 U/ml BD 
Vacutainer, NJ, USA) and sodium citrate (0.109M, BD Vacutainer, NJ, USA). Blood from 
each tube was tested in a 1:1 dilution with 0.9% NaCl. In addition, blood 
anticoagulated with sodium citrate was tested in a 1:1 dilution with 3 mmolL CaCl2/ 
0.9% NaCl solution. 
2.2.3.3 Protocol 3 – Time delay to testing 
To test the effect of time delay between sample collection and Multiplate testing on 
platelet aggregation, blood was drawn from 20 patients and tested using the standard 
Multiplate protocol at the following 6 time intervals post blood sampling: 15, 30, 45, 
60, 120 and 180 minutes.  
2.2.3.4 Protocol 4 – Use of Manual Pipette 
To test the effect of using a manual pipette on the analytical precision of the assay, 
blood was collected from 20 patients into a hirudin tube and tested at 30 minutes in 
two parallel tubes using calibrated manual pipettes. A 1mL pipette was used for NaCl 
and whole blood, and a 100μL pipette for ADP. 
2.2.4 Statistics  
Continuous variables are reported as mean (± standard deviation). Statistical analysis 
was performed using student’s t-test, one-way ANOVA or linear regression where 
appropriate. Statistical significance was taken at 5%. Calculations were performed 
using the GraphPad Prism Software package (GraphPad Software Inc, CA, USA).
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2.3 Results 
2.3.1 Analytical Precision  
The CV for 30 samples anticoagulated with hirudin and analysed using the standard 
Multiplate protocol plus ADP stimulation is shown in Figure 2-4. The mean CV for ADP 
induced platelet aggregation was 10.8% (95% CI, 7.5% - 14.1%). Arachadonic Acid (AA) 
stimulated platelet aggregation was also tested (Figure 2-5) and the mean CV was 11% 
(95% CI, 8.3% – 15.3%). There was no relationship between coefficient of variation 
and level of platelet aggregation with either ADP or AA stimulation.  
 
Figure 2-4 Coefficient of variance (CV) in platelet aggregation using standard 
Multiplate protocol with ADP stimulation.  
The CV was calculated by the standard deviation divided by the mean of the two tests from the 
same patient sample was expressed as CV% and plotted against absolute platelet aggregation 
(AU). There was no correlation between increased variance with the increase in platelet 
aggregation (r2 0.005). Each point represents duplicate patient samples (n=30).   
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 Figure 2-5 Coefficient of variance (CV) in platelet aggregation using 
standard Multiplate protocol with Arachadonic Acid (AA) stimulation. 
The CV was calculated by the standard deviation divided by the mean of the two tests from the 
same patient sample, expressed as CV% and plotted against absolute platelet aggregation 
(AU). There was no correlation between increased variance with the increase in platelet 
aggregation (r2 0.05). Each point represents duplicate patient samples (n=30).   
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2.3.2 Choice of anticoagulant 
The choice of anticoagulant had a marked effect on residual platelet aggregation 
(Figure 2-6). Platelet aggregation was increased in heparin-treated whole blood (52.0 
± 32 AU) when compared to hirudin (36.5 ± 31 AU, P = 0.0015), with an average 
relative increase of 65%. Conversely, platelet aggregation was reduced in blood 
treated with sodium citrate (25.0 ± 21 AU), resulting in an average reduction of 30.6% 
when compared to hirudin (P = 0.003). However, addition of CaCl2 to the citrate-
treated blood restored platelet aggregation (34.0 ± 25 AU, P = 0.45) to levels similar 
to those seen with hirudin anticoagulation.  
 
 
Figure 2-6 Effect of anticoagulant on variance in platelet aggregation. 
Platelet aggregation tested using whole blood collected into tubes containing hirudin, heparin 
and citrate. Citrate-treated blood was tested with and without CaCl2. *P=0.0015, **P=0.0034. 
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2.3.3 Effect of time delay between sampling and testing 
Platelet aggregation was sensitive to the time delay between sampling and analysis 
(Figure 2-7). There was no difference in platelet aggregation at 15 minutes (38.8 ± 29 
AU, P = 0.614) or 45 minutes (37.1 ± 27 AU, P = 0.377) compared to 30 minutes (62.0 
± 35 AU). However, when platelet aggregation at 30 minutes was compared to 60 min 
(34.2 ± 25 AU, P <0.05), 120 minutes (19.8 ± 12 AU, P < 0.001) and 180 minutes (16.7 
± 9 AU, P < 0.001), there was a significant reduction in aggregation, especially the last 
two-time points.  
Figure 2-7 Effect of time delay from collection to assay performance on 
platelet aggregation. 
Platelet aggregation measured in hirudin-treated blood at 15, 30, 45, 60, 120 and 180 minutes 
post sampling. * P < 0.05, **P<0.001. 
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2.3.4 Manual Pipetting  
The CV for 20 samples anticoagulated with hirudin and analysed using the modified 
Multiplate® protocol with a calibrated manual pipette are shown in Figure 2-8. The 
mean CV was 9.2% (95% CI, 6.1 – 12.1) with the use of a manual pipette. This value 
did not differ significantly from the mean CV observed using the Multiplate automated 
pipette (P = 0.55). 
 
Figure 2-8 Coefficient of variance (CV) in platelet aggregation using calibrated 
manual pipette and ADP stimulation 
The CV calculated by the standard deviation divided by the mean of the two tests from the 
same patient sample was expressed as CV% and plotted against absolute platelet reactivity 
(AU). There was no correlation between increased platelet reactivity and variance (r2 0.006). 
Each point represents duplicate patient samples (n=20).    
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2.4 Discussion 
Although there have been studies looking at different pre analytical factors that may 
influence platelet aggregation and the analytical precision of the Multiplate assay, this 
is the first study to bring all of these factors together and evaluate ADP and AA 
dependent platelet aggregation in ACS patients on dual antiplatelet therapy. We have 
found an inter-assay mean coefficient of variation of 10.8% with ADP stimulation and 
11% with AA stimulation using the manufacturers recommended methodology. The 
assessment of platelet aggregation was influenced by time of assessment and the type 
of anticoagulant used. Use of manual rather than automated pipette was not 
associated with a significant decrease in the mean coefficient of variation 
 
Several other studies have reported the CV using the Multiplate system. In groups of 
healthy volunteers coefficients of variation ranging from 3.9% to 14.9% have been 
reported (290-295). Coefficients of variation for the Multiplate system in ACS patients 
on dual antiplatelet therapy of 5.8% and 6.2% were also reported in two of these 
studies (290, 292). However, hirudin was used as the anticoagulant in only one of 
these studies (294), and many studies were performed with a very small number of 
subjects or did not outline their methodology in detail. Our measurement of mean CV 
for ADP at 10.8% and 11% with AA is within the range of previous studies, and has 
been determined from a significantly larger patient group.  
 
It is possible that a small variation in the quantity of ADP delivered, leading to variation 
in the final concentration of ADP within the test cell, contributes to the analytical 
imprecision of the assay. Because the automated pipette in the Multiplate® system 
delivers volumes over a wide range (20 μL to 300 μL), we believed that the use of a 
calibrated 100 μL manual pipette would reduce any variation in delivered ADP.  
However, the use of a manual pipette did not lead to a significant reduction in the CV. 
Thus the analytical precision of the assay is not significantly influenced by the use of 
the 300 μL-automated pipette.  
The agonist AA is relatively unstable and the manufacturer’s guidelines recommend a 
one time thawing and stability for only 24 hours at room temperature. It is possible 
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that a small amount of variation in the analytical precision could be due to the 
decreasing stability of the AA agonist over time. However, the use of this assay was 
tightly controlled and fresh AA was used daily. 
  
The Multiplate records both sets of electrode pairs within the same test cell. This acts 
as an internal quality check (IQC) that the test cell is functioning appropriately and if 
there is a difference of more than 20% between the two tests, the user is asked to 
repeat the measurement. We found that an increase in the IQC did not correlate with 
an increase in the CV for ADP or AA induced platelet reactivity and did not differ when 
measuring different levels of platelet reactivity (data not shown). Many of the other 
platelet function assays do not offer internal quality assessments or visual checks such 
as platelet aggregation tracings to ensure the measurement is acceptable 
 
The Multiplate is a simple relatively inexpensive point of care assay, which has a 
flexible platform to measure several clinically relevant pathways of platelet activation. 
The level of reproducibility of the assay reported here is slightly higher than has been 
reported using VerifyNow (6%) (195), or light transmission aggregometry (LTA) (6.8%) 
(296) which is considered to be the gold standard of platelet function testing but is 
complex and laborious. Despite this level of inter-assay variability, measurement of 
platelet aggregation using the Multiplate assay correlated well with the clinical 
endpoints of increased stent thrombosis and bleeding risk (278) (297). It has also been 
proposed that the Multiplate offers a more physiological representation of platelet 
reactivity in vivo. As the test requires strong interactions between platelets and 
thrombin in whole blood to maintain connections and remain attached to the 
electrodes, this reactivity is closer to the response of platelets seen in the body, such 
as attaching to an injured vascular wall or atherosclerotic plaque. The LTA assay 
requires isolated platelets to aggregate in a liquid phase and the VerifyNow system 
provides fibrinogen-coated beads for platelets to attach to, which is further removed 
from the in vivo setting.  
In this study we found the anticoagulant tube used to collect blood had a significant 
effect on platelet aggregation. Hirudin is the anticoagulant recommended for use with 
the Multiplate analyser by the manufacturer. Hirudin is a direct thrombin inhibitor and 
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has the advantage of allowing analysis of platelet function under physiological calcium 
concentrations. By contrast, anticoagulation with the calcium-chelating agent sodium 
citrate reduces free plasma and cytosolic calcium levels and has been shown to reduce 
platelet activation and aggregation as measured by other methods (298, 299). It is 
therefore not surprising that anticoagulation with sodium citrate in our study reduced 
platelet aggregation by 31% when compared to hirudin and the addition of CaCl2 
resulted in levels of platelet aggregation similar to those seen in hirudin-treated blood. 
Other studies in healthy volunteers have reported similar findings (295, 300). 
Anticoagulation with heparin does not affect calcium concentrations but does cause 
platelet activation (301-304). Consistent with this, treatment with heparin in our study 
resulted in a 65% increase in residual platelet aggregation. Our findings suggest that 
it is important to standardise the anticoagulant used and for the reasons stated above 
we would recommend using hirudin. 
 
For platelet function testing to be effective, the results need to be obtained quickly 
and easily. The Multiplate assay delivers results within 10 minutes and the 
manufacturer recommends testing 30 to 180 minutes post-sampling. In this study we 
found platelet aggregation varied significantly over the 180-minute testing time with 
reduced platelet aggregation at later time points. Therefore the manufacturer’s 
guideline for testing over a period of 180 minutes is not recommended and would 
increase variance in measurement. We would suggest that the assay should be 
performed within 15 to 45 minutes of blood sampling. The mechanisms responsible 
for the change in reactivity over time ex-vivo, are likely be multifactorial and are 
poorly defined at present.  
2.5 Limitations 
To test the CV of ADP and AA induced platelet reactivity we measured 30 patients with 
2 replicates in each person, and 20 measurements with single replicates for the other 
testing parameters. With a sample size of 30 we had modest 95% confidence intervals 
(CI) of 7.5% to 14.1% CV with ADP and 8.3% to 15.3% CV with AA stimulated blood. If 
we had tested more individuals we could have reduced the 95% CI of our calculated 
CVs and increased our confidence in the CV of the assay. However, every test has a 
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consumable cost of approximately $17 so the addition of extra measurements would 
have incurred a much greater cost. A CV of between 7.5% and 14% is acceptable and 
additional features such as the internal quality check makes it practical to use in 
clinical studies. Similarly, with a sample size of 20 we had the power to detect a 
difference of 15% in platelet reactivity between time points and anticoagulant tubes 
at a significance level of 0.05. By increasing the sample size, we could have more 
power to detect a smaller difference between time points or anticoagulant tubes. 
However, this level of power allowed us to determine a time point and anticoagulant 
that can be standardised and therefore reduce some of the variance in the assay.  
 
From this study we could not determine which time point or anticoagulant is the ‘best’ 
or optimal one to use. We can however, pick a time point of 30 minutes and the 
manufacturers guide of hirudin anticoagulated tubes to use in the rest of our studies, 
with a known level of standard error and both are practical for testing in a clinical 
setting.  
2.6 Conclusion 
Pre-analytical and analytical variables affect the assessment of ADP and AA-induced 
platelet aggregation with the Multiplate assay. This study highlights the importance 
of standardising these methodological elements to reduce variation. Therefore, a time 
delay of 30 minutes post sampling, hirudin anticoagulated tubes for blood sampling 
and use of the automated pipette will be standardised throughout the rest of the 
thesis to measure ADP and AA induced platelet aggregation. Despite alternative 
platelet function assays having lower CVs, the Multiplate is more economical, flexible 
and easy to use. These factors along with a moderate CV of 10-11%, provides a 
reasonable system to test platelet reactivity in clinical studies. 
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3 Chapter 3 – Platelet reactivity in 
Acute Coronary Syndromes 
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3.1 Introduction 
Multiple studies have demonstrated a clear association between a suboptimal 
response to clopidogrel and an increased risk of cardiovascular events in patients with 
ACS or undergoing PCI (238, 279). The majority of these studies have been conducted 
in North American and European populations with minor or no inclusion of Maori, 
Pacific Islander or Asian ethnicities. The genetic make up of a NZ ACS population differs 
substantially from international trials, in that it has a considerable portion of Maori 
and Pacific Islanders. Previous studies have suggested that ethnicity has a significant 
impact on the response to clopidogrel (305, 306) and therefore collection of local data 
is important to identify patients at increased risk. 
 
The treatment of HOTPR with subsequent loading doses of clopidogrel or increased 
maintenance doses have been ineffective at significantly lowering residual platelet 
reactivity in a large proportion of the patients treated. New P2Y12 inhibitors such as 
prasugrel have demonstrated a more potent and consistent inhibition of platelets 
than clopidogrel (307). The TRITON-TIMI 38 trial compared clopidogrel to prasugrel in 
ACS patients undergoing PCI and found that use of prasugrel resulted in a reduction 
in ischaemic events but this was at the cost of an increased risk of bleeding [10]. The 
utility of prasugrel in patients with HOTPR has not been examined. There are a number 
of different methodological approaches to assess platelet reactivity including: 
VerifyNow, light transmission aggregometry, VASP and the Multiplate as outlined in 
the previous chapter.  
 
The aims of this study were: 
1. To determine the incidence of HOTPR in a NZ ACS population  
2. To investigate the presence of clinical predictors of HOTPR  
3. To examine the effectiveness of prasugrel in reducing platelet reactivity in 
those patients with HOTPR. 
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3.2 Methods 
3.2.1 Study Population: 
Patients presenting to Wellington Regional Hospital with ACS between October 2010 
and March 2011 were eligible for inclusion in the study if there was an invasive 
approach (coronary angiography ± PCI) planned and they were adequately pretreated 
with aspirin and clopidogrel. An ACS was defined as symptoms suggestive of 
myocardial ischaemia lasting > 10 minutes and either troponin elevation or ≥1mm of 
new ST segment deviation or T wave inversion on an electrocardiogram in at least 2 
contiguous leads. Adequate pretreatment was defined as chronic therapy with aspirin 
(75mg) and clopidogrel (75mg) and / or loading with aspirin 300 mg at least 2 
hours and clopidogrel 300 mg at least 6 hours or prior to enrolment. This time point 
is based on the average time to achieve peak platelet inhibition in patients receiving 
clopidogrel (309). Exclusion criteria included a platelet count less than 100 x 109/L, 
known platelet function disorder, administration of a fibrinolytic agent within 24 
hours of enrolment or administration of a glycoprotein IIb/IIIa receptor antagonist 
within a week prior to enrolment. The study was reviewed and approved by the 
Central Regional Ethics Committee.  
3.2.2 Data Collection 
Patient demographics, clinical characteristics, medications including antiplatelet 
therapy, clinical management, procedural variables and in-hospital outcomes were 
obtained prospectively from review of the medical records and cardiac catheterization 
database. Ethnicity was self-identified by the patient. All aspects of clinical 
management, including prescription of antiplatelet therapy, were at the discretion of 
the attending physicians.  
3.2.3 Blood Collection and Platelet Function testing 
Blood for platelet function testing was collected and testing as described in section 
2.2.2. Patients that were identified as having HOTPR were presented to the consultant 
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cardiologist performing the angiogram and it was their decision whether the patient 
received prasugrel. Contraindications to prasugrel were; weight under 65kg, age over 
75 and renal dysfunction classified as an eGFR<45. Where patients with HOTPR were 
treated with prasugrel a further blood sample for measurement of platelet reactivity 
was taken at least 2 hours post administration of a 60mg loading dose unless a 
glycoprotein IIb/IIIa receptor antagonist had been administered. Cardiac enzymes 
including high sensitivity Troponin T (hs-TnT) and electrocardiograms were routinely 
performed prior to cardiac catheterization and following PCI. 
3.2.4 Definitions 
The clopidogrel dose was defined as “high” if patients had received a 600 mg loading 
dose followed by a 150mg daily maintenance dose. Intermediate dose was defined as 
either a 600 mg loading dose followed by a 75 mg daily maintenance dose or a 300mg-
loading dose coupled with a 150 mg maintenance dose. Low dose was defined as a 
300 mg loading dose followed by a 75mg daily maintenance dose or chronic therapy 
with 75 mg daily of clopidogrel. HOTPR was defined as 47 AU and a cutoff value of 
18 AU was used to define an enhanced response to clopidogrel. These cutoff values 
have been determined from a comparative analysis of the risk for bleeding and stent 
thrombosis across different levels of P2Y12 receptor inhibition (310). A periprocedural 
enzyme rise was defined as an increase in hs-TnT to > three times the upper reference 
limit (>39ng/L) for those with preprocedural hs-TnT levels within the normal range. In 
those with elevated preprocedural hs-TnT that were stable or falling a further 
elevation of hs-TnT >39 ng/L was required. 
3.2.5 Statistical Analysis 
A power calculation was performed based on a total population of 250 patients and 
HOTPR rate of around 33% based on the literature. In a population of 250 ACS patients 
we expected approximately 200 Europeans, 35 Maori and Pacific Islanders and 15 
other ethnicities based on the demographics of our referral population and catchment 
area. The confidence intervals for these populations were 6.52 for Europeans, 15.53 
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for Maori and Pacific Islanders and 23.8 for other ethnicities. Therefore we had the 
power to detect a difference of 20% or more in the rate of HOTPR between Europeans 
and Maori and Pacific Islanders.  
 
Continuous variables are expressed as median and interquartile range (IQR). 
Categorical variables are expressed as frequencies and percentages. We compared 
the proportion of patients with HOTPR by diabetes, ethnicity and dose group using 
Chi-Squared test. Absolute values for residual platelet reactivity (AU) were compared 
by ethnicity, diabetes and dose groups using the Kruskal Wallis test. The relationship 
between body mass index (BMI) and residual platelet reactivity was assessed by 
Spearman’s correlation coefficient (rho). Residual platelet reactivity before and after 
treatment with prasugrel was compared using Wilcoxon Signed rank test. All statistical 
tests were performed using PASW 18.0 (IBM, NY, USA). 
3.3 Results 
3.3.1 Baseline demographics and prevalence of HOTPR 
During the study 250 patients with ACS met the inclusion criteria and were enrolled in 
the study. Their baseline demographics, clinical characteristics and laboratory data are 
shown in Table 3-1. The median age was 62 (54-72) years with 74.8% being male and 
20.8% having diabetes. STEMI was the presentation in 28.4%, NSTEMI in 62.4% and 
unstable angina in 9.2%. The majority identified themselves as European 81.2%, a 
further 14% as Maori or Pacific Islanders and 4.8% as other ethnicities. Platelet 
reactivity was measured in all 250 patients with the Multiplate analyser prior to 
cardiac catherterisation. Of the 250 patients tested, 95 patients (38%) had HOTPR. 
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Table 3-1 Patient baseline demographics, clinical characteristics and 
laboratory data 
 
 N=250 HOTPR  
(N=95) 
NO HOTPR 
(N=155) 
P value 
Age (years) 62 (54-72) 62.0 (55-71) 61.0 (53-72) 0.679 
Male, n (%) 187 (74.8) 73 (76.8) 114 (73.5) 0.560 
BMI 28 (19-56) 29 (26-33) 27 (25-31) 0.066 
Ethnicity, n (%)     
      European 203 (81.2) 71 (74.7) 132 (85.2) 0.041 
Maori and Pacific 
Islander 
35 (14) 20 (21.1) 15 (9.7) 0.019 
      Other 12 (4.8) 4 (4.2) 8 (5.2) 0.649 
Risk Factors, n (%)     
      Hypertension 145 (58.0) 55 (57.9) 90 (58.1) 0.979 
      Dyslipidaemia 137 (54.8) 53 (55.7) 84 (54.2) 0.806 
      Diabetes 52 (20.8) 26 (27.3) 26 (16.7) 0.045 
      Current Smoker 65 (26.0) 27 (28.4) 38 (24.5) 0.494 
Medical History, n (%)     
Previous MI 56 (22.4) 26 (27.4) 30 (19.4) 0.140 
Previous PCI 40 (16.0) 21 (22.1) 19 (12.3) 0.039 
Previous CABG 20 (8.0) 9 (9.5) 11 (7.1) 0.501 
Clinical Presentation, n 
(%) 
    
      STEMI 71 (28.4) 28 (29.5) 43 (27.8) 0.768 
      NSTEMI 156 (62.4) 58 (61.1) 98 (63.2)  0.731 
      Unstable Angina 23 (9.2) 9 (9.5) 14 (9.1) 0.919 
Laboratory data     
      Creatinine (umol/L) 88 (76-102) 89 (77-102) 88(74-102) 0.357 
      Platelet Count 
(109/L) 
220 (187-
267) 
223 (190-
278) 
217 (187-
264) 
0.135 
PPI use, n (%) 
Clopidogrel Dosing 
High  
Intermediate 
Low 
65 (26.0) 
 
41 (16.4) 
55 (22.0) 
154 (61.6) 
22 (23.2) 
 
11 (11.6) 
14 (14.7) 
70 (73.7) 
43 (27.7) 
 
30 (19.4) 
41 (26.5) 
84 (54.2) 
0.423 
 
0.107 
0.30 
0.003 
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3.3.2 Predictors of HOTPR 
To investigate the predictors of HOTPR, baseline demographics, clinical characteristics 
and laboratory data were tested against rates of HOTPR in a univariate analysis. 
Ethnicity, diabetes and clopidogrel dosing were found to be predictors of HOTPR. 
Maori and Pacific Islanders had higher residual platelet reactivity (50 AU (35-70) 
versus 38 AU (250-570), p = 0.014) and a higher rate of HOTPR compared to Europeans 
(57% versus 35.9%, p = 0.013, Table 3-2 and Figure 3-1).  
 
Table 3-2 Patient Ethnicity and platelet reactivity 
 Maori and Polynesian 
(35) 
European (203) P value 
HOTPR (%) 20 (57.0) 71 (35.9) 0.013 
Platelet reactivity (AU) 50 (34 - 77) 38 (25 - 57) 0.014 
 
Figure 3-1 Patient ethnicity and platelet reactivity.  
The rate of HOTPR (A) analysed by chi-square test (p = 0.013) and the absolute levels of 
platelet reactivity (B) analysed by Kruskal Wallis test (p = 0.01) in Maori and Pacific Islanders 
compared to Europeans. The red dotted line represents the 47 AU HOTPR cut-point. Median 
and IQR absolute platelet reactivity are displayed. 
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Patients with diabetes were also found to have higher residual platelet reactivity (43 
AU (29-77) versus 38 AU (25-55), p = 0.029) and higher rates of HOTPR compared to 
non-diabetics (50% versus 34.8%, p = 0.045, Table 3-3 and Figure 3-2).  
Table 3-3 Diabetes and platelet reactivity 
 Diabetic (52) Non-Diabetic (198) P Value 
HOTPR (%) 26 (50.0) 69 (34.8) 0.045 
Platelet reactivity (AU) 43 (29 - 77) 38 (25 - 55) 0.029 
 
Figure 3-2 Diabetes and platelet reactivity 
The rate of HOTPR (A) analysed by chi-square test (p = 0.045) and the absolute levels of 
platelet reactivity (B) analysed by Kruskal Wallis test (p = 0.029) in diabetics and non-diabetics. 
The red dotted line represents the 47 AU HOTPR cut-point. Median and IQR absolute platelet 
reactivity are displayed. 
The rate of diabetes was higher in Maori and Pacific Islanders compared to Europeans 
(38.8% versus 15.3%, p = 0.001). Maori and Pacific Islanders with diabetes also had 
the highest absolute levels of platelet reactivity 75AU (41 – 90) versus European 
diabetics 40 AU (23 – 70), non-diabetic Maori and Pacific Islanders 40 AU (24 – 56) and 
non-diabetic Europeans (38 AU (25 – 54), p = 0.004, Table 3-4, Figure 3-3B). The rates 
of HOTPR displayed a similar trend with the highest in Maori and Pacific Islander 
diabetics (71%), followed by European diabetics (42%), non-diabetic Maori and Pacific 
Islanders (45%) and non-diabetic Europeans (33%, p = 0.03, Table 3-4, Figure 3-3A).  
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Table 3-4 Diabetes, ethnicity and platelet reactivity 
Figure 3-3 Diabetes, ethnicity and platelet reactivity 
The rate of HOTPR (A) analysed by one way ANOVA (p = 0.004) and the absolute levels of 
platelet reactivity (B) analysed by one way ANOVA (p < 0.05) and Kruskal Wallis test *p < 0.05, 
**p < 0.01, *** p < 0.001 in Maori and Pacific Islanders compared to Europeans with and without 
diabetes. The red dotted line represents the 47 AU HOTPR cut-point. Median and IQR absolute 
platelet reactivity are displayed. 
Although all patients were pre-treated with aspirin and clopidogrel, a variety of 
clopidogrel dosing regimens were used with the majority of patients (61.6%) being 
treated with a low dose regimen. To understand the relationship between clopidogrel 
dose and residual platelet reactivity, we compared the rates of HOTPR in patients who 
received low, intermediate, and high dose regimens (Table 3-5). Our findings show 
that patients treated with a low dose regimen had significantly higher rates of HOTPR 
compared to those treated with intermediate or high dose regimens (p = 0.009, Figure 
3-4A). Additionally, the mean residual platelet reactivity decreased with increasing 
clopidogrel dose (p = 0.007, Figure 3-4B). There was no significant correlation between 
BMI and residual platelet reactivity (rho = 0.1, p = 0.1). Mean residual platelet 
reactivity and rates of HOTPR were also not affected by concomitant treatment with 
a proton pump inhibitor or the type of ACS at presentation. 
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Table 3-5 Clopidogrel dose and platelet reactivity 
Figure 3-4 Clopidogrel dose and platelet reactivity.  
The rate of HOTPR (A) analysed by one-way ANOVA (p = 0.009) and the absolute levels of 
platelet reactivity (B) analysed by one-way ANOVA (p = 0.007) in patients receiving low, 
intermediate and high doses of clopidogrel. The red dotted line represents the 47 AU HOTPR 
cut-point. Median and IQR absolute platelet reactivity are displayed. 
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3.3.3 Effectiveness of prasugrel on HOTPR 
Of the 95 patients with HOTPR, 29 patients were treated with prasugrel and 
underwent platelet function testing at least 2 hours after loading with 60mg. The 
remaining 66 patients did not receive prasugrel due to contraindications or because 
they were being medically managed, undergoing CABG, received glycoprotein IIb/IIIa 
inhibitors during their angiogram or the managing clinician chose not to use prasugrel. 
Residual platelet reactivity was lowered markedly by prasugrel treatment (66 AU (56-
77) before versus 23 AU (11-34) after, p < 0.001). Residual platelet reactivity was 
lowered below the HOTPR cut-point in 26 (89.7%) patients. The 3 patients whose 
reactivity remained above the 47 AU cut-point still had a dramatic lowering of residual 
platelet reactivity following prasugrel administration (Figure 3-5). In 10 patients 
(34.5%), treatment with prasugrel resulted in a platelet reactivity level below the cut-
point defining an enhanced response. 
 
Figure 3-5 Platelet reactivity pre and post prasugrel administration 
Platelet reactivity (AU) of patients with HOTPR pre and post 60 mg prasugrel loading. The red 
dotted line represents the 47 AU HOTPR cut point. 
All patients involved in the study underwent coronary angiography. Of these 42 
(16.8%) had minor coronary disease, 99 (39.6%) single vessel disease, 63 (25.2%) 2 
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vessel disease and 46 (18.4%) 3 vessel disease. Sixty-nine patients (27.6%) were 
managed medically, 154 (61.6%) treated with PCI and 27 (10.8%) referred for CABG. 
In-hospital there were no cases of death, stent thrombosis, target vessel 
revascularisation or major bleeding. In the patients undergoing PCI, periprocedural 
enzyme rises occurred in 32 (20.8%), while clinical periprocedural myocardial 
infarction occurred in 7 (2.8%). Periprocedural enzyme elevation occurred in 13 
(26.5%) of those with HOTPR compared to 19 (18.3%) without HOTPR p=0.23.3.4  
3.4 Discussion 
Our study is the first to look at the frequency of HOTPR following treatment with 
clopidogrel in a NZ population. HOTPR was common in our population and importantly 
there was an ethnic disparity with Maori and Pacific Islanders having a much higher 
rate of HOTPR. Diabetes was also associated with higher rates of HOTPR. Although 
treatment with high dose clopidogrel was associated with a reduction in residual 
platelet reactivity, 26% of patients treated with the high dose regimen still had HOTPR. 
To our knowledge this study was the first to examine the effect of prasugrel on platelet 
reactivity in ACS patients with HOTPR. We found that prasugrel therapy in those with 
HOTPR resulted in a consistent and marked further reduction in platelet reactivity 
 
The current study is the first to include Maori and Pacific Islanders in significant 
numbers. Both of these ethnic groups have disproportionately high rates of 
cardiovascular disease and adverse outcomes following cardiovascular events (306). 
The very frequent occurrence of HOTPR despite adequate clopidogrel therapy in this 
group may contribute to their poor outcomes following cardiovascular events and is a 
potential target for intervention with more potent antiplatelet agents. 
 
One contributing factor to the observed high rates of HOTPR in Maori and Pacific 
Islanders may be the increased carriage of loss of function SNPs in the CYP2C19 gene 
[15]. These SNPs have been shown to result in reduced formation of clopidogrel’s 
active metabolite, reduced platelet inhibition and an increased risk of thrombotic 
events following PCI (306). The most frequent and important of these polymorphisms 
is the CYP2C19*2. It has been previously demonstrated that the allele CYP2C19*2 
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occurs more frequently in Maori (24%) compared to NZ Europeans (15%)(230). 
Another polymorphism CYP2C19*3 that results in reduced function also occurs more 
frequently in Maori (1.8%) than Europeans (0.4%)(230). These findings suggest that 
CYP2C19 polymorphisms may be contributing to the phenotypic differences found in 
this study. However, it is likely that multiple genetic and environmental factors play a 
role. Previous studies have suggested that CYP2C19 loss of function polymorphisms 
only account for a small minority of the inter-individual variability in the response to 
clopidogrel therapy found in other populations (236, 309).  
 
Patients with diabetes mellitus are at high risk for recurrent cardiovascular events 
after an ACS (246). Multiple studies have suggested that platelets of diabetic patients 
are larger, hyper-reactive and show increased adhesion and aggregation (250, 255). It 
is therefore not surprising that in our study we observed a higher rate of HOTPR in 
patients with diabetes mellitus. This finding is also consistent with those of a number 
of other studies that have also demonstrated increased rates of HOTPR in diabetic 
patients using different platelet function tests (310-312). The combination of 
increased platelet reactivity and reduced responsiveness to clopidogrel may explain 
the increased benefit seen in randomized trials with more potent antiplatelet agents, 
such as prasugrel and glycoprotein IIb/IIIa inhibitors in diabetic patients (313, 314). 
We also observed that Maori and Pacific Islanders had higher rates of diabetes 
compared to Europeans, which has also been reported in previous studies (315) and 
may be contributing to the ethnicity disparity in the response to clopidogrel. Our 
results noting Maori and Pacific Island diabetics having the highest levels of absolute 
platelet reactivity and HOTPR rates suggests that both ethnicity and diabetes are 
important contributors to platelet reactivity. However, with the small subgroup sizes 
we were underpowered to determine whether these are independent predictors, 
although this trend highlights an interesting question to pursue further.  
Treatment with a high dose clopidogrel regimen resulted in greater platelet inhibition 
and a reduction in the number of patients with HOTPR when compared to a standard 
(low) dose regiment in our study. However, the absolute reduction in platelet 
inhibition achieved with high dose clopidogrel was modest and a considerable portion 
of patients still had HOTPR despite use of a high dose. The ARMYDA-150 mg and 
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GRAVITAS randomized controlled trials compared the effect of high and low 
maintenance dose clopidogrel on platelet inhibition. Consistent with our findings both 
of these studies demonstrated greater platelet inhibition with high dose clopidogrel 
(316, 317). However, use of high dose clopidogrel has had little impact on clinical 
events. In the GRAVITAS study treatment with high dose clopidogrel did not reduce 
adverse events following PCI. The large CURRENT-OASIS 7 study found that short-term 
treatment with a high dose clopidogrel regimen did not result in a reduction in the 
primary end point (cardiovascular death or nonfatal MI) but did find a significant 
reduction in stent thrombosis in those undergoing PCI (318). 
 
This study is also the first to report the effect of prasugrel on platelet function in ACS 
patients treated with aspirin and clopidogrel who have HOTPR. We found that 
prasugrel resulted in a consistent and marked reduction in platelet reactivity in this 
group with an average reduction in residual platelet reactivity of 47 AU. Following 
prasugrel loading, residual platelet reactivity was lowered below the HOTPR cut-point 
in 89.7% of patients. Of note, in 34.5% of patient’s residual platelet reactivity was 
inhibited below the level associated with an increased risk of bleeding. The fact that 
the majority of HOTPR can be overcome by prasugrel suggests that the variability in 
the response to clopidogrel is largely due to variability in active metabolite generation. 
The additional inhibition achieved with prasugrel was of a much greater magnitude 
than that associated with high dose clopidogrel. However, we can not rule out the 
potential for a natural decline in platelet reactivity over time independent of prasugrel 
loading as testing was not repeated on patients that did not receive prasugrel. 
Although the results of high dose clopidogrel to date have been disappointing, the use 
of prasugrel as an alternative agent in patients with HOTPR looks promising and the 
clinical safety and efficacy of this approach is currently being evaluated in clinical 
trials.  
3.5 Limitations 
As the study was observational, the dose of clopidogrel as well as the timing and use 
of prasugrel was at the operator’s discretion rather than systematically determined 
by a protocol. The testing of platelet reactivity was not at a standard time after 
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symptom onset, or after commencement of dual antiplatelet therapy, and differences 
in the level of platelet reactivity over time cannot be excluded. Samples were not 
collected for genetic testing and therefore the role of genetic polymorphism in the 
phenotypic differences observed could not be assessed. Due to the size of the cohort 
and the relatively low proportion of Maori and Pacific Islanders, multivariate analysis 
could not be carried out to determine whether ethnicity, diabetes and clopidogrel 
dose were independent predictors of HOTPR. Finally, this study was not powered to 
look at the effect of HOTPR or prasugrel therapy on clinical events. 
3.6 Conclusion 
This study demonstrates that HOTPR is common in a NZ population and occurs more 
frequently in Maori and Pacific Islanders. The use of high dose clopidogrel resulted in 
a modest reduction in residual platelet reactivity but a suboptimal response 
frequently remained. However, use of prasugrel in those with HOTPR following 
clopidogrel therapy resulted in a consistent and marked reduction in platelet 
reactivity, which was lowered below the threshold associated with ischaemic risk in 
the vast majority. This study highlights further questions that exist surrounding the 
HOTPR phenotype in a NZ ACS population and abroad. Firstly, which predictors of 
HOTPR are independent risk factors and to what extent is HOTPR in Maori and Pacific 
Islanders driven by diabetes and CYP2C19 loss of function carriage. Furthermore, is 
the association between HOTPR and poor outcomes in ACS patients independent of 
diabetes and ethnicity or is it simply a marker of risk. Our findings suggest that HOTPR 
can be overcome with more potent P2Y12 inhibitors, but before interventional studies 
are conducted guided by platelet function testing, a better understanding of this 
complex and multifactorial phenotype is essential for success. 
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4.1 Introduction 
The previous chapter identified several clinical predictors of high residual platelet 
reactivity including ethnicity, diabetes and clopidogrel dose in a NZ ACS population. 
However, we were not able to investigate the impact of the previously described 
CYP2C19 genetic variants on clopidogrel response. The prevalence of the CYP2C19*2 
allele, resulting in a reduced clopidogrel metabolism, has been reported to be more 
common in Maori and Pacific Islanders compared to Europeans (230), although the 
prevalence of this polymorphism is unknown in an NZ ACS population. Furthermore, 
the prevalence of the CYP2C19*17 allele, associated with significantly lower levels of 
ADP-induced platelet reactivity (237), is unknown in a NZ ACS population. It is also 
unknown how these genetic variants impact on residual platelet reactivity and to what 
extent in the presence of other influencing factors such as diabetes and clopidogrel 
dose.  
 
In this chapter the overall aim was to further investigate the clinical predictors of high 
residual platelet reactivity as well as the prevalence and impact of genetic variants in 
the CYP2C19 gene on platelet reactivity. In addition, multivariate analysis was 
conducted to determine whether these predictors were independent of each other 
and determine the most significant drivers of high residual platelet reactivity. 
 
The specific aims of the study were: 
1. To determine the clinical, demographic and laboratory parameters that 
are correlated with high residual platelet reactivity. 
2. To identify the prevalence and impact of the CYP2C19*2 and *17 alleles 
on residual platelet reactivity. 
3. To investigate the relationship between predictors of residual platelet 
reactivity using multivariate analysis.  
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4.2 Methods 
4.2.1 Study Population 
Patients presenting to Wellington Regional Hospital with ACS between January and 
December 2012 were eligible for inclusion in the study if there was an invasive 
approach (coronary angiography ± PCI) planned and they were adequately pre-treated 
with aspirin and clopidogrel. To ensure the necessary statistical power to assess the 
impact of ethnicity we recruited 282 ACS patients (232 Caucasian, 40 Maori and Pacific 
Islanders) and enriched the population with an additional 30 Maori and Pacific 
Islander ACS patients. By enriching the population to have double the Maori and 
Pacific Islander patients compared to the cohort in Chapter 3 we increased our power 
to detect a difference in the rate of HOTPR between ethnicities of 15% or more. An 
ACS was defined as symptoms suggestive of myocardial ischaemia lasting > 10 minutes 
and either troponin elevation or ≥1mm of new ST segment deviation or T wave 
inversion on an electrocardiogram in at least 2 contiguous leads (289). Adequate pre-
treatment was defined as chronic therapy with aspirin (75mg) and clopidogrel 
(75mg) and / or loading with aspirin 300 mg at least 2 hours and clopidogrel 300 
mg at least 6 hours prior to enrolment. Exclusion criteria included a platelet count less 
than 100 x 109/L, known platelet function disorder, administration of a fibrinolytic 
agent within 24 hours of enrolment or administration of an oral antiplatelet agent 
other than aspirin of clopidogrel within 2 weeks enrolment. The study was reviewed 
and approved by the Lower Regional South Ethics Committee (LRS/11/09/035).  
4.2.2 Data Collection 
Patient demographics, clinical characteristics, medications including antiplatelet 
therapy, clinical management and procedural variables were obtained prospectively 
from review of the medical records and cardiac catheterization database. Ethnicity 
was self-identified by the patient. All aspects of clinical management, including 
prescription of antiplatelet therapy was at the discretion of the attending physicians.  
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4.2.3 Blood Collection and Platelet function testing 
Blood for platelet function testing was collected for testing as described in section 
2.2.2. High sensitivity Troponin T (hs-TnT) and electrocardiograms were performed as 
part of clinical practice by cardiac care nurses prior to cardiac catheterization and 
following PCI.  
4.2.4 Isolation of Genomic DNA 
Genomic DNA was extracted from EDTA anticoagulated whole blood using the 
Promega Wizard Genomic DNA Purification Kit (Promega, WI, USA). Following the 
manufacturer’s instructions, 3mL of whole blood was added to 9mL of red cell lysis 
buffer and incubated with rocking for 8 minutes at RT. After incubation, cell 
suspension was centrifuged at 5000 rpm for 5 minutes. Supernatant was discarded 
leaving a white cell pellet, which was washed in excess sodium chloride 0.9%. The 
washed white cell pellet was resuspended in nuclei lysis solution (3mL) before the 
addition of protein precipitation solution (1ml) and vortexed for 30 seconds. Samples 
were centrifuged at 5000 rpm for 5 minutes and the clear supernatant was transferred 
in to a separate tube, avoiding the transfer of cellular debris. 3mL of isopropanol was 
added to supernatant and mixed until DNA precipitated out of solution, evident by 
white threads. Samples were centrifuged for 1 minute at 5000 rpm and the 
supernatant was decanted to leave a DNA pellet. The DNA pellet was carefully washed 
with 3mL of 70% ethanol and the remaining pellet was dried in the 37°C incubator for 
1 hour or until the pellet was clear. Following drying, the pellet was resuspended in 
200μL DNA rehydration solution and placed in the 37°C incubator overnight to 
dissolve. DNA suspension was then stored at 4°C for genetic analysis. 
 
Genotyping of CYP2C19*2 and *17 was performed by Eng Wee Chau and Leon Smyth 
under the supervision of Prof. Martin Kennedy from the University of Otago, 
Christchurch. All DNA samples were normalized to 20-50 ng/µL. However, even after 
normalisation DNA concentrations were found to be quite variable. Subsequent PCR 
analysis was performed with greater caution and, as will be described in the following 
section, ambiguous genotype calls were resolved by various other methods. 
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4.2.5 Validation of CYP2C19*2 and CYP2C19*17 HRM Assays 
All genetic work Both CYP2C19*2 and CYP2C19*17 were genotyped by high-resolution 
melting (HRM) assays. The genotyping assay for CYP2C19*2 was mainly based on a 
method previously published by Temesvári et al. (2011) (319), and was further 
validated in-house. CYP2C19*17 HRM assay was developed and validated on 27 
samples whose -806C>T genotypes were determined via a sequencing method 
described elsewhere in this thesis. 
Figure 4-1 High resolution melting curve assay 
The defining variant for CYP2C19*17, -806C>T located in the promoter region, was genotyped 
by a high-resolution melting assay, where three groups of genotypes were defined by clearly 
distinctive melting profiles: CC (blue), CT (green), and TT (red-brown). 
4.2.6 Genotyping of CYP2C19*2 and CYP2C19*17 
Generally, 10μL PCR reactions were set up and cycled in the Eco Real-Time PCR System 
(Illumina Inc., California, USA). A no-template control was included in every 
genotyping run. For CYP2C19*2, a 100-bp fragment was amplified in the following 
reaction mix: 1X Reaction Buffer B1, 1.5 mM Mg2+, 0.2 mM of each dNTP, 0.2 µM of 
2C19*2 HRM-F, 0.2 µM of 2C19*2 HRM-R, 1.5 mM of SYTO® 9 Green Fluorescent 
Nucleic Acid Stain (Life Technologies, California, USA), and 0.5 U of HOT FIREPol® DNA 
Polymerase (Solis BioDyne, Estonia). The thermal profile consisted of an initial 
activation step of 95 °C for 10 min, then 40 cycles of 95 °C for 10 seconds (s), 54 °C for 
30 s, and 72 °C for 30 s. For CYP2C19*17, a 62-bp fragment was amplified with 1X 
Reaction Buffer B1, 1.5 mM Mg2+, 0.2 mM of each dNTP, 0.2 µM of 2C19*17 HRM LitF, 
0.2 µM of 2C19*17 HRM LongR, 1.5 mM SYTO® 9 Green Fluorescent Nucleic Acid Stain 
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(Life Technologies, California, United States), and 0.5 U of HOT FIREPol® DNA 
Polymerase (Solis BioDyne, Estonia). The cycling conditions were 95 °C for 10 min, 
then 45 cycles of 95 °C for 10 s, 52 °C for 15 s, and 72 °C for 15 s. To generate a HRM 
profile, all PCR products were completely denatured by heating at 95 °C for 15 s, 
allowed to re-anneal at 55 °C for 15 s, and denatured again by gradual heating to 95 
°C, during which fluorescence data was collected every 0.1 °C. Ambiguous genotype 
calls i.e., samples which had an unusual melting curve visually, were resolved by 
Sanger sequencing or restriction digest.  
Table 4-1 Primer Sequences 
Primer name  Primer sequence (5’-3’) 
2C19*17 HRM-F CTTAGATATGCAATAATTTTCCCAC 
2C19*17 HRM-R CTTTCCATAAAAGCAAGGTT 
2C19*17 HRM LitF AAATTTGTGTCTTCTGTTCTCAAA 
2C19*17 HRM LongR TGCCCATCGTGGCGCATTAT 
2C19Ex5F CAACCAGAGCTTGGCATATTG 
2C19Ex5R TGATGCTTACTGGATATTCATGC 
2C19Prom4F GCCCTTAGCACCAAATTCTCT 
2C19Prom4R CACCTTTACCATTTAACCCCC 
 
4.2.7 Restriction Fragment Length Polymorphism (RFLP) and Sanger 
Sequencing 
For RFLP analysis of CYP2C19*2, a 409-bp fragment was amplified in a 10 µL reaction 
containing 1X Reaction Buffer, 1.5 mM Mg2+, 0.2 mM of each dNTP, 0.2 µM of 
2C19Ex5F, 0.2 µM of 2C19Ex5R, and 0.25 U of TAQ-TI Heat-Activated DNA Polymerase 
(Fisher Biotec, Western Australia). The thermal profile consisted of an initial 
denaturation step at 94 °C for 2 min, followed by 35 cycles of 94 °C for 15 s, 56 °C for 
15 s, and 72 °C  for 30 s, and a final elongation step of 72 °C  for 1 min. Restriction 
digest was carried out by directly incubating the PCR mix with 10 U of SmaI (New 
England BioLabs Inc., Massachusetts, USA) at room temperature for two hours. 
Digested PCR products were resolved by 1.5% agarose gel electrophoresis. The 
presence of CYP2C19*2 abolishes SmaI recognition site; as a result the PCR fragment 
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would remain undigested.  A 483-bp fragment encompassing the -806C>T variant was 
similarly amplified with the primer pair 2C19Prom4F and 2C19Prom4R; the reaction 
volume was increased to 20 µL and annealing temperature to 65 °C. The resulting PCR 
products were purified through the AcroPrepTM 384 Filter Plate, Omega 30K (Pall 
Corporation, Michigan, USA), and subsequently Sanger-sequenced using the BigDye® 
Terminator v3.1 Cycle Sequencing Kit as per the manufacturer’s instructions.  
4.2.8 Definitions 
The clopidogrel dose was defined as “high” if patients had received a 600 mg loading 
dose followed by a 150mg daily maintenance dosing. Intermediate dose was defined 
as either a 600 mg loading dose followed by 75 mg daily maintenance dose or a 300mg 
loading dose coupled with 150 mg maintenance dose. Low dose was defined as a 300 
mg loading dose followed by 75mg daily maintenance dose or chronic therapy with 75 
mg daily of clopidogrel. Patients with a platelet count over 300 x 109/L were defined 
as having a high platelet count. Obesity was defined as a BMI ≥ 30 and the 
classification of loss of function (LOF) allele and gain of function (GOF) allele was either 
heterozygous or homozygous for CYP2C19*2 SNP and CYP2C19*17 respectively.  
4.2.9 Statistical analysis 
In the previous study, the continuum of residual platelet reactivity was categorised in 
a binary fashion into HOTPR and non-HOTPR using the cut-point of 47 AU as previously 
described by the Sibbing group (184). This method was used to allow us to identity the 
prevalence of HOTPR in a NZ population and compare the rate with other reported 
studies using the same methods. The limitation with using a defined cut point is you 
lose information and miss potentially important relationships. In this study we wanted 
to further investigate the relationship between clinical and genetic factors with high 
and low residual platelet reactivity. To have the most sensitivity we decided to analyse 
the relationship between these factors with residual platelet reactivity as a continuous 
variable.  
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Continuous variables are expressed as median and interquartile range (IQR). 
Categorical variables are expressed as frequencies and percentages. We compared 
the proportion of Maori and Pacific Islanders or Europeans with diabetes, LOF and 
GOF alleles using the Chi-Squared test. Platelet reactivity distribution did not pass the 
D’Agostino & Pearson omnibus normality test. Therefore all univariate analysis was 
carried out using non-parametric tests. Absolute values for residual platelet reactivity 
(AU) were compared by ethnicity, diabetes, dose groups, high platelet count, obesity 
and LOF and GOF genotypes using the Mann-Whitney test. The relationship between 
age, renal function and residual platelet reactivity was assessed by Spearman’s 
correlation coefficient (rho). To perform parametric multivariate analysis, platelet 
reactivity was log transformed and compared against significant univariate predictors 
of residual platelet reactivity using a multiple linear regression model. Regression 
analysis and Chi-Squared tests were performed using PASW 18.0 (IBM, NY, USA), all 
other analysis and graphs were generated using GraphPad prism 5 (GraphPad 
Software Inc., CA, USA).  
CHAPTER 4 
 
 97 
4.3 Results 
4.3.1 Demographics 
During the study period 312 patients were enrolled in the study. The baseline 
demographics for the population are displayed in Table 4-2. This study cohort had a 
higher proportion of Maori and Pacific Islanders (22.4%) with the additional selected 
recruitment of these patients compared to the study population in Chapter 3, whereas 
all other demographics were comparable. 
Table 4-2 Patient baseline demographics 
 N = 312 
Age (years) 63 (31 – 89) 
Male, n (%) 225 (72) 
BMI 28 (17 - 50) 
Ethnicity, n (%)  
European 232 (74.3) 
Maori and Pacific Islander 70 (22.4) 
Other 10 (3.2) 
Risk Factors, n (%)  
Hypertension 213 (68) 
Dyslipidaemia 209 (66.9) 
Diabetes 79 (25.3) 
Current Smoker 60 (19.2) 
Medical History, n (%)  
Previous MI 93 (29.8) 
Previous PCI 52 (16.6) 
Previous CABG 21 (6.7) 
Clinical Presentation, n (%)  
STEMI 58 (18.5) 
NSTEMI 239 (76.6) 
Unstable Angina 15 (4.8) 
Laboratory data  
Creatinine (umol/L) 84 (51 – 1058) 
Platelet Count (109/L) 220 (109 – 626) 
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4.3.2 Predictors of platelet reactivity 
To investigate the impact of different predictors on platelet reactivity, demographics, 
clinical characteristics and laboratory data were tested against absolute levels of 
platelet reactivity in univariate analysis. Patients with diabetes had significantly higher 
levels of platelet reactivity compared to non-diabetics (44 AU (4 – 140) vs. 34 AU (4 – 
148), p = 0.002, Figure 4-2A. Platelet reactivity was also compared between patients 
that received different doses of clopidogrel. As with the last cohort there was 
significant variance in the dose of clopidogrel that patients were allocated, with 50% 
of patients receiving low dose clopidogrel, 22% on a medium dose and 28% on a high 
dose. Patients receiving low doses of clopidogrel had significantly higher levels of 
platelet reactivity compared to the medium or high dose patients (43 AU (6-143) vs. 
31 AU (6-140), p = 0.013, and 31 AU (4 – 104), p = 0.002, Figure 4-2B). There was no 
difference in platelet reactivity between medium and high dose patient groups.  
 
Platelet count was measured in all patients, and patients with a high platelet count 
had a level of platelet reactivity 1.8 times higher than patients with a normal platelet 
count (53 AU (6 – 148) vs. 34 AU (4 – 104), p = 0.001, Figure 4-2C). Similarly, patients 
who were obese as defined by a BMI ≥ 30, had significantly higher levels of platelet 
reactivity compared to patients with a BMI < 30 (40 AU (4 – 148) vs. 33 (4 – 141), p = 
0.01, Figure 4-2D) 
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Figure 4-2 Clinical predictors of platelet reactivity 
Absolute levels of platelet reactivity (AU) as measured by the Multiplate in patients with diabetes 
and no diabetes (A), by clopidogrel dose group including low, medium and high doses (B). 
Platelet reactivity was also compared by high platelet count (>300 x 109/L) vs. normal platelet 
count (<300 x 109/L) (C) and by BMI (D). Data presented as Median and IQR, analysed using 
the Mann-Whitney test. * p <0.05, **p < 0.01.  
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The impact of the SNPs CYP2C19*2 and CYP2C19*17 on platelet reactivity was also 
investigated. The prevalence of CYP2C19*2 was high in the cohort with 32% (100) of 
patients having at least 1 of the loss of function (LOF) allele, 28.5% (89) were 
heterozygous for the LOF allele and 3.5% (11) were homozygous for the LOF allele. 
The carriage of at least one LOF allele (Figure 4-3A) resulted in 1.3 times higher levels 
of platelet reactivity compared to wild type (w/t) (44 AU (6 – 126) vs. 33 (4 – 148), p = 
0.02). However, when the different genotypes were separated (Figure 4-3B), the 
highest levels of platelet reactivity were seen in LOF homozygotes (*2/*2) and were 
significantly higher compared to w/t (59 AU (20 – 126) vs. 33 AU (4 -148), p 0.03). The 
heterozygotes had a numerically higher level of platelet reactivity (43 AU (6 – 109), 
but this was not significantly different to w/t (33 Au (4-148), p = 0.07) or homozygotes 
(59 AU (20 – 126), p = 0.2). 
 
Figure 4-3 CYP2C19*2 loss of function allele (LOF) and platelet reactivity 
Absolute level of platelet reactivity (AU) as measured by Multiplate, in patients wild type (w/t) 
and at least 1 loss of function (LOF) allele (A). Platelet reactivity was also compared between 
the different CYP2C19*2 genotypes, 1*/1* - wild type, 1*/2* heterozygote and *2/*2 homozygote 
(B). Data presented as Median and IQR, analysed using the Mann-Whitney test.  *p < 0.05, **p 
<0.01.  
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The gain of function SNP CYP2C19*17 was also identified in patients and the levels of 
platelet reactivity were compared between genotypes. The prevalence of 
CYP2C19*17 was also high in the cohort with 34% (106) of patients having at least 1 
of the gain of function (GOF) allele, 30.4% (95) were heterozygous for the GOF allele 
and 3.5% (11) were homozygous for the GOF allele. The carriage of at least 1 GOF 
allele did not have any noticeable impact on platelet reactivity levels (Figure 4-4A, 33 
AU (4 – 141) vs. 36 AU (4 – 148), p = 0.3). Furthermore, analysis of the different 
genotypes (Figure 4-4B) also displays little difference between wild type, 
heterozygous and homozygote genotypes on platelet reactivity (36 AU (4 – 148), 36 
AU (6 – 140), 31 (4 – 141), p = 0.47).    
 
Figure 4-4 CYP2C19*17 Gain of Function (GOF) allele and platelet reactivity 
Absolute level of platelet reactivity (AU) as measured by the Multiplate, in patients wild type 
(w/t) and at least 1 gain of function (GOF) allele (A). Platelet reactivity was also compared by 
CYP2C19*17 genotype, 1*/1* - wild type, 1*/17* heterozygote and *17/*17 homozygote (B) 
Data presented as Median and IQR, analysed using the Mann-Whitney test 
The level of platelet reactivity was not significantly different between ethnicities 
(Figure 4-5A), although numerically Maori and Pacific Islanders had slightly higher 
levels of platelet reactivity compared to Europeans (38 AU (4 – 145) vs. 34 AU (4 – 
141), p = 0.14). Of note, Maori and Pacific Islanders had both higher rates of diabetes 
(35.7% vs. 21.5%, p = 0.032, Figure 4-5B) and a higher prevalence of the CYP2C19*2 
LOF allele (47% vs. 26%, p = 0.001, Figure 4-5C) compared to Europeans. Interestingly, 
Maori and Pacific Islanders also had a significantly lower prevalence of the 
CYP2C19*17 GOF allele (11.4% vs. 41.2%, p = 0.0001, Figure 4-5D) compared to 
Europeans.  
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Figure 4-5 Ethnicity and platelet reactivity 
Absolute levels of platelet reactivity (AU) as measured by the Multiplate in European and Maori 
and Pacific Island patients (A). Data presented as medians and IQR. The rate of patients with 
diabetes (B) and the proportion of patients positive for the LOF allele (C) and GOF allele (D) in 
European vs. Maori and Pacific Islander ethnicities, proportion of population (%) shown for 
each. Analysis performed by student t test. * p < 0.05, ** p < 0.01, ***p < 0.001.  
There was no significant correlation between age (rho = 0.002, p = 0.2) or renal 
function (rho = 0.0001, p = 0.8) as measured by creatinine level and residual platelet 
reactivity. Mean residual platelet reactivity was also not affected by concomitant 
treatment with a proton pump inhibitor or the type of ACS at presentation. There 
were no clinical, demographic or laboratory variables such as renal function, age and 
sex, that significantly correlated with low levels of platelet reactivity in this cohort. 
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4.3.3 Multivariate analysis of platelet reactivity predictors 
To test whether predictors that were found to be significant indicators of high levels 
of platelet reactivity in univariate analysis were independent predictors, multivariate 
linear regression analysis was performed on the following variables: obesity, diabetes, 
high platelet count, LOF allele carriage and clopidogrel low dose (Table 4-3). The 
model suggested these variables accounted for 11% (adjusted R2 0.110) of the 
variance in platelet reactivity. Of these variables, diabetes, high platelet count and low 
clopidogrel dose were found to be independent predictors of high platelet reactivity. 
Obesity and LOF allele carriage did not independently predict platelet reactivity. High 
platelet count had the greatest impact on platelet reactivity with a β coefficient of 
0.151 ± 0.05 (p = 0.002), followed by diabetes 0.094 ± 0.03 (p = 0.009) and clopidogrel 
low dose 0.084 ± 0.03 (p = 0.006). 
 
Table 4-3 Multivariate Linear Regression Coefficients  
Variable Coefficient (β) Std. Error Standardized β p Value 
Intercept 1.588 0.05  0.0001 
Obesity 0.043 0.03 0.075 0.179 
Diabetes 0.094 0.03 0.145 0.009 
High platelet count 0.151 0.05 0.172 0.002 
LOF allele carriage 0.051 0.03 0.084 0.126 
Clopidogrel low dose 0.084 0.03 0.152 0.006 
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4.4 Discussion 
This study sought to further investigate the complex nature of residual platelet 
reactivity in ACS patients and the different clinical, demographic, genetic and 
laboratory parameters that influence platelet reactivity. Of the different parameters 
that were collected, diabetes, clopidogrel dose, high platelet count, obesity and 
carriage of the LOF allele were all correlated with high residual platelet reactivity in 
univariate analysis. The prevalence of both the LOF allele and GOF allele was high in 
the NZ ACS population, with particularly high rates of CYP2C19*2 in Maori and Pacific 
Islanders. In multivariate analysis, only diabetes, high platelet count and clopidogrel 
dose were independently associated with higher levels of residual platelet reactivity. 
 
As described in the previous chapter, diabetes is a state of increased platelet activity 
and aggregation and in this cohort; diabetes continues to be a strong predictor of high 
residual platelet reactivity. The presence of diabetes resulted in a 3-fold increase in 
platelet reactivity compared to patients without diabetes. In this cohort we were able 
to perform multivariate analysis and determined that diabetes is an independent and 
significant risk factor for high platelet reactivity. Other studies have also found 
absolute platelet reactivity levels to be higher and the rate of non-responders to be 
more common in patients with diabetes (310, 320, 321). Previous studies have 
demonstrated that platelets are hyper-reactive in patients with diabetes and result in 
a poor response to P2Y12 inhibitors. Proposed mechanisms include: increased 
glycation of platelet membrane proteins, which may alter P2Y12 functioning; 
overexpression of platelet integrins, such as glycoprotein IIb/IIIa; disturbed calcium 
homeostasis and enhanced inflammatory status (322, 323). Some studies propose 
that high platelet reactivity can be attributed to a higher BMI in diabetic patients (326). 
However our data demonstrates diabetes as a risk factor independent of BMI. 
 
Furthermore, as observed in the previous cohort, clopidogrel dose was a significant 
independent predictor of high platelet reactivity and the administration of low doses 
correlated with significant increases in platelet reactivity. The administration of 
medium or high doses of clopidogrel resulted in a modest decrease in platelet 
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reactivity compared to low doses. Although there was no difference between medium 
and high doses suggesting a threshold of platelet inhibition that clopidogrel can 
achieve. 
 
The factor that had the greatest impact on high residual platelet reactivity in the 
multivariate model was a high platelet count. This was not identified as a significant 
contributor to platelet reactivity in the previous cohort but high platelet count has 
been reported in earlier studies to correlate with high residual platelet reactivity 
(236). There may be several reasons as to why higher platelet counts are contributing 
to higher levels of platelet reactivity. It is reasonable to argue that increases in platelet 
numbers and therefore an increase in P2Y12 receptor targets, would lead to higher 
rates of residual platelet reactivity due to the consequential insufficient dose of 
clopidogrel. Other studies have also hypothesized that an increase in platelet turnover 
can contribute to higher levels of residual platelet reactivity (325, 326). A high platelet 
turnover is often observed in ACS when platelets are being consumed by thrombus 
and is associated with a high platelet count, which results in an increase in a 
population of immature reticulated platelets (329). Reticulated platelets represent 
younger, more hyperactive platelets, with an increased volume and greater number 
of dense granules than older circulating platelets (328). They also have a greater 
prothrombotic potential; they aggregate more rapidly with collagen and have higher 
levels of intracellular thromboxane A2 as well as expression of P-selectin and GpIIb/IIIa 
(329, 330). These factors combined may reduce the ability of antiplatelet therapies to 
effectively inhibit aggregation and result in higher levels of residual platelet reactivity. 
Lastly, it has been found that low platelet count can influence Multiplate testing 
independent of platelet function, but this has not been the case for high platelet count 
(331) (332). Further investigation is required to determine if high platelet count is a 
risk factor for high residual platelet reactivity, independent of the platelet function 
assay being used. 
 
One of the central findings in this study is the high prevalence of the CYP2C19*2 LOF 
allele displayed in a NZ ACS population and the significant difference in expression 
between ethnicities. The presence of at least 1 LOF allele was also a significant 
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univariate predictor of high residual platelet reactivity, which was largely driven by 
the high platelet reactivity levels found in patients homozygous for the CYP2C19*2 
polymorphism. Studies conducted in the general NZ population have shown a higher 
prevalence of *2 alleles at 24% in Maori and Pacific Islanders compared to NZ 
Europeans at 13% (229, 333). However, our study in ACS patients found a much higher 
prevalence of the CYP2C19*2 LOF compared to previous findings, with 32% of the 
overall population and 47% of Maori and Pacific Islanders positive for the allele. Other 
studies have found significant differences in the reported rate of CYP2C19 
polymorphisms in the same race (227). For example, in two studies of Caucasian 
ethnicity, CYP2C19*3 frequency was reported at 0 and 6.5% (334, 335) and in two 
studies of African American ethnicity, CYP2C19*2 frequency was reported at 18 and 
25% (336). These differences are most likely due to the effect of low sample numbers 
on reported rates. This may also explain the discrepancy between our reported rate 
of LOF allele carriage in Maori and Pacific Islanders and that reported by Lea et al. 
(230) who also had a small cohort size of 60 Maori and Pacific Islanders. This is not the 
first study to find differences in the rate of CYP2C19 polymorphisms between 
ethnicities. However, in comparison Maori and Pacific Islanders have a high 
prevalence of the CYP2C19*2 LOF allele. A cumulative meta-analysis comparing the 
frequency of the CYP2C19 polymorphisms found African American, American and 
Europeans have the lowest average prevalence of CYP2C19*2 at 15%, followed by East 
Asian at 29% and South/central Asian at 35% (227).  
 
Reduced clopidogrel response in CYP2C19*2 carriers has been established from 
pharmocokinetic and pharmodynamic studies, which lead to the FDA black box 
warning to prescribe clopidogrel based on CYP2C19 genotype (337). The impact of 
CYP2C19*2 carriage on MACE risk is debatable in the literature with some meta-
analyses reporting an increase in cardiovascular risk, particularly stent thrombosis in 
patients undergoing percutaneous coronary intervention (PCI) (232, 233). However 
other studies have directly challenged this link and report a marginal increase in MACE 
for patients with the LOF allele (234, 235). The reported inconsistencies linking 
CYP2C19*2 and MACE are most likely due to the small influence (5-12%) the LOF allele 
has on the variability in clopidogrel response (236). In addition, our study found the 
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LOF allele was not an independent predictor of high residual platelet reactivity and is 
not significantly contributing to the variability seen in platelet reactivity in this ACS 
cohort. As discussed in section 1.4.11, genetic polymorphisms also affect other genes 
that are central to active clopidogrel metabolite production and a combination of 
these polymorphisms may have significant influence on residual platelet reactivity 
beyond CYP2C19*2. 
 
The gain of function (GOF) CYP2C19*17 polymorphism has been associated with 
significantly lower levels of ADP-induced platelet aggregation or Low on treatment 
platelet reactivity (LOWPR) in previous studies (237). In contrast, our study 
demonstrated no meaningful change in platelet reactivity between patients who were 
wild type, heterozygotes or homozygotes for the *17 polymorphism. However, we did 
find a significant difference in GOF allele prevalence between ethnicities. The carriage 
of the GOF allele has been reported to be more prevalent in Caucasians (21%) 
compared to other ethnicities (228) and our study further supports this with an even 
higher rate at 41% of Europeans positive for the GOF allele. Our study is also the first 
to report the prevalence of the CYP2C19*17 polymorphism in Maori and Pacific 
Islanders which was found to be significantly lower than Europeans at 11%. This rate 
is similar to what is seen in African American populations (16%) and higher than 
reports from Asian populations (4%) (228). 
 
LOWPR or hyper-response to clopidogrel measured by platelet function assays have 
been linked to increased major bleeding in both PCI treated patients and those going 
on to cardiac surgery (338-340). There has also been enhanced interest in using 
platelet function testing to guide antiplatelet therapy treatment particularly before 
CABG surgery as a number of studies have shown LOWPR to be predictive of an 
increased transfusion requirement post-surgery (341, 342). A consensus regarding the 
impact of the GOF allele on platelet reactivity and clinical outcomes has yet to be 
reached and our findings would suggest the GOF allele does not impact residual 
platelet reactivity significantly. Interestingly, we also did not encounter any other 
clinical or demographic parameter that was significantly correlated with lower levels 
of residual platelet reactivity. 
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In this cohort we did not find a significant difference in residual platelet reactivity 
between ethnicities. This finding is surprising given our results from the previous 
chapter, showing a significant increase in HOTPR in Maori and Pacific Islanders. This 
finding was also one of the key drivers to explore the HOTPR phenotype further and 
was one of the reasons to selectively recruit a larger proportion of Maori and Pacific 
Islanders. Furthermore, Maori and Pacific Islanders did have significantly higher rates 
of diabetes and the LOF allele, which were both correlated with higher levels of 
platelet reactivity. However, a small trend of increased platelet reactivity was 
demonstrated in this cohort and this finding in a larger group of participants suggest 
that ethnic differences are only having a minor influence on platelet reactivity. Maori 
and Pacific Islanders are a high-risk population with considerably poor cardiovascular 
outcomes compared to the general population. Further investigation into the factors 
contributing to cardiovascular risk is essential to tackling the health inequalities seen 
in these ethnicities. 
 
The finding that only a small percentage of the variability in platelet reactivity can be 
attributed to diabetes, clopidogrel dose and platelet count, indicates there still 
remains unidentified factors that are having a significant impact on platelet reactivity 
and highlights the complexity of this phenotype. One potential factor that will 
undoubtedly be having a large influence on platelet reactivity is the heightened 
inflammatory state and abundance of platelet activating factors that are released 
during an ACS. By measuring platelet function during this time, the background noise 
of inflammation may be overshadowing the impact of other predictors on residual 
platelet reactivity, particularly those that remain in a constant state such as genetic 
polymorphisms. Diabetes and platelet count are known to be dynamic factors that 
respond to changes in inflammation and oxidative stress and may track with ACS 
progression and resolution. This may explain why diabetes and platelet count are the 
most significant predictors of residual platelet reactivity in our ACS cohort.  
 
The optimal time to measure platelet function is at the centre of significant debate 
and an important issue when considering personalising antiplatelet therapy based on 
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platelet function assays. Some studies have suggested that platelet function testing at 
the time of an ACS is an unreliable predictor of the antiplatelet response during 
maintenance therapy (343). This finding again highlights the dynamic nature of 
platelet reactivity and suggests clinical factors that are influencing residual platelet 
reactivity at the time of infarct, may not be the same factors or impacting to the same 
degree on platelet reactivity during maintenance therapy. However, it is also 
important to point out that the key purpose of platelet function testing is to identify 
patients at increased risk, both ischaemic and bleeding risk. This risk is highest directly 
after an ACS (343) and potentially the most benefit from altering antiplatelet therapy 
is in this early period. Therefore, it is important to investigate platelet function as well 
as other clinical and genetic factors and determine which variables or combination of 
variables is the most predictive of ischaemic and bleeding outcomes.  
4.5 Limitations 
As the study was observational, the dose and loading time of clopidogrel was at the 
operator’s discretion rather than systematically determined by a protocol. The testing 
of platelet reactivity was not at a standard time after symptom onset, or after 
commencement of dual antiplatelet therapy, and differences in the level of platelet 
reactivity over time cannot be excluded. However, all blood samples were taken 
before angiography and no longer than 7 days post admission to limit this variance. 
The inclusion/exclusion criteria were also designed to ensure all patients would 
experience the maximal effect from antiplatelet therapy at the time of testing.  
4.6 Conclusion 
This study highlights the complex nature of residual platelet reactivity during an ACS, 
with many components influencing the response to clopidogrel. Diabetes, high 
platelet count and clopidogrel dose were all significant and independent predictors of 
high residual platelet reactivity. However, only a small percentage of the variability in 
platelet reactivity could be attributed to these predictors suggesting unidentified 
factors are having considerable influence on residual platelet reactivity. The large 
inter-individual variability in the response to clopidogrel can be considered as a matter 
of systems pharmacology rather than a phenomenon determined by a single-gene or 
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clinical factor, and prediction of an individual’s response to clopidogrel may require 
integration of information on genetics and clinical variables, both captured in an 
individual’s on-treatment platelet reactivity status. Furthermore, determining the 
ability of this phenotype to predict patient risk, potentially integrated with other 
patient parameters, is central to progressing platelet function testing as a viable 
clinical tool.  
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5 Chapter 5: Platelet reactivity and 
outcomes in Acute Coronary 
Syndromes 
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5.1 Introduction 
In the preceding chapter we demonstrated that several clinical factors contributed to 
the observed variability in residual platelet reactivity. In particular, diabetes, high 
platelet count and a low clopidogrel dose were all significant independent predictors 
of high residual platelet reactivity while the CYP2C19*2 genotype had only a minor 
impact on the platelet reactivity phenotype. Previous studies have demonstrated 
separately that the HOTPR phenotype (344) or LOF genotype (232, 233) are associated 
with an increased risk of major adverse cardiovascular (MACE) events in various CAD 
populations. However, outcome studies in these populations have not demonstrated 
whether the increased risk attributed to either phenotype or genotype are 
independent of each other. Furthermore, it has not been investigated whether the 
HOTPR phenotype predicts MACE risk independently of important clinical risk factors 
such as diabetes, which we know contributes to high residual platelet reactivity.  
 
Therefore the aims of this chapter were: 
1. To investigate the relationship between phenotype, genotype and 
predictors of phenotype with MACE and bleeding events in an ACS 
population and whether these various predictors were independent of 
one another.  
2. In addition to investigating risk in an ACS population, to also explore 
the relationship between platelet reactivity and risk in the patients 
undergoing PCI, as this population may benefit the most from 
personalized antiplatelet therapy. 
5.2 Methods 
5.2.1 Study population 
From the recruited cohort in Chapter 4, 294 (95%) of the patients had completed 
follow up to 1 year. Of the remaining 18 patients, 10 patients had medical documents 
that could not be accessed and 8 patients were unreachable by phone. 
CHAPTER 5 
 
 113 
5.2.2 Data collection 
Patient demographics, clinical characteristics, medications including antiplatelet 
therapy, clinical management and procedural variables were obtained prospectively 
from review of the medical records and cardiac catheterisation database. Cardiology 
registrars at Wellington Hospital collected procedural variables and in-hospital 
outcomes. The cardiology research nurses collected follow-up data with telephone 
calls at 30 days and 1 year. Where necessary, a review of case notes was performed 
and the appropriate general practitioner contacted to further classify clinical 
outcomes. 
5.2.3 Platelet function testing and Genotyping 
Blood for platelet function testing was collected for testing as described in section 
2.2.2. Genotyping for of CYP2C19*2 and CYP2C19*17 were performed on isolated 
genomic DNA using the RFLP and sanger sequencing techniques as described in 
section 4.2.7.  
5.2.4 End points and definitions 
The primary endpoint was a composite of major adverse cardiovascular events 
(MACE) including death, nonfatal myocardial infarction, nonfatal ischaemic stroke and 
stent thrombosis.  
5.2.4.1 Major adverse cardiac event (MACE)  
Death encompassed all-cause mortality including cardiovascular death. Acute MI was 
defined using the third universal definition of myocardial infarction (289). This 
included the detection of a significant hs-TnT rise and the presence of symptoms 
suggestive of myocardial ischaemia, new or presumed new ST-segment-T wave 
changes or new LBBB, development of new pathological Q waves, or imaging showing 
new myocardial loss. Evaluation of definite stent thrombosis was performed according 
to the Academic Research Consortium criteria (345). Acute ischaemic cerebrovascular 
accident (CVA) was defined as signs of CVA confirmed with imaging studies.  
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5.2.4.2 Bleeding 
The Bleeding Academic Research Consortium Definition for Bleeding (BARC) (346) was 
used to define bleeding. Major bleeding was determined as fatal bleeding or BARC 
type 3 or type 4 CABG bleeds. Minor bleeding included BARC type 2 bleeds.  
Type 4 CABG-related bleeds include perioperative intracranial bleeding, reoperation 
for bleeding after closure of sternotomy, transfusion of ≥ 5 U of whole blood or packed 
red blood cells within 48 hour period and a chest tube output ≥ 2 L within a 24 hour 
period. Type 3 bleeds include any overt bleeding with the need for transfusion or a 
drop in hemoglobin of more than 30 g/L due to the bleed. Cardiac tamponade, 
bleeding requiring surgical intervention, bleeding requiring intravenous vasoactive 
agents, intracranial hemorrhage or intraocular bleeds are also included. 
Type 2 bleeds are any overt bleeding events that do not fit the criteria for type 3 or 4 
but still require either nonsurgical, medical intervention by a healthcare professional 
or hospitalisation.  
5.2.4.3 Hospital readmission 
All hospital readmissions were noted and notes were called on each visit to further 
classify events. 
5.2.5 Statistics 
Categorical variables are expressed as frequencies and percentages. Univariate 
analysis of demographic and biomarker variables as categories with outcome data was 
performed using Chi-Squared tests. Multivariate analysis of significant univariate 
predictors of outcome was performed using a multinominal logistic regression 
analysis. Cut-points derived from ROC curve analysis was determined as the multiplate 
AU value with the highest sensitivity and highest specificity-1. Regression analysis, Chi-
Squared tests and ROC curve analysis were performed using PASW 18.0 (IBM, NY, 
USA), all other analysis and graphs were generated using GraphPad prism 5 (GraphPad 
Software Inc., CA, USA). 
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5.3 Results 
All patients in the study underwent coronary angiography and their management is 
summarised in Table 5-1. Radial access was the predominant route of access used in 
79% of cases. PCI was performed in 53.8% of patients at the time of their index 
angiogram and the remaining patients being either medically managed (34%) or 
referred for CABG (12.2%).  
Table 5-1 Coronary angiogram procedure variables  
 N=294 
Underwent coronary angiography 294 (100) 
Radial access 234 (79) 
Stenosis >50% in ≥1 coronary artery 255 (86.7%) 
Management  
Medical Management 100 (34) 
PCI 158 (53.8) 
CABG 36 (12.2) 
5.3.1 Patient outcome 
At 1 year follow up, 31 patients (10.5%) experienced MACE. This included 10 deaths 
(3.4%), of which 9 were identified to be due to cardiovascular causes and 1 due to 
cancer. Nonfatal myocardial infarction occurred in 17 patients (5.8%) and ischaemic 
CVA in 6 (2%) patients. The rate of stent thrombosis was relatively low, occurring in 4 
patients (1.4%) during the follow-up period.  
 
Bleeding (≥ BARC 2) occurred in 40 patients (13.6%) at 1 year follow up. There were 9 
major bleeds (3.0%) made up of 5 BARC type 3 (1.7%) and 4 BARC type 4 CABG 
bleeding (1.4%). The remaining 31 patients (10.5%) had minor bleeds classified as 
BARC type 2 bleeds. Of note, 14 of the non-CABG bleeds were related to coronary 
angiogram access site complications. 
 
A further 83 patients were readmitted to hospital who did not experience MACE or 
bleeding (28.2%). Of interest, 12 patients were admitted with unstable angina (4.0%) 
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and 5 of these patients underwent revascularization (1.7%). A further 7 patients were 
admitted with congestive heart failure (2.4%).  
5.3.2 ROC curve analysis of residual platelet reactivity and outcome 
To assess the predictive value of residual platelet reactivity to identify patients at 
increased risk of MACE and bleeding, ROC curve analysis was conducted. Residual 
platelet reactivity was found to be a moderate predictor of MACE with an area under 
the curve of 0.631 (0.542 – 0.744) (Figure 5-1). The ROC curve demonstrated the lack 
of a single cut-point that was predictive of MACE risk, including the previously 
established 47 AU. A cut point of 35 AU for HOTPR was derived from the platelet 
reactivity value with the highest sensitivity and smallest loss of specificity (Table 5-2), 
which has a sensitivity of 0.710 and specificity of 0.51.  
 
Figure 5-1 ROC curve analysis of residual platelet reactivity and MACE  
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Table 5-2 ROC curve coordinates 
MEA value  Sensitivity  Specificity 
31 0.743 0.463 
32 0.743 0.482 
33 0.743 0.494 
34 0.743 0.514 
35 0.743 0.529 
36 0.686 0.553 
37 0.686 0.560 
38 0.657 0.572 
39 0.657 0.576 
40 0.657 0.591 
41 0.657 0.599 
43 0.629 0.623 
45 0.600 0.646 
46 0.543 0.661 
47 0.514 0.677 
 
With the new HOTPR cut-point of 35 AU, an additional 42 patients were included in 
the HOTPR group compared to categorizing using the 47 AU cut-point (Figure 5-2). 
This change resulted in a HOTPR rate of 51.7% compared to 37.5% with the previous 
classification.  
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Figure 5-2 Residual platelet reactivity and HOTPR cut-points 
Residual platelet reactivity as measured by the Multiplate (AU) plotted for each patient. The 
blue dotted line represents the 47 AU HOTPR cut-point as described by Sibbing et al (310). 
The red dotted line represents the 35 AU HOTPR derived from ROC curve analysis in this 
study.  
In ROC curve analysis of major bleeding (Figure 5-3) there was no relationship 
between residual platelet reactivity and outcome with an area under the curve of 
0.492. ROC curve analysis was then performed with all bleeding as the outcome 
(Figure 5-4) and no relationship was observed between residual platelet reactivity and 
bleeding The area under the curve was 0.499 indicating residual platelet reactivity is 
not a significant predictor of bleeding, major or minor.  
 
Figure 5-3 ROC curve analysis of residual platelet reactivity and major bleeding 
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Figure 5-4 ROC curve analysis of residual platelet reactivity and all bleeding 
 
5.3.3 Predictors of MACE 
Univariate analysis was conducted to assess whether the factors that were predictive 
of high residual platelet reactivity were also predictive of outcome (Figure 5-5). HOTPR 
with the cut-point of 35 AU resulted in a 2.5 fold increase risk of MACE (2.5, 1.1 – 5.6, 
p = 0.023) this is compared to the historical HOTPR cut-point of 47 AU which identified 
patients with a 2.2 fold increased risk (2.2, 1.1 – 4.7, p = 0.034). Diabetes was also 
found to be a significant predictor of MACE (3.2, 1.5 – 6.8, p = 0.002) whereas obesity 
(BMI > 30, 0.9, 0.4 – 2.1, p = 0.9), LOF allele (0.74, 0.31 – 1.7, p = 0.4), homozygous 
LOF allele (*2/*2) carriers (1.06, 0.12 – 7.0, p = 0.9), low clopidogrel dose (1.3, 0.6 – 
2.8, p = 0.4) and high platelet count (1.2, 0.4 – 3.7, p = 0.7) were not significantly 
correlated with increased MACE risk. In multivariate analysis both diabetes and HOTPR 
>35 AU were found to be significant independent predictors of MACE (Figure 5-6).  
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Figure 5-5 Univariate predictors of MACE 
Clinical and demographic variables represented as odds ratios for predictors of MACE at 1 year 
and 95% confidence intervals. 
 
Figure 5-6 Multivariate predictors of MACE 
Clinical and demographic variables represented as odds ratios for predictors of MACE at 1 year 
and 95% confidence intervals. 
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5.3.4 Predictors of bleeding 
Univariate analysis was also conducted to determine predictors of bleeding. None of 
the factors analysed were found to be predictive of bleeding (Figure 5-7). These 
included femoral access (1.8, 0.8 – 3.6, p = 0.155), low weight (BMI <20, 0.6, 0.2 – 1.5, 
p = 0.2), low platelet count (<150 x109/L, 1.5, 0.4 – 4.8, p = 0.5), diabetes (0.9, 0.4 – 
2.0), high clopidogrel dose (1.4, 0.7 – 2.8, p = 0.3), heterozygous (*1/*17) GOF allele 
(0.9, 0.2 – 3.7, p = 0.7) and patients homozygous (*17/*17) for the GOF allele (0.6, 0.1 
– 5.0, p = 0.6). As previously demonstrated in ROC curve analysis, residual platelet 
reactivity was not predictive of bleeding.  
 
Figure 5-7 Univariate predictors of bleeding 
Clinical and demographic variables represented as odds ratios for predictors of bleeding at 1 
year and 95% confidence intervals. 
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5.3.5 Subgroup analysis of PCI cohort 
Further analysis was performed in the PCI subgroup to investigate whether residual 
platelet reactivity was a stronger predictor in this population. Procedure variables for 
the cohort are summarized in Table 5-3. 
Table 5-3 PCI procedure variables 
 N = 158 
Average number of lesions treated 1.3 ± 0.5 
Average number of vessels treated 1.2 ± 0.4 
Average number of stents 1.4 ± 0.7 
Proportion of stents implanted DES 76% 
Average stent length (mm) 24.4 ± 13.6 
Average stent diameter (mm) 3.0 ± 0.9 
 
Within the PCI cohort 15 patients experienced MACE, which resulted in a similar MACE 
rate (9.7%) compared to the total population (10.5%). MACE events in the PCI cohort 
were comprised of 4 cardiovascular deaths (2.5%), 8 acute MI (5.2%), 2 ischaemic CVA 
(1.3%) and 4 stent thrombosis (2.6%).  
 
ROC curve analysis of residual platelet reactivity and MACE in the PCI cohort displayed 
a modest relationship with a similar area under the curve of 0.649 (0.470 -0.828) to 
the ROC curve in the total population. A HOTPR cut-point was also derived from the 
platelet reactivity value with the highest sensitivity and smallest loss of sensitivity 
(Table 5-4), which equated to an AU of 43, sensitivity of 0.733 and specificity of 0.594.  
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Figure 5-8 ROC curve analysis of residual platelet reactivity and MACE in PCI 
subgroup 
Table 5-4 PCI ROC curve coordinates 
MEA value  Sensitivity  Specificity 
33 0.733 0.434 
34 0.733 0.469 
35 0.733 0.490 
36 0.733 0.538 
37 0.733 0.545 
38 0.733 0.559 
39 0.733 0.566 
40 0.733 0.573 
41 0.733 0.580 
43 0.733 0.594 
45 0.667 0.601 
46 0.667 0.629 
47 0.667 0.657 
 
Univariate analysis to investigate the predictors of MACE in the PCI cohort produced 
similar results as seen in the full population (Figure 5-9). Diabetes was associated with 
an increased risk of MACE (6.4, 2.1 – 19.6, p = 0.001) as well as the HOTPR ≥43 AU cut-
point (3.8, 1.2 -12.5, p = 0.02) and HOTPR ≥47 AU (3.2, 1.1 – 9.8, p = 0.03) in the PCI 
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cohort. The HOTPR >35AU cut-point was no longer a significant predictor of MACE in 
the PCI cohort as well as genotype, obesity, high platelet count and low clopidogrel 
dose. Evident from the wide confidence intervals displayed for the univariate 
predictors, conducting subgroup analysis reduces the number of MACE events and 
therefore statistical power. Multivariate analysis was conducted and found diabetes 
continued to be a significant predictor of MACE (5.1, 1.6 – 16.2, p = 0.005) whereas 
both HOTPR cut-points of 47 AU or 43 AU were not independent predictors (Figure 
5-10).   
 
Figure 5-9 Univariate predictors of MACE in the PCI subgroup 
Clinical and demographic variables represented as odds ratios for predictors of MACE at 1 year 
and 95% confidence intervals. 
 
Figure 5-10 Multivariate analysis of univariate MACE predictors in the PCI 
subgroup 
Clinical and demographic variables represented as odds ratios for predictors of MACE at 1 year 
and 95% confidence intervals. 
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5.4 Discussion 
This was the first study to investigate the relationship between phenotype, genotype 
and other clinical risk factors with outcome and identify which factors were 
independent predictors in the same cohort. We found the HOTPR phenotype and not 
the LOF genotype predicted MACE at 1 year. Furthermore, diabetes, which was shown 
to be a predictor of the HOTPR phenotype, was also a strong predictor of MACE 
independent of HOTPR. Bleeding rates were low in this cohort and were not predicted 
by low residual platelet reactivity or other clinical factors.  
 
Several studies including those conducted by Gurbel et al, Price et al, Sibbing et al and 
Matetzky et al., have demonstrated the HOTPR phenotype as measured by various 
platelet function tests is a strong predictor of MACE in CAD patients (181, 182, 185, 
347). Similarly, meta-analyses of outcome trials predominantly made up of patients 
undergoing PCI on clopidogrel, have demonstrated an increased risk of MACE in 
patients homozygous and heterozygous for the LOF allele (232). However, our study 
suggests that phenotype and not genotype predicts risk of MACE in an ACS population. 
As previously identified in Chapter 4, carriage of the LOF allele has a moderate impact 
on high residual platelet reactivity and is only 1 of many factors that influence this 
phenotype. We also investigated whether other factors that influenced residual 
platelet reactivity were also predictors of MACE. Patients with diabetes are known to 
have poor cardiovascular outcomes compared to non-diabetic cardiac patients (246) 
and as our study and others have shown diabetes is a significant contributor to HOTPR. 
However, to our knowledge this is the first study to demonstrate that HOTPR and 
diabetes are independent predictors of MACE risk. Therefore platelet function testing 
could offer additional information on a patients risk beyond a patients’ diabetes 
status.  
 
We also examined the other identified HOTPR predictors and found obesity (BMI >30), 
low clopidogrel dose and high platelet count did not predict MACE in our population. 
We did not investigate the predictive value of an exhaustive list of demographic and 
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clinical factors in this cohort, as we did not have the power to make multiple 
comparisons in this cohort.  
 
This study also highlighted that defining HOTPR by a single cut-point on a continuum 
of platelet reactivity is somewhat problematic. Undeniably, high residual platelet 
reactivity is associated with an increased risk of MACE, but where the optimal cut-
point is remains unknown. The ROC curve derived in the whole population identified 
a HOTPR cut-point of 35 AU, which is significantly lower than the HOTPR definition 
used previously and would result in half of the patients being classified at higher risk. 
Furthermore, the ROC curve derived in the PCI cohort sub analysis was different again, 
although confidence intervals where wide, with an optimal cut-point at 43 AU, which 
is more in line with the established multiplate cut-point (47 AU) determined by Sibbing 
and co (282). The issues with identifying the optimal cut-point are due to several 
factors that either increase the variability in the measurement of platelet reactivity or 
skew the risk of MACE.  
 
One issue in the current study is the relatively small population size, which reduces 
the level of confidence around the derived cut-point compared to the Sibbing group, 
which derived their cut-point from a much larger cohort of 1608 patients. 
Furthermore, as we have demonstrated in chapter 2, the assay itself has an inherent 
variability of 10% in the measurement of platelet reactivity. In addition to this, several 
pre-measurement factors such as anticoagulant and time can compound this 
variability and widen the confidence around a platelet function measurement 
identifying someone at risk. The adverse events we include to identify the optimal cut-
point are not homogenous. The degree in which high residual platelet reactivity is 
driving the risk of death, stroke, MI and stent thrombosis will vary and including these 
events as a composite endpoint may reduce our power to define the most sensitive 
cut-point. However, there are also limitations to only using a single outcome such as 
stent thrombosis at 30 days used by Sibbing et al. The resulting applicability of a cut-
point defined only by stent thrombosis may be inadequate as a tool to personalize 
antiplatelet therapy and reduce adverse events. There also exists variability in the risk 
of patients experiencing adverse events that we perform platelet function testing in. 
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The Sibbing study (344) derived their HOTPR threshold in a mixed population of stable 
and acute CAD patients where their risk of MACE would vary considerably. Our study 
exclusively examined an acute population as these patients have the highest risk of 
recurrent thrombotic events and therefore may benefit the most from adequate 
antiplatelet therapy. 
 
Bleeding complications in patients with ACS have been associated with an increased 
risk of subsequent adverse outcomes including MI, stroke, stent thrombosis and death 
(348-352). Recognition of this relationship between bleeding, mortality and morbidity 
has lead to a new emphasis on identifying those at risk of bleeding and strategies to 
minimize bleeding. In our cohort residual platelet reactivity did not predict major 
bleeding or all bleeding and no other significant predictors of major or all bleeding 
were identified. Although the link between HOTPR and ischaemic events is well 
established, the relationship between low platelet reactivity and bleeding is less clear. 
Although a number of previous studies in patients undergoing PCI have demonstrated 
an association between low platelet reactivity and bleeding (338, 353-355) this 
relationship was not observed in a number of other large-scale platelet function 
studies including the POPULAR, GRAVITAS and ARCTIC studies (287, 356-358).  
 
The rate of major bleeding in the cohort was low (3%). The high rate of radial access 
and the low rates of GP IIb/IIIa antagonist use in our study are likely to have 
contributed to this. The standardized definition recently proposed by the Bleeding 
Academic Research Consortium was used in the study (346). Previous observational 
studies and clinical trials have used a wide variety of other bleeding definitions making 
comparisions of bleeding rates across trials difficult (346). As a result of the low 
bleeding rate our study was underpowered to look at the relationship between 
bleeding and platelet reactivity, genotype or clinical factors. Major bleeding in our 
study included a combination of non-CABG and CABG related bleeding. The role that 
residual platelet function plays in these different types of bleeding might vary but 
because of the low number of events we were not able to examine these subgroups. 
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Based on the observations linking HOTPR with an increased risk of ischaemia and 
LOWPR with an increased risk of bleeding, the concept of a therapeutic window for 
platelet reactivity has been proposed (206, 281). Following this observation, several 
studies have aimed to improve patient outcome by targeting the therapeutic window 
using platelet function testing or genotyping. Two small studies by Bonelle et al. 
randomised patients undergoing PCI to a guided antiplatelet using the VASP assay or 
standard antiplatelet therapy. Those who were found to have HOTPR in the guided 
arm were given an additional 600mg loading of clopidogrel. This treatment was 
successful in reducing on treatment platelet reactivity and also decreased the rate of 
early stent thrombosis without an increase in major bleeding compared to the non-
guided approach (283, 284). The selective addition of GPIIb/IIIa antagonists in patients 
with HOTPR as identified with the VerifyNow assay, has also been shown to improve 
patient outcomes without increasing bleeding in the 3T/2R trial (359). 
 
However, the three largest randomized trials using platelet function testing to tailor 
antiplatelet therapy failed to demonstrate any benefit from this approach. There were 
several issues with the study design of these trials that may have contributed to the 
negative results. The GRAVITAS trial was the first large scale trial (n = 2214) that 
utilized the VerifyNow P2Y12 assay to identify patients with HOTPR and subsequently 
doubled clopidogrel dosing (287). High-dose clopidogrel treatment was ineffective in 
reducing the 6-month composite ischemic event occurrence (cardiovascular death, 
nonfatal MI, and stent thrombosis); both treatment groups had an unexpectedly low 
event rate (2.3%). Similarly, the ARCTIC study enrolled 2440 patients undergoing PCI 
to receive guided therapy with the VerifyNow or non-guided therapy. Several different 
treatments were available to clinicians in the guided arm including reloading with 
clopidogrel (600mg), switching to prasugrel or administration of a GPIIb/IIIa inhibitor 
during PCI. The study was also neutral with no improvement in clinical outcomes for 
patients receiving guided therapy compared to standard clopidogrel therapy without 
monitoring (287). The TRIGGER-PCI trial, which compared prasugrel vs. clopiodgrel in 
patients with HOTPR as identified by the VerifyNow, was stopped by the steering 
committee prematurely after randomization of 423 patients (out of the planned 2150) 
due to an interim analyses indicating a lower than expected incidence in the primary 
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endpoint. Given the low rate of ischemic events the clinical utility of this strategy could 
not be demonstrated (288). 
 
The limitations in these clinical trials are due to the treatment strategy, the study 
population and the method of identified high-risk patients. Firstly the treatment 
strategy utilized in the GRAVITAS study of single re-loading (600mg) and double 
maintenance therapy (150mg) was not potent enough to overcome HOTPR in a large 
proportion of those tested. A dramatic 40% of patients in the guided therapy arm with 
HOTPR remained non-responders after receiving additional clopidogrel. In the ARCTIC 
study, prasugrel was a treatment option for clinicians, although this treatment only 
became available towards the end of the enrolment period and of the cohort only 
3.3% were switched to the more potent P2Y12 inhibitor. The large majority of patients 
(80.2%) received increased doses of clopidogrel, which has been shown to be 
ineffective in lowering platelet reactivity in those with HOTPR. Both pharmacokinetic 
studies and large clinical trials have demonstrated ticagrelor and prasugrel therapy, 
result in lower on treatment platelet reactivity levels and a decrease in MACE 
compared to clopidogrel (203, 217, 360, 361). Furthermore, in chapter 3 we 
demonstrated the treatment of patients with HOTPR with prasugrel resulted in a 
marked reduction in residual platelet reactivity in all patients. Therefore it is not 
surprising that this inadequate personalized therapy of additional clopidogrel, failed 
to show clinical benefit.  
 
The populations in all of these studies were largely stable patients undergoing elective 
PCI and high-risk patients (STEMI) were excluded. The recent ADAPT-DES registry 
indicates that intensified antiplatelet therapy may not benefit low-risk patients but 
might improve patient outcomes in high-risk patients; high risk ACS or patients with a 
high risk for stent thrombosis; diabetes, multiple stents and multivessel disease (364). 
Therefore exclusion of high-risk patients in these large trials could have contributed 
to the lack of benefit in the personalized therapy arm. The GRAVITAS and TRIGGER-
PCI trials were also statistically underpowered to a point where TRIGGER-PCI was 
stopped prematurely and GRAVITAS has a much lower primary endpoint rate than 
expected (calculated as 5% vs. observed 2.3%). This could also be due to the low-risk 
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population that was recruited. It has been suggested that as for studies with tailored 
therapy of prasugrel or ticagrelor, a much higher sample size (at least 17,000 patients) 
would be required to show statistical differences (365).  
 
Lastly, the assay and cut-point used to identify HOTPR needs to be considered in these 
studies. The three trials employed the VerifyNow P2Y12 assay with a threshold of 235 
PRU to identify HOTPR. Subsequent analysis of the GRAVITAS trial hypothesized that 
the original threshold may have been too high with a clustering of events above and 
below the threshold and conversely, a PRU<208 was strongly associated with an event 
free survival at 60 days (364). This adjusted threshold of 208 PRU was also confirmed 
in the ADAPT-DES, a study investigating ischaemic outcomes and clinically relevant 
bleeding at 1-year follow-up, in more than 8500 patients treated with clopidogrel and 
undergoing PCI. A PRU>208 resulted in a 2.5 fold increase risk of stent thrombosis and 
myocardial infarction (364). Therefore the method used to identify patients at risk 
may not have been sensitive enough.  
 
Several key issues around the measurement of platelet reactivity and personalisation 
of antiplatelet therapy remain and require further investigation before platelet 
function testing can be considered for clinical use. As this study has demonstrated, 
finding the optimal cut-point for HOTPR is challenging but key to identifying those who 
will benefit the most. As identified in chapter 2, the standardised measurement of 
platelet reactivity is important to reduce analytical variation and the use of a wide 
sampling to testing time frame may have significantly reduced the sensitivity and 
specificity of the cut-point derived by Sibbing et al (344). The appropriate population 
to test residual platelet reactivity is also unknown. As previously discussed, there is 
limited evidence to show personalised antiplatelet therapy is beneficial in stable CAD 
patients from the ADAPT-DES registry. However, previous studies in ACS populations 
have largely focused on platelet function testing in PCI patients and the predictive 
value of HOTPR in medically managed populations or patients undergoing CABG need 
to be established. An extension of this study to address these limitations is planned to 
identify the optimal cut-point for HOTPR using a consistent Multiplate methodology 
in a larger cohort of 700 ACS patients.  
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In New Zealand there is a significant increase in the use of ticagrelor, due to 
government funding of this therapy in ACS patients from 1 July 2013. As the 
antiplatelet therapy landscape evolves, the use of platelet function testing to tailor 
therapy must also evolve. Although ticagrelor was shown to be superior to clopidogrel 
at reducing MACE in ACS patients it also increases the risk of non-CABG related major 
bleeding (365). Therefore, instead of the routine use of ticagrelor in all patients who 
present with an ACS, it may be possible to use platelet function testing to identify a 
group of patients who would have adequate platelet inhibition and protection from 
ischaemic events on clopidogrel without an increased bleeding risk. This strategy may 
lead to equivalent outcomes at a considerably lower cost, although such a strategy 
has not yet been proven to work.  
5.4.1 Limitations 
As the study was observational and all aspects of clinical management were at the 
consultant’s discretion, we cannot exclude the possible influence of other medications 
or clinical and procedure variables on our results. The study was underpowered to 
investigate the relationship between multiple demographic and clinical factors with 
the risk of MACE and bleeding. It would have been interesting to determine the 
presence of other clinical risk factors that could potentially inform a modified risk 
score in ACS patients. However, to conduct a study that included a large number of 
patients with 1 year follow up in the time frame of the thesis was not possible.  
5.4.2 Conclusion 
In this study, HOTPR phenotype and not CYP2C19*2 genotype is a predictor of 
ischaemic risk in an ACS population. However, identifying the optimal cut-point for 
classifying HOTPR remains complex and challenging. Diabetes was also found to be a 
strong predictor of ischaemic risk. Importantly this study demonstrated that HOTPR 
and diabetes independently predict MACE at one year. In the PCI cohort, HOTPR 
remained a predictor of MACE at one year on univariate but not on multivariate 
analysis. The bleeding rate was low in our cohort and low residual platelet reactivity 
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was not predictive of these events. Identifying the optimal cut-point for classifying 
HOTPR and whether residual platelet reactivity can be used improve the predictive 
power of existing risk stratification models or personalise antiplatelet therapy requires 
further investigation. 
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6 Chapter 6: Platelet reactivity, 
biomarkers and outcome following 
vascular surgery 
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6.1 Introduction 
Postoperative MI and major cardiac complications occur in more than 4% of the 
patients with either an established diagnosis of CAD or risk factors for CAD, who 
undergo major non-cardiac surgery (366). Patients undergoing vascular surgery 
appear to be at particularly high risk of perioperative cardiac complications such as 
death and nonfatal myocardial infarction. Previous studies suggested that myocardial 
injury (troponin elevation) occurred in 21-24% of patients undergoing vascular surgery 
and that this elevation of post-operative troponin levels is  strongly associated with 
an increased mortality (367-369). Treatment with aspirin has been shown to 
substantially reduce this risk (59). However, as seen in the previous chapters, the 
biological response to antiplatelet therapy varies significantly between ACS patients 
and it is logical to assume that this variance would also exist in vascular patients.  
 
In ACS patients our previous studies have demonstrated that residual platelet 
reactivity is predictive of outcome. To date, the relationship between residual platelet 
reactivity and outcomes in patients undergoing major elective vascular surgery has 
not been established, despite their high risk for cardiac complications. Furthermore, 
the utility of other biomarkers such as high sensitivity troponin (hs-TnT), C-reactive 
protein (CRP) and NT-proBNP (brain naturetic protein), that have shown to be highly 
predictive of poor outcome in a CAD population, have not been thoroughly examined 
in vascular patients. There remains a lack of evidence based risk stratification tools to 
apply in vascular populations that can identify those at increased risk of ischaemic and 
bleeding events both perioperatively and long term. 
 
Therefore the aim of this chapter was to:  
1. To investigate the relationship between residual platelet reactivity on 
aspirin as well as the cardiac biomarkers hs-TnT, NT-proBNP and CRP 
with adverse cardiovascular and bleeding outcomes in patients 
undergoing major vascular surgery.  
2. To examine the relationship between these biomarkers with 
perioperative and long-term outcomes.  
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6.2 Methods 
6.2.1 Study Population 
Patients presenting to Wellington Regional Hospital for elective major vascular 
surgery between April 2011 and December 2012 were eligible for inclusion in the 
study if they were adequately pre-treated with aspirin. Elective major vascular surgery 
included carotid endarterectomy, open abdominal aortic aneurysm repair and infra-
inguinal procedures including femoral-popliteal bypass and femoral enadarterectomy. 
Adequate pre-treatment was defined as chronic therapy with aspirin (100mg/day for 
more than 7 days) or loading with aspirin 300 mg at least 2 hours prior to enrolment. 
Exclusion criteria included a recent ACS (< 3 months), platelet count less than 100 x 
109/L, known platelet function disorder, treatment with an antiplatelet agent other 
than aspirin, acute limb ischaemia, symptomatic AAA, current active infection and 
those unable to give informed consent. The study was reviewed and approved by the 
Central Regional Ethics Committee (NTX-11-03-018).  
6.2.2 Data Collection 
Patient demographics, clinical characteristics, medications including antiplatelet 
therapy, clinical management and procedural variables were obtained prospectively 
from review of the medical records. All aspects of clinical management were at the 
discretion of the attending physicians. All ischaemic and bleeding complications 
occurring during the hospital admission were recorded. Patients were also contacted 
by phone at 30 days and 1 year by a cardiology research nurse, to assess clinical 
outcomes. Where necessary, review of case notes and contact with the general 
practitioner was performed to further classify clinical outcomes. 
6.2.3 Study design, ECG and blood collection 
The study was a prospective observational study of patients undergoing major elective 
vascular surgery. Electrocardiograms (ECGs) and venous blood samples were collected 
from all patients at baseline, before surgery and on postoperative days 1 and 2. 
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Further blood samples for hs-TnT measurement and electrocardiograms were 
performed where clinically indicated. Blood for platelet function testing was collected 
as described in section 2.2.2. Blood for high sensitivity troponin T (hs-TnT), C-reactive 
protein (CRP) and N terminus pro-B type Naturetic Peptide (NT-ProBNP) was collected 
into a serum-separator collection tube (BD Diagnostics, NJ, USA) 
6.2.4 Platelet function testing and biomarker analysis 
Platelet function testing was performed as described in section 2.2.2. Whole blood 
based impedence aggregometry was performed using the Multiplate analyser using 
0.5mM arachadonic acid to stimulate platelets and test the thromboxane pathway. 
The upper and lower quintiles of residual platelet reactivity were empirically defined 
as HOTPR and LOWPR respectively.  
 
All hs-TnT, NT-proBNP and CRP measurements were performed in the Wellington 
Regional Hospital Medical Laboratory using the Cobas CE modular system (Roche 
Diagnostics, Basel, Switzerland). A hs-TnT level ≥ 14 ng/L was considered elevated. 
Elevated NT-proBNP was age adjusted and a positive value was defined as >53 pmol/L 
for age <50 years, >106 pmol/L for age 50-75 years and >212 pmol/L for age >75 years. 
The lower limit of detection for CRP was 3 mg/L. For CRP the upper quintile was 
emperically defined as an elevated value. 
6.2.5 End points and definitions  
6.2.5.1 Primary end point 
The primary endpoint was major adverse cardiovascular events (MACE) at one year. 
MACE was defined as a composite of cardiovascular death, nonfatal myocardial 
infarction, nonfatal ischaemic stroke, periprocedural myocardial injury and graft 
occlusion at one year. Secondary endpoints included MACE at 30 days, bleeding at 30 
days and 1 year and rehospitalisation.  
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6.2.5.2 Ischaemic events  
Cardiovascular death was considered as any death with a demonstrable 
cardiovascular cause or any death that is not clearly attributable to a non-
cardiovascular cause. Acute myocardial infarction was defined using the third 
universal definition of myocardial infarction (289), including a detection of a 
significant hs-TnT rise in the presence symptoms suggestive of myocardial ischaemia, 
new or presumed new ST-segment-T wave changes or new LBBB, development of new 
pathological Q waves, or imaging evidence of new myocardial loss. An isolated 
significant elevation in hs-TnT of more than 50% compared to baseline hs-TnT levels 
and an absolute rise of at least >20ng/L with no other evidence of myocardial 
ischaemia was considered as periprocedural myocardial injury. Acute ischaemic 
cerebrovascular accident (CVA) was defined as signs of CVA confirmed with imaging 
studies. Graft Occlusion was defined as any graft occlusion confirmed by duplex 
ultrasound or angiography.  
6.2.5.3 Bleeding events 
Major bleeding was defined as fatal bleeding, intracranial bleeding, drop in 
postoperative hemoglobin of > 50 g/L perioperatively, transfusion of ≥ 2 units of Red 
Blood Cells (RBC), bleeding requiring reoperation or bleeding requiring readmission to 
hospital.  
6.2.6 Statistical analysis 
In this chapter a different statistical approach has been used to investigate the 
relationship between biomarkers, clinical factors and patient outcome compared to 
the statistical analysis in the ACS cohort. In the preceding chapters the number of 
comparisons has been deliberately limited to reduce the probability of false positive 
results. However, in the current study, due to a limited recruitment (see limitations 
section 6.5), a limited comparison approach would potentially lead to a greater 
problem with false negative findings (372). Therefore, the multiple comparisons are 
displayed as forest plots for completeness and potential incorporation into larger 
meta-analyses and to also display the variability due to the reduced power in the 
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cohort. Interpretation of all of these results needs to be undertaken with care, mindful 
of the large confidence intervals observed within these forest plots. 
 
Categorical variables are expressed as frequencies and percentages. Continuous 
variables not normally distributed following D’Agostino & Pearson normality testing 
are expressed as median and IQR. Surgical variables were found to be normally 
distributed and are expressed as mean and standard deviation and analsyed using 1 
way ANOVA. Univariate analysis of demographic and biomarker variables as 
categories with outcome data was performed using Chi-Squared tests. Multivariate 
analysis of significant univariate predictors of outcome was performed using a 
multinominal logistic regression analysis. Regression analysis, Chi-Squared tests and 
ROC curve analysis were performed using PASW 18.0 (IBM, NY, USA), all other analysis 
and graphs were generated using GraphPad prism 5 (GraphPad Software Inc., CA, USA). 
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6.3 Results 
6.3.1 Demographics 
During the study period 106 patients were enrolled in the study. Of those enrolled 6 
patients were subsequently excluded for the following reasons, 3 patients decided to 
have their surgery performed in a private hospital due to the waiting time in the public 
hospital, 2 patients presented acutely prior to their scheduled elective surgery and 
one was initially planned to have an open AAA but subsequently the vascular team 
decided to use an endovascular approach. One year follow-up was completed in all of 
the remaining 100 patients and the baseline demographics are displayed in Table 6-1. 
Table 6-1 Patient baseline demographics 
 N = 100 
Age (years) 72 (45 – 88) 
Male, n 61 
BMI 27 (16 - 38) 
Ethnicity, n   
European 91 
Maori and Pacific Islander 7 
Other 2 
Risk Factors, n  
Hypertension 86 
Dyslipidaemia 80 
Diabetes 33 
Current Smoker 15 
Previous Smoker 59 
Previous TIA/Stroke 31 
Previous Vascular Surgery 30 
Ischaemic Heart Disease 43 
Laboratory data  
Creatinine (umol/L) 96 (47 – 270) 
Platelet Count (109/L) 229 (124 – 479) 
Haemoglobin (g/L) 133 (95 – 168) 
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Admission medications were recorded for each patient (Table 6-2). As per the 
inclusion criteria, all patients were on aspirin therapy. There was also a high 
administration of statin therapy (86%) and the majority of patients were on a form of 
hypertension medication.  
Table 6-2 Admission medications 
Medication N=100 
Aspirin 100 
Beta Blocker 50 
Statin 86 
ACE inhibitor 44 
Diuretic 25 
Warfarin 3 
Nitrate 7 
Calcium Channel Blocker 37 
 
Baseline measurements of the biomarkers, platelet reactivity, hs-TnT, NT-proBNP and 
CRP were performed in every patient and there was a wide range of baseline values 
for all 4 biomarkers (Table 6-3, Figure 6-1). Platelet reactivity ranged from 2 – 142 AU 
with the upper quintile (>24 AU) and lower quintile (<7 AU) empirically defined as 
HOTPR and LOWPR respectively. Hs-TnT also varied greatly at admission, with the 
highest value at 152 ng/L and 35% of patients had a baseline hs-TnT that was elevated 
above the upper limit of normal (≥14 ng/L). NT-proBNP was determined in all patients 
and elevated levels were determined by adjusting for age, resulting in the 
identification of 13 patients with elevated levels. CRP was detectable in 41% of 
patients at baseline (>3 mg/L). As nearly 59% of patients had an undetectable level of 
CRP, elevated levels were also empirically defined as the upper quintile of 
measurements (>6 mg/L). 
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Table 6-3 Baseline measurement of biomarkers  
Multiplate platelet reactivity (AU) 16.5 (2 – 142) 
Hs-TnT (ng/L) 9.5 (3 – 153) 
Elevated hs-TnT 35% 
NT-proBNP (pmol/L) 33.5 (1 – 521) 
Elevated NT-proBNP 13% 
CRP (mg/L) 3 (3 – 46) 
Elevated CRP 20% 
Figure 6-1 Variability of baseline biomarkers 
Baseline residual platelet reactivity (A), hs-TnT (B), CRP (C) and NT-proBNP (D) were 
measured in all patients. The red and blue dotted line for residual platelet reactivity represents 
the upper (>24 AU) and lower quintiles (>7 AU) respectively (A). The red dotted line for hs-TnT 
represents the upper limit of normal (>14 ng/L) and an undetected level was lower than 4 ng/L. 
The red dotted line for CRP represents the upper quintile (>6 mg/L) and an undetected level 
was lower than 3 mg/L. The three dotted lines for NT-proBNP represent the age-adjusted cut-
point for elevated levels.     
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The type of anesthesia, duration of surgery and estimated blood loss was recorded 
during surgery by the anesthetist and vascular surgeon for each patient (Table 6-4). 
The majority of patients received a general anesthetic (84%). Epidural alone was used 
solely in patients undergoing infra-inguinal surgery and some patients undergoing an 
AAA received a combined approach. The mean procedure time across all surgeries was 
161 mins ± 69 and differed significantly across the three surgery sub groups (p < 
0.0001). The longest surgery times were in the AAA group (224 mins ± 51) and shortest 
in patients undergoing carotid endarterectomy surgery (108 mins ± 31). Similarly, 
estimated blood loss was significantly higher in the group undergoing AAA at 1045 mL 
± 973 compared to infra-inguinal surgery (236 mL ± 462) or carotid endarterectomy 
(41 mL ± 103, p < 0.0001). 
Table 6-4 Surgery details 
 All patients 
n = 100 
Carotid 
n = 37 
AAA 
n = 22 
Infra-inguinal 
n = 41 
P 
value 
Anesthesia      
General 84 37 15 32  
Epidural 4 0 0 4  
Combined 12 0 7 5  
Procedure time 
(mins) 
161 ± 69 108 ± 31 224 ± 51 174 ± 68 < 
0.0001 
Blood loss 
during surgery 
(mL) 
342 ± 662 41 ± 103 1045 ± 
973 
236 ± 462 < 
0.0001 
6.3.2 Perioperative measurement of hs-TnT 
As 35% of patients had elevated hs-TnT levels at baseline, a significant hs-TnT rise 
perioperatively was determined by the change in hs-TnT between baseline and post-
operative measurements. As displayed in Figure 6-2A, 17 patients had a significant rise 
in hs-TnT compared to baseline. However, as depicted in Figure 6-2B, where patients 
did not have a significant rise in hs-TnT post operatively compared to baseline, if hs-
TnT were only measured on day 1 or day 2, 31% of the total population would appear 
to have elevated levels which would indicate a possible acute MI and lead to further 
unnecessary investigations.   
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Figure 6-2 Hs-TnT measurement perioperatively 
Hs-TnT measurements at baseline (Day 0) and Day 1 and 2 post-operatively in patients with a 
significant rise in hs-TnT (A) and patients who did not have a significant rise compared to 
baseline (B). The red dotted line represents the upper limit of normal (14ng/L).  
6.3.3 Patient outcomes following vascular surgery 
To look at predictors of patient outcome following vascular surgery, data was 
collected in-hospital, at 30 days and at 1 year following surgery. Overall 34 patients 
experienced MACE with a total of 39 events occurring in these patients. Furthermore, 
major bleeding occurred in 29 patients with a total of 32 events occurring in these 
patients. Patient outcome data was also divided into short (0 - 30 days post surgery) 
and long-term (30 days – 1 year post surgery) time periods as the nature of events 
short term differed compared to events occurring after 30 days. 
6.3.4 Short term outcomes 
During the time period from surgery up to day 30, 23 patients experienced MACE. 
Some patient’s experienced more than one event, these included 9 periprocedural 
myocardial injury, 8 acute MI events, 1 CVA and 5 graft occlusions. The majority of 
these events occurred on day 1 or day 2 post-operatively (Figure 6-3). During the same 
time period, 29 patients experienced major bleeding events. In the 24 patients, 15 
patients received transfusions of ≥2 RBC units, 3 patients had hematomas requiring 
reoperation, 8 patients had a haemoglobin drop of more than 50 g/L and 5 patients 
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were readmitted with major bleeding. Of the patients who had bleeding or 
experienced MACE in this time period, 13 patients experienced both outcomes. Post 
discharge there was a further 12 patients who re-presented to hospital with varied 
problems including; wound infection, gastroenteritis, fever, exacerbation of COPD, 
non cardiac chest pain and bowel issues. 
 
Figure 6-3 Short term timing of events post surgery 
Each dote represents an individual MACE (red) or bleeding (blue) event during the patients 
hospital admission. Mean and SEM are displayed. 
6.3.5 Long term outcomes 
In the time period between 30 days and 1 year post surgery, a further 12 patients 
experienced MACE. Five patients died in the follow up period, 1 cardiovascular death 
and 4 documented as non-cardiac deaths, 5 patients were also readmitted with graft 
occlusion as confirmed by duplex. Acute MI occurred in 2 patients and 2 patients were 
readmitted with an ischaemic CVA. There was a consistent incidence of MACE events 
over this time period (Figure 6-4). During this period, 3 patients experienced major 
bleeding complications resulting in a readmission to hospital. A further 23 patients 
had re-admissions to hospital during the follow up period. These included 16 elective 
vascular procedures (angioplasty or surgery) for progression of vascular disease and 7 
other minor elective procedures. An additional 16 patients presented to ED with 
varying complaints, but these presentations did not require admission.  
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Figure 6-4 Timing of events from 30 days to 1 year post discharge 
Each dote represents an individual MACE (red) or bleeding (blue) event between 30 days and 
1 year post discharge from hospital.  
6.3.6 Predictors of adverse outcomes in vascular patients 
6.3.6.1 Adverse outcomes at 1 year 
Several clinical factors predicted an increased risk of MACE at 1 year in univariate 
analysis (Figure 6-5). These included a BMI <25 (3.4 (1.5 – 8.3), p = 0.005), elevated 
baseline hs-TnT (3.6 (1.5 – 8.6), p = 0.003), elevated CRP (2.3 (1.0 – 5.3), p = 0.047) and 
renal impairment (2.3 (0.98 – 5.4), p = 0.05). Of these factors an elevated baseline hs-
TnT (3.7 (1.4 – 10.1), p = 0.008) and a BMI < 25 (4.1 (1.5 – 11.1), p = 0.005) were found 
to be independent predictors of MACE at 1 year in multivariate analysis (Figure 6-6). 
HOTPR and elevated NT-proBNP did not significantly correlate with MACE at 1 year.  
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Figure 6-5 Predictors of MACE at 1 year 
Clinical and demographic variables represented as odds ratios for predictors of MACE at 1 year 
and 95% confidence intervals. 
 
Figure 6-6 Multivariate analysis of predictors of all MACE 
Clinical and demographic variables represented as odds ratios for predictors of MACE at 1 year 
and 95% confidence intervals. 
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ROC curve analysis was also conducted to investigate if there was any relationship 
between residual platelet reactivity and MACE at 1 year (Figure 6-7). The ROC curve 
displayed no relationship with an area under the curve 0.482 and no discernable cut-
point that would identify patients at increased risk of MACE.   
 
 
Figure 6-7 ROC curve analysis of residual platelet reactivity and MACE 
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Major bleeding was also examined at 1 year and the only predictor of increased 
bleeding risk was AAA surgery (8.5 (2.9 – 24.8), p = 0.001). LOWPR, elevated hs-TnT, 
elevated BNP and elevated CRP did not predict bleeding risk  
Figure 6-8 Predictors of bleeding at 1 year 
Clinical and demographic variables represented as odds ratios for predictors of bleeding at 1 
year and 95% confidence intervals. 
ROC curve analysis was also conducted to investigate the relationship between 
residual platelet reactivity and bleeding at 1 year (Figure 6-9). The ROC curve displayed 
no relationship with an area under the curve 0.563 and no discernable cut-point that 
would identify patients at increased risk of bleeding. 
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Figure 6-9 ROC curve analysis of residual platelet reactivity and bleeding 
 
6.3.6.2 Adverse outcomes short term 
Several clinical and demographic factors were identified to be predictive of MACE at 
30 days in univariate analysis (Figure 6-10). These included a BMI <25 (4.3 (1.6 – 11.3), 
p = 0.002), elevated baseline hs-TnT (2.5 (1.0 – 6.7), p = 0.05), and previous HF (2.8 
(0.96 – 8.7), p = 0.05). All of these factors were found to be independent predictors of 
MACE at 30 days in multivariate analysis (Figure 6-11). HOTPR, elevated NT-proBNP 
and elevated CRP did not significantly correlate with short term MACE.  
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Figure 6-10 Predictors of short term MACE  
Clinical and demographic variables represented as odds ratios for predictors of MACE at 30 
days and 95% confidence intervals. 
 
Figure 6-11 Multivariate analysis of short term MACE predictors 
Clinical and demographic variables represented as odds ratios for predictors of MACE at 30 
days and 95% confidence intervals. 
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Short term bleeding was also examined and the only variable that was found to be 
significantly associated with an increased risk of bleeding was undergoing AAA surgery 
(Figure 6-12). Patients in this group had a 10 times higher risk of bleeding during their 
hospital admission (10.0 (3.3 – 29.7), p = 0.001). There was no correlation between 
baseline biomarkers and short term bleeding. 
 
 
Figure 6-12 Predictors of short term bleeding  
Clinical and demographic variables represented as odds ratios for predictors of bleeding at 30 
days and 95% confidence intervals 
Platelet reactivity was plotted for each bleeding and MACE from day 1 up to day 30 
post surgery (Figure 6-13). This identified a group of patients that had co-localisation 
of both MACE and bleeding events.  
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Figure 6-13 Platelet reactivity and short term events 
The distribution of platelet reactivity (U) compared to bleeding and MACE during the hospital 
admission. Each dot represents an individual MACE (red) or bleeding (blue) event in-hospital. 
Both X axis display platelet reactivity. 
To assess whether clinical and demographic parameters could identify patients at risk 
of both major bleeding and MACE in this period, univariate analysis was conducted 
with the endpoint of bleeding plus MACE (Figure 6-14). In this analysis, patients 
undergoing AAA surgery (4.1 (1.2 – 13.9), p = 0.017) and patients with an elevated 
baseline hs-TnT (3.5 (1.1 – 11.8), p = 0.03) had an increased risk of experiencing both 
bleeding and MACE in the short term. An elevated baseline NT-proBNP (2.87 (0.98 – 
9.52), p = 0.07) resulted in a trend for more bleeding and MACE. Multivariate analysis 
identified AAA surgery (10.9 (2.0 – 59.5), p = 0.005) and elevated hs-TnT (6.9 (1.2 – 
39.5), p = 0.02) as independent predictors of the combination of bleeding and MACE 
in the time period up to 30 days post surgery (Figure 6-15). 
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Figure 6-14 Predictors of patients at risk of both short term MACE and bleeding  
Clinical and demographic variables represented as odds ratios for predictors of MACE and 
bleeding at 30 days and 95% confidence intervals 
 
Figure 6-15 Multivariate analysis of predictors of patients at risk of short term 
MACE and bleeding  
Clinical and demographic variables represented as odds ratios for predictors of MACE and 
bleeding at 30 days and 95% confidence intervals 
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6.3.6.3 Long term adverse outcomes  
Predictors of bleeding and MACE between 30 days and one year were also 
investigated. Only elevated hs-TnT (4.1 (1.2 – 13.6), p = 0.013) and elevated CRP (3.3 
(1.1 – 10.3), p = 0.047) were associated with an increased risk of MACE during this 
time period (Figure 6-16). However, elevated hs-TnT was the only significant 
independent predictor in multivariate analysis resulting in a 3.7 (1.1 - 12.3, p = 0.034) 
increased risk of MACE between 30 days and 1 year (Figure 6-17). 
 
 Figure 6-16 Predictors of long term MACE 
Clinical and demographic variables represented as odds ratios for predictors of MACE between 
30 days and 1 year and 95% confidence intervals 
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 Figure 6-17 Multivariate analysis of predictors of long term MACE  
Clinical and demographic variables represented as odds ratios for predictors of MACE between 
30 days and 1 year and 95% confidence intervals 
There were no baseline clinical factors or biomarker that significantly predicted an 
increased risk of long term bleeding (Figure 6-18). 
 
Figure 6-18 Predictors of long term bleeding 
Clinical and demographic variables represented as odds ratios for predictors of bleeding 
between 30 days and 1 year and 95% confidence intervals 
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Platelet reactivity was plotted for each bleeding and MACE event from 30 days up to 
1-year post surgery (Figure 6-19). In contrast to short-term events, there was no co-
localisation of MACE and bleeding in this time period. Furthermore, platelet reactivity 
levels were not significantly different in patients experiencing MACE compared to 
those having major bleeds.  
Figure 6-19 Platelet reactivity and long term events 
The distribution of platelet reactivity (AU) compared to bleeding and MACE from 30 days up to 
1 year post surgery. Each dote represents an individual MACE (red) or bleeding (blue) event 
at 1 year. Both X axis display platelet reactivity. 
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6.4 Discussion 
This is the first study to investigate the relationship between residual platelet 
reactivity and other baseline cardiac biomarkers with outcomes following elective 
major vascular surgery. Residual platelet reactivity both high and low was not found 
to be significantly associated with MACE or bleeding following surgery in this cohort. 
Elevated baseline hs-TnT appeared to be the most predictive biomarker and was 
significantly associated with the risk of MACE in both the short-term and long-term. 
Bleeding occurred early following surgery in the majority of patients and AAA surgery 
was the only predictor of bleeding. Interestingly, we found a number of MACE and 
bleeding events were co-located, which may indicate that mechanisms other than a 
thrombotic process could be driving ischaemic events in these patients.  
 
We found the response to aspirin in our vascular cohort to be highly variable ranging 
between 2 AU to 142 AU. The level of on treatment residual platelet reactivity did not 
correlate with adverse outcomes in this vascular cohort and we could not derive a cut-
point for HOTPR from ROC curve analysis. Using the previously recommended cut 
point for aspirin HOTPR of 30 AU, which has been derived in a healthy population 
(295), only 10% of patients in our study would be classified as having a suboptimal 
response to aspirin. Our findings are consistent with a previous report, which 
estimated that high on treatment platelet reactivity was present in between 5% and 
27.5% of patients with PVD depending on the assay used (371). 
 
To date the few studies that have examined the relationship between residual platelet 
reactivity and adverse events in those undergoing vascular surgery have 
demonstrated mixed findings. Rajagopalan and colleagues assessed platelet function 
with the VerifyNow arachidonic acid assay in 136 aspirin treated patients undergoing 
elective surgery for subcritical limb ischemia or infrarenal AAA repair. They found that 
postoperative but not baseline arachidonic acid stimulated platelet aggregation was 
higher in those with a postoperative troponin rise (153). Another study of patients on 
aspirin therapy undergoing elective vascular surgery found that when platelet 
function was assessed using whole blood impedance aggregometry with arachidonic 
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acid stimulation those with residual platelet reactivity in the upper quartile had almost 
twice the rate of in-hospital cardiovascular events (154). Finally, a study conducted in 
patients with peripheral arterial vascular disease undergoing transluminal angioplasty 
found a high level of residual platelet reactivity on aspirin as measured by light 
transmission aggregometry, did not correlate with the rate of stent 
thrombosis/restenosis (372). 
 
There are a number of possible explanations as to why residual platelet reactivity 
didn’t correlate with ischaemic outcomes in our study. It is likely that a significant 
proportion of perioperative myocardial infarctions are due to an imbalance between 
myocardial oxygen supply and demand (type 2 MI). Multiple factors including high 
circulating catecholamine levels, vasospasm, endothelial dysfunction, hypotension 
and hypoxia in the perioperative period have the potential to cause a type 2 MI (375). 
Consistent with this concept a recent study demonstrated that coronary plaque 
rupture was present in slightly less than half of those suffering periprocedural MI 
following non-cardiac surgery (374). Whilst platelet activation plays a central role in 
type 1 MI, it may not play the same role in perioperative type 2 MI and as a result may 
not be predictive of these events. 
 
Another potential explanation for the failure of residual platelet reactivity to predict 
ischaemic events is that we studied a population with stable PVD. Although we found 
the response to aspirin to be highly variable, only 10% of patients had platelet 
reactivity values  >30 AU or high on treatment platelet reactivity. Studies in patients 
presenting with ACS have clearly shown high on treatment platelet reactivity to be 
predictive of future ischaemic events (375). However, studies of platelet function in 
those with stable coronary artery disease been less convincing and have failed to 
demonstrate an incremental predictive value over common risk factors for the 
occurrence of major adverse cardiovascular events (375, 376). Previous studies have 
shown patients presenting with critical limb ischaemia to have very high levels of 
platelet activation (377). Therefore it is possible that a poor response to aspirin may 
occur more frequently in a population presenting acutely for vascular surgery and may 
be more predictive of outcome.  
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The introduction of high-sensitivity cardiac troponin assays, which have a 10 times 
greater sensitivity compared with previous assays, has allowed the accurate 
determination of very low levels of circulating troponin (378, 379). As a result the 
elderly, and those with other comorbidities such as renal impairment, stable coronary 
disease and heart failure frequently have detectable circulating troponin, which may 
be elevated above the upper limit of normal (382). It is therefore not surprising 35% 
of our cohort had elevation of baseline hs-TnT above the upper limit or normal. 
Measurement of cardiac troponin has become the cornerstone for the diagnosis of 
myocardial infarction. Because of the possibility of background chronic elevations a 
rising or falling pattern of troponin levels is key to the diagnosis of MI. In our study 
there were 28 patients who had an elevated baseline hs-TnT that remained stable and 
elevated post operatively that potentially could have been misclassified as having a 
periprocedural event if post operative hs-TnT alone had been measured. 
 
Baseline hs-TnT was the biomarker most predictive of ischaemic events in our study. 
An elevated baseline hs-TnT was independently predictive of MACE at both 30 days 
and 1 year. Other studies have reported that an elevated post-operative troponin or 
periprocedural enzyme rise is predictive of long term outcomes (366, 367). To our 
knowledge this is the first study to demonstrate the utility of preoperative high 
sensitivity troponin in predicting risk of cardiovascular events in patients undergoing 
vascular or non-cardiac surgery. Elevated baseline hs-TnT has consistently been 
demonstrated to be a strong predictor of poor cardiovascular outcomes in a range of 
other patient populations. These include but are not limited to; patients with acute 
(383) and chronic coronary disease (382), in patients with congestive heart failure 
(383), in hemodialysis patients (386) and even healthy older patients (385). Our 
findings suggest that further investigation is warranted to confirmed the uitility of 
preoperative hs-TnT for risk stratification and to determine whether this is additive to 
existing risk stratification models. 
 
Elevated baseline CRP was associated with a higher risk of MACE at 1 year in univariate 
analysis but was not found to be a significant predictor in multivariate analysis. CRP is 
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an acute-phase protein and appears in the circulation in response to inflammatory 
cytokines, such as IL-6 and can act as a biomarker for systemic inflammation (386). 
Elevated levels of CRP in patients experiencing an ACS have shown to be a predictor 
of poor cardiovascular outcomes both short and long term (387, 388). The biomarker 
has also found to predictive of mortality in end-stage renal disease patients, 
independent of other classic biomarkers (389). Elevated CRP as a predictor of long-
term MACE in vascular patients, may reflect a higher level of background inflammation 
and indicate a more unstable atherosclerotic process, as seen in CAD populations 
(392). 
 
NT-proBNP is one of a family of cardiac peptides secreted almost exclusively by the 
myocardium in a nonspecific response to wall stress (391). Several studies have 
identified strong associations between elevated preoperative levels of NT-proBNP 
with adverse cardiac events both perioperatively and long term following non-cardiac 
surgery (392-394). Our study found a weak relationship between elevated baseline 
NT-proBNP and the occurrence of both bleeding and MACE in-hospital. Due to 
reduced power and large confidence intervals around the elevated risk, this 
association was not significant. However, previous HF was found to be a significant 
predictor of short-term MACE. A history of HF has also been identified as a cardiac risk 
factor for patients undergoing non-cardiac major surgery and proposed as an 
important component to be incorporated in to preoperative risk scores (397). It 
remains unclear how much additive prognostic value NT-proBNP levels can offer to 
stratify risk in vascular surgery patients. 
 
 The other clinical factors that were found to be independently associated with 
increased MACE risk were a BMI < 25 and AAA surgery. A lower BMI has previously 
been associated with a higher risk of death following major cardiac surgery compared 
to normal weight or obese patients (396). However, this may also be a reflection of a 
patients’ frailty, which has also been linked to poor outcome and has increasing 
interest as an important factor to integrate into pre-operative risk scores for cardiac 
surgery (397). Open AAA surgery was associated with an increased risk of short term 
MACE and co-located with bleeding. This finding is not surprising as it is well 
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established that AAA surgery is the type of vascular surgery associated with the 
highest risk of ischaemic events (398). Interestingly, AAA surgery was not associated 
with long-term MACE risk in our cohort. This is consistent with the large randomised 
trials investigating open AAA repair versus endovascular approaches, which found 
that the risk of open AAA occurs predominantly in the perioperative setting with a 
large decline in adverse events past 30 days (399). 
 
Major bleeding was found to be common with the vast majority of events occurring 
within the first 30 days. The AAA surgery group had 10 times higher risk of major 
bleeding and was the only significant factor identified. Several previous trials of 
therapy for AAA patients have also observed high rates of major bleeding. In the Dutch 
Randomized Endovascular Aneurysm Management (DREAM) trial, 39% of the 345 
patients submitted to aortic aneurysm repair received blood transfusions (398). 
Furthermore, in the Open Versus Endovascular Repair (OVER) trial, the authors 
observed a median of 1000mL blood loss during surgery in the 429 open AAA patients 
enrolled (399). This is similar to the observed 1045mL average blood loss in our AAA 
surgery patient group.  
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6.5 Limitations 
Firstly, in order to have the power to detect a relationship between biomarkers and 
patient outcome, the study was designed to recruit 240 patients undergoing major 
vascular surgery. Although this power calculation was based on a predicted adverse 
cardiovascular outcome rate of 21-24% and we experienced a much higher rate at 
34%, a cohort size of 100 patients leaves the study underpowered. When the 
inclusion/exclusion criteria were being determined, we did not fully appreciate the 
way in which the vascular service operated, particularly how they managed surgery 
waiting times and operation theatre scheduling. A management scheme which 
appears to be somewhat unique to the Wellington service, resulted in a large 
proportion of planned elective cases being pushed through on a semi-acute theatre 
list to get around limited vascular theatre access and long waiting lists. This resulted 
in a significantly reduced pool of eligible patients to recruit from. With a larger patient 
group we may have been able to detect significant relationships between some of the 
biomarkers and other clinical factors with cardiovascular and bleeding outcomes. The 
heterogeneity of the vascular procedures in the study could be considered a 
limitation. However, many previous studies have recruited similar population groups 
(367-369). All patients have atherosclerotic vascular disease and underwent major 
surgery. Our study population is somewhat restrained compared to other studies that 
have included a mix of those undergoing vascular surgery with endovascular 
interventions (154, 400) and elective and acute patients which arguably results in 
more variance in levels of perioperative risk between patients.  
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6.6 Conclusion 
Patients undergoing major vascular surgery remain at a high risk of experiencing 
perioperative and long-term adverse events. We have demonstrated for the first time 
that elevated hs-TnT at baseline is an independent risk factor for short and long term 
MACE in patients undergoing vascular surgery. Our findings suggest further 
investigation of the utility of baseline hs-TnT for pre-operative risk stratification is 
warranted. Although an elevated CRP was predictive of MACE at one year on 
univariate analysis, in multivariate analysis it was no longer predictive. Residual 
platelet reactivity on aspirin was not associated with either MACE or bleeding 
outcomes in our cohort. Major bleeding was frequent with the vast majority occurring 
early. This observation and the observation that bleeding and MACE frequently 
occurred concurrently suggests that the use of more potent antiplatelet therapy in the 
perioperative period in an attempt to reduce adverse events may not be a successful 
strategy. The majority of bleeding occurred in-hospital and AAA surgery was the only 
significant determinant of a major bleed occurring. This study supports further 
investigation of the incorporation of biomarkers, particularly hs-TnT into risk models 
that will enable the identification of patients that will benefit from additional 
preoperative evaluation. 
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7 Chapter 7: Platelet-T cell interactions  
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7.1 Introduction 
Historically, platelets have been noted for their significant thrombotic role in 
atherosclerotic plaque rupture. The previous chapters have focused on residual 
platelet reactivity as a driver or primarily thrombotic risk in patients with coronary 
artery disease and vascular disease. More recently, platelets have been established as 
cells that directly contribute to plaque progression (as reviewed in Section 1.3.2), 
which may also contribute to risk. This involvement has been demonstrated in several 
atherosclerotic mouse and in vitro human development models, revealing platelets 
bind to the endothelium and leukocytes, primarily through P-selectin, resulting in 
enhanced leukocyte recruitment and migration into the plaque (75). Additionally the 
high expression of CD40L (CD154) on platelet membranes and the release of soluble 
CD40L contribute significantly to the pro-inflammatory milieu of atherosclerotic 
plaques (94).  
 
Platelet-monocyte interactions have been thoroughly investigated in atherosclerosis 
including ACS. Platelet-monocyte conjugates have been shown to be increased in ACS 
patients, with platelet interactions inducing a more pro-inflammatory phenotype in 
circulating monocytes (403). High levels of the CD14++CD16+ monocyte subtype-
platelet conjugates has been correlated with a higher troponin release ACS and is 
predictive of poor outcome as indicated by a decreased left ventricular ejection 
fraction (404). Interestingly, loading ACS patients with clopidogrel decreased platelet-
monocyte conjugates, monocyte activation and the plasma levels of pro-inflammatory 
mediators RANTES and CD40L (405); further adding to the hypothesis that platelets 
drive pro-inflammatory environments.  
 
The interactions between platelets and lymphocytes are less well understood. It is 
confirmed that platelets and lymphocytes can bind and form conjugates which are 
preferentially formed with T cells. This connection is established via platelet P-selectin 
and lymphocyte P-selectin glycoprotein ligand-1 (PSGL-1) leading to enhanced 
migration of lymphocytes to plaques (406). In contrast, CD40-CD40L cross-linking 
enhances T cell cytokine production (407). Platelets also release several soluble 
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factors that may influence T cell activation, including platelet factor 4 (PF4), 
transforming growth factor-β (TGF-β) and RANTES. However work done to date has 
been conducted in predominantly mouse models of disease or in healthy individuals 
and may not be relevant to how platelets function in patients with atherosclerosis. 
Therefore the focus of this chapter was to investigate differences in platelet–T cell 
interactions in patients with atherosclerotic vascular disease compared to healthy 
controls.  
 
The specific aims of this study were:  
1. To determine the level of platelet-T cell conjugates in healthy and 
vascular patients.  
2. To investigate differences in platelet conjugates with T cell subgroups 
(CD4, CD8 and natural killer T cells) between the two patient groups. 
3. To assess alterations in the activation phenotype of CD4 and CD8 T cells 
between healthy and disease state and any changes in platelet 
interactions with these cells.  
 
7.2 Methods 
7.2.1 Study population 
Two patient groups were included to investigate platelet – T cell conjugates. All 
patients provided written informed consent and the study was reviewed and 
approved by the Upper South A Regional Ethics Committee (URA/11/05/016). 
7.2.1.1 Healthy volunteers 
Participants enrolled in the study were between the ages of 18 – 50 years with no 
known cardiovascular disease, or other acute illness within the preceding six weeks. 
Exclusion criteria included diabetes, smokers, pregnancy, intercurrent illness and 
those who were on regular cardiovascular or immune modulating medication or had 
been treated with antiplatelet therapies or non-steroidal anti-inflammatory drugs 
(NSAID) within the last 7 days. 
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7.2.1.2 Vascular patients 
Patients in whom the presence of peripheral atherosclerotic vascular disease had 
been confirmed angiographically were recruited into the vascular cohort. Exclusion 
criteria included treatment with an antiplatelet agent or NSAID within 7 days of 
enrolment, a platelet count less than 100 x 109/L, a known platelet function or 
bleeding disorder or intercurrent illness.  
7.2.2 Blood collection and antibody staining 
Blood for platelet-lymphocyte conjugate analysis was collected into a single hirudin 
tube as previously described (section 2.2.2). Whole blood was stained in duplicate 
with the four antibody panels made up in FACS buffer (Table 7-1) at 30 minutes post 
blood sampling. Appropriate isotype controls were stained alongside panel samples 
(Appendix 2). A total staining volume of 50 μL (1:1 dilution of blood to antibody mix) 
was incubated in 1.5 mL eppendorfs for 20 minutes at room temperature (RT) in the 
dark. Following staining, 450 μL of FACS Lyse containing 1% paraformaldehyde (PFA) 
(BD Biosciences, NJ, USA) was added and gently mixed to lyse red blood cells and fix 
the sample for acquisition.  
7.2.3 Flow cytometry 
Flow cytometry was used to identify T cell and platelet populations and acquired using 
the Millipore Guava easyCyte 8HT system (Merck Millipore, Darmstadt, Germany). 
Samples were diluted with FACS buffer before acquisition to achieve an optimal cell 
concentration between 300-500 cells/μL. Anti–mouse Ig, κ/compensation beads (BD 
Biosciences, NJ, USA) were acquired at the same time as samples for compensation 
during analysis. Data was analysed using FlowJo software (Tree star, Ashland, OR, 
USA). 
At least 5000 T cell events were collected in every sample by gating on the CD3 positive 
cells. Platelet-Tcell conjugates with the different T cell subgroups were determined by 
the gating strategies outlined in Figures 7-1, 7-2 and 7-3. 
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Table 7-1 Platelet-T cell conjugates antibody panels 
 Panel 1 Panel 2 Panel 3 Panel 4 
Channel Antibody Final Conc Antibody Final Conc Antibody Final Conc Antibody Final Conc 
FITC CD3 500ng/mL CD3 500ng/mL CD3 500ng/mL CD3 500ng/mL 
PE CD8 15ng/mL CD44 1μg/mL CD44 1μg/mL CD56 250ng/mL 
PerCP CD42a 1.25μg/mL CD42a 1.25μg/mL CD42a 1.25μg/mL CD42a 1.25μg/mL 
PE-Cy7 CD4 500ng/mL CD4 500ng/mL CD8 250ng/mL CD4 500ng/mL 
APC CD25 250ng/mL CD62L 500ng/mL CD62L 500ng/mL CD25 250ng/mL 
* A list of all antibody formats, clones, isotypes and manufactures can be found in Appendix 2. 
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Figure 7-1 Gating strategies to identify CD8 and CD4 platelet-T cell conjugates.  
T cells were identified by their SSC properties and expression of CD3 (A). CD4 and CD8 T cells were then identified by their expression of CD4 (B) and CD8 
(E) respectively. Gating on these separate T cell population, CD42a could be used to identify platelet positive populations (C & F) as compared to the isotype 
control (D & G).   
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Figure 7-2 Gating strategy to identify activation phenotype of CD4 and CD8 T 
cells 
CD4 and CD8 T cells were then identified by their expression of CD4 (A) and CD8 (E) 
respectively The cell markers CD62L and CD44 were used to identify memory and effector T 
cells on pre gated CD4 (B) and CD8 populations (F). The platelet marker CD42a was used to 
identify memory T cell- platelet conjugates (C & G) and effector T cell-platelet conjugates (D & 
H) as compared to isotype control (right panel).   
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Figure 7-3 Gating strategies to identify T regulatory (Treg) cells and Natural 
Killer T cells (NKT). 
T cells were identified by their SSC properties and expression of CD3 (A). Treg cells were 
identified by their expression of CD4 and CD25 (C) as compared to isotype control (B). NKT 
cells were identified by the expression of CD56 (D) as compared to the isotype control (C). 
7.2.4 Statistics  
Platelet-T cell conjugate data was normally distributed as confirmed by D’Agostino & 
Pearson normality testing. Platelet-T cell conjugates are expressed at mean 
percentages ± the standard deviation. Platelet-T cell conjugates were compared 
between healthy and vascular cohorts using student t test. Statistical analysis and 
graphs generated using GraphPad prism 5 (GraphPad Software Inc., La Jolla, CA, USA). 
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7.3 Results 
7.3.1 Demographics  
The healthy volunteer group was relatively young with a mean age of 31 and did not 
have any known cardiovascular disease or risk factors as per the inclusion/exclusion 
criteria (Table 7-2). The vascular patient group was more than twice the age of the 
healthy volunteers at 77 and displayed multiple cardiovascular risk factors and 3 of 
the patients had documented ischaemic heart disease or previous stroke. Only 2 
patients were receiving statin therapy and several were on blood pressure lowering 
agents. The two populations were sex matched with 4 males in each group. 
Table 7-2 Demographics of healthy volunteers and vascular patients 
 Healthy volunteers 
(n=10) 
Vascular patients 
(n=10) 
Male, n 4 4 
Age  31 ± 9 77 ± 8 
Current Smoker 0 4 
Diabetes 0 4 
Hypertension 0 6 
Hyperlipidaemia 0 2 
Ischaemic heart disease 0 2 
Previous stroke 0 1 
Medications 
Statin 0 2 
Beta blocker 0 3 
ACE inhibitor 0 2 
Calcium channel blocker 0 1 
Diuretic 0 3 
7.3.2 Platelet-T cell conjugates  
Firstly, the overall T cell population was analysed and total platelet-T cell conjugates 
were compared between the two participant groups. The percentage of platelet-T cell 
conjugates was significantly increased in patients with vascular disease (37.7% ± 10%) 
compared to healthy controls (23.9% ± 8.7%, p = 0.005, Figure 7-4). 
CHAPTER 7 
 
174 
 
Figure 7-4 Platelet-T cell conjugates 
Whole blood from healthy volunteers (n=10) and vascular patients (n=10) were stained with 
anti-CD42a and anti-CD3 antibodies to identify platelet-T cell conjugates using flow cytometry. 
Platelet-T cell conjugates are presented as the % of T cells positive for the CD42a marker. Data 
is plotted for all 10 patients in each group as mean ± SD in healthy volunteers and patients with 
vascular disease. Student T test * p=0.005.  
7.3.3 CD4 T cell interactions 
To investigate differences in platelet interactions with T cell subgroups, we initially 
looked at CD4 T cell populations and found significant changes in this subgroup 
between patient groups. The majority of T cells in both healthy volunteers and 
patients with vascular disease expressed CD4, comprising approximately 70% of the T 
cells (Figure 7-5A). Although there was no significant difference in the proportion of 
CD4 T cells between healthy and vascular patients, the level of platelet-CD4 T cell 
conjugates was significantly higher in the vascular patients (Figure 7-5B). Platelet-CD4 
T cell conjugates increased by 40% from 26.6% ± 5.9% in healthy volunteers to 37.6% 
± 7.9% in vascular patients, p =0.004. There were also differences in the activation 
phenotype of the CD4 T cells between the two patients groups. In the healthy 
volunteers, the majority of CD4 T cells were of a memory phenotype with a smaller 
proportion exhibiting effector phenotype markers (Figure 7-5C). In the vascular 
patients the majority of CD4 T cells were of an effector phenotype resulting in a 2 fold 
increase from healthy levels (31.8% ± 7% to 64.8% ± 11%, p < 0.0001). Accordingly 
there was a substantial drop in memory CD4 cells in vascular patient samples 
compared to healthy volunteers (61.3% ± 11% to 33.3% ± 13%. P <0.0001). Although 
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there was a large shift in the activation state of CD4 T cells between patient groups, 
there was no significant difference in the level of platelet-T cell conjugates between 
these different activation phenotypes (Figure 7-5D).  
Figure 7-5 CD4 T cell interactions with platelets 
Whole blood from healthy volunteers (n=10) and vascular patients (n=10) were stained with 
anti-CD42a, anti-CD3, anti-CD4, anti-CD62L and anti-CD44 antibodies to identify platelet-CD4 
T cell conjugates and CD4 activation phenotypes using flow cytometry. These antibodies were 
used to specifically identify: the proportion of T cell population expressing CD4 (A), platelet-
CD4 T cell conjugates (B), the proportion of CD4 T cells displaying effector and memory 
activation phenotypes (C) and the proportion of effector and memory CD4 cells that are platelet 
bound (D) in healthy volunteers and vascular patients. Data is plotted for all 10 patients in each 
group as mean ± SD Student T test * p < 0.001.  
A subset of CD4 T cells; T regulatory (Treg) cells were investigated and found to be in 
low circulating numbers making up on average 1.1% ± 0.7% of CD4 positive cells. In 
vascular patients the proportion of Treg cells doubled to a mean of 2.1% ± 1.2% (p= 
0.04, Figure 7-6A). However, the level of platelet conjugates in the Treg population 
did not significantly change between the healthy volunteers and vascular patients 
(28.3% ± 9.2% vs. 35.84% ± 12.5%, p = 0.14, Figure 7-6B)  
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Figure 7-6 T regulatory (Treg) cell interactions with platelets 
Whole blood from healthy volunteers (n=10) and vascular patients (n=10) were stained with 
anti-CD42a, anti-CD3, anti-CD4 and anti-CD25 antibodies to identify Treg cells and platelet-
Treg conjugates using flow cytometry. Data shows the proportion of CD4 T cells expressing the 
Treg marker CD25 (A) and the level of platelet-Treg conjugates (B) in healthy volunteers and 
vascular patients. Data is plotted for all 10 patients in each group as mean ± SD. Student T test 
*p = 0.04 
7.3.4 CD8 T cell interactions 
Platelet interactions were also investigated in CD8 T cells. Similar to the CD4 T cell 
population, the proportion of CD8 T cells did not change between healthy volunteers 
and vascular patients but made up a smaller proportion at 22% (Figure 7-7A). In 
contrast to platelet-CD4 T cell interactions, the level of platelet-CD8 T cell conjugates 
were not significantly elevated in vascular patients (33% ± 9%) compared to healthy 
volunteers (31% ± 8%, Figure 7-7B). The activation phenotypes were also investigated 
in CD8 T cells. Similar to the observed activation phenotypes of CD4 cells, there was a 
1.4 fold increase in the effector phenotype in vascular patient samples (35.4% ± 10%) 
compared to healthy volunteers (25% ± 9%, p = 0.03). However, there was no 
difference in the memory CD8 cells between the two groups and these remained the 
predominant activation phenotype in both healthy volunteers and vascular patients 
(Figure 7-7C). Furthermore, the level of platelet-CD8 conjugates did not differ 
between effector/memory phenotypes or patient population (Figure 7-7D).  
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Figure 7-7 CD8 T cell interactions with platelets. 
Whole blood from healthy volunteers (n=10) and vascular patients (n=10) were stained with 
anti-CD42a, anti-CD3, anti-CD8, anti-CD62L and anti-CD44 antibodies to identify platelet-CD8 
T cell conjugates and CD8 activation phenotypes using flow cytometry. These antibodies were 
used to specifically identify: the proportion of the T cell population expressing CD8 (A), platelet-
CD8 T cell conjugates (B), the proportion of CD8 T cells displaying effector and memory 
activation phenotypes (C) and the proportion of effector and memory CD8 cells that are platelet 
bound (D) in healthy volunteers and vascular patients. Data is plotted for all 10 patients in each 
group as mean ± SD. Student T test * p < 0.05.  
7.3.5 Natural Killer T cells 
Natural killer T (NKT) cells were found to constitute approximately 2.8% ± 1.9% of T 
cells in healthy volunteers. NKT cells were more populous in vascular patients with an 
increase of 40% compared to healthy levels (4.5% ± 2%), however this difference was 
not statistically significant (P = 0.06, Figure 7-8A). Furthermore, there was a trend of 
increased platelet binding to NKT cells in vascular patients compared to healthy 
controls (25% ± 7% vs. 35% ± 15%, p = 0.08, Figure 7-8B). 
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Figure 7-8 Natural Killer T (NKT) cell interactions with platelets 
Whole blood from healthy volunteers (n=10) and vascular patients (n=10) were stained with 
anti-CD42a, anti-CD3 and anti-CD56 antibodies to identify NKT cells and platelet-NKT 
conjugates using flow cytometry. Data shows the proportion of T cells expressing the NKT 
marlker CD56 (A) and the level of platelet-NKT conjugates (B) in healthy volunteers and 
vascular patients. Data is plotted for all 10 patients in each group as mean ± SD. Student T test 
– ns.  
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7.4 Discussion 
This study investigated platelet-T cell interactions in a healthy and an atherosclerotic 
inflammatory disease state and found significant differences between the two groups. 
Platelet-T cell conjugates were found to be more prevalent in vascular patients. 
Platelet binding to CD4 T cells also occurred more frequently in vascular patients when 
compared to healthy volunteers. However, there was no significant change in platelets 
binding to CD8 or NKT cells between the two groups. The activation phenotypes of 
CD4 T cells also changed dramatically, with a predominant memory phenotype seen 
in healthy volunteers switching to an effector response in vascular patients. This 
switch in activation was not observed in the CD8 T cells. For both the CD4 and CD8 T 
cell subgroups, there was no change in platelet binding to the different activation 
phenotypes or change between the healthy volunteers and vascular patients.  
 
We observed a high level of platelet-T cell conjugates in vascular patients at an 
average of 37% compared to 20% in healthy volunteers. This is the first study to look 
at platelet-T cell conjugates in atherosclerotic vascular disease in humans compared 
to healthy volunteers specifically. Previous studies have investigated other immune 
cells interacting with platelets such as circulating platelet-neutrophil, platelet-
monocyte and overall platelet-leukocyte conjugates in atherosclerosis, diabetes, 
cerebral stroke and other inflammatory states (406, 407). These studies also observed 
a significant increase in platelet-immune cell conjugates but did not investigate the 
particular differences in the T cell population.  
 
The higher level of platelet–T cell conjugates found in the vascular disease population 
may be due to several factors influencing both the platelets and T cells reactivity. 
Resting platelets do not express P-selectin or CD40, but upon activation these two 
ligands are quickly trafficked to the surface. In advanced atherosclerosis such as 
vascular disease, platelets display a higher activity and express significant levels of 
both ligands which are the main linkers to attach to T cells and potentially influence 
function and differentiation (78). Stimulation of platelets with classical agonists such 
as ADP and thromboxane A2 has been shown to increase platelet-leukocyte 
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conjugates (408) in healthy and ACS populations however this has not been confirmed 
in T cells.  
 
The communication between platelets and T cells is most likely bidirectional and the 
activation state of the T cell will also influence its ability to bind platelets. In vitro 
stimulation of human T cells with anti-CD3/anti-CD28 showed an enhanced CD40L 
surface expression on T cells leading to more potential communication with platelets 
through the CD40-CD40L system (409). In a further study done in healthy volunteers, 
expression of this ligand on T cells resulted in contact mediated activation of platelets 
via the CD40 dependent pathway resulting in RANTES release from platelets, which 
can influence T cell trafficking (410). Additionally, a study conducted in healthy 
volunteers found T cells that were larger in size and more granular coupled with high 
expression levels of the activation marker CD69, had more platelets attached 
compared to the smaller less active T cells (411). As this study looked purely at the 
level of interaction between platelets and T cells and we did not block the cells activity 
we cannot determine which cell is determining the interaction. Although, we would 
hypothesise that activation of either cell will enhance platelet–T cell conjugation.  
 
Other disease states, such as diabetes can also influence platelet and T cell function. 
A high proportion of patients with atherosclerosis, particularly those with lower 
extremity vascular diseases, have diabetes and as reviewed in section 1.4.4.3, this 
highly inflamed state can produce abnormally reactive and pro-inflammatory 
platelets. This vascular cohort also had other co-morbidities and underlying illness, 
including hyperlipidaemia, hypertension, and smoking which could be nurturing both 
pro and anti-inflammatory states. Due to these other conditions, many of the patients 
were on several drug therapies, which may also be influencing platelet and T cell 
responses. Surprisingly, at the time of enrolment only 2 of the vascular cohort were 
receiving statin therapy, which as a front line therapy for vascular disease has been 
shown to have profound effects on not only lipid levels but the immune system as well 
(412).  
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The level of platelet–T cell conjugates observed in our healthy donor population was 
relatively high at 20% compared to other reports of platelet–lymphocyte conjugates 
in healthy volunteers (3 - 15%)(411, 413). This can be partially explained by the 
different parameters other studies expressed their platelet-leukocyte populations and 
the experimental conditions used. Several studies have expressed platelet–
lymphocyte conjugates based on size and CD45 expression, which includes both T and 
B cells. As B cells have shown to have a low propensity to bind with platelets (414), 
this may decrease overall averages reported. Several studies have used sodium citrate 
as their anticoagulant for blood collection and as shown in Chapter 2, citrate can cause 
a decrease in platelet reactivity due to the depletion of calcium, which may potentially 
result in an artificially low platelet–T cell conjugate level. Studies investigating 
platelet-leukocyte binding in different anticoagulants, found a dramatic reduction in 
citrated blood compared to bivalirudin and heparin, due the calcium dependent 
nature of P-selectin binding with PSGL-1 (417). 
 
Within the T cell subgroups, we found interesting changes in the T helper cells that 
were not displayed in the cytotoxic CD8 cells. Platelets binding with CD4 cells occurred 
more frequently in vascular patients compared to CD8 or NKT cells. CD4 T helper cells 
are abundant in atherosclerotic plaques and their important role in atherogenesis has 
been highlighted by earlier animal studies showing that transfer of CD4 T cells 
aggravates (418), whereas CD4 deficiency attenuates (417) development in ApoE 
knockout mice. This significant increase in platelet–CD4 T cell binding observed in 
patients with vascular disease, could indicate important communications occurring 
between these two cell types in atherosclerosis.  
 
The predominant activation phenotype of CD4 T cells shifted from a memory 
phenotype in healthy donors to an effector phenotype in vascular patients. CD4 T 
effector cells are antigen-experienced cells that offer immediate effector functions 
and migrate into plaques to sustain inflammation (418). A study looking at CD4 naïve, 
effector and memory cells found high levels of effector cells were associated with a 
greater intima-media thickness of the common carotid artery and were more common 
in patients with chronic angina or ACS compared to healthy controls (418). However, 
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with this change in activation we did not see a significant difference in platelet binding 
between the different activation states or patient groups. Furthermore we observed 
an increase in Tregs in vascular patients but no increase in platelet binding. This 
difference may be partially due to the smaller cell numbers and statistical power when 
analyzing platelet binding within CD4 subgroups. It also could indicate the platelets’ 
effect on CD4 T cells is mediated through mechanisms other than platelet binding.  
 
Platelets can exert their effects on immune cells not only through cell-to-cell contact 
but also through powerful soluble mediators. Platelets release many soluble factors, 
which can have mitogenic effects on a diverse range of cells including lymphocytes. In 
vitro human and animal models have demonstrated the soluble factors RANTES and 
platelet-derived growth factor (PDGF) promote proliferation of CD4 T cells (419, 420). 
Other soluble mediators such as Platelet factor 4 (PF4), TGFβ and thromboxane A2 
have more complex actions on proliferation and either promote or inhibit 
proliferation depending on the local environment and the CD4 subset that is being 
targeted (423). Similarly, platelets release a multitude of cytokines, chemokines and 
growth factors that effect CD4 T cell differentiation and cytokine production. As with 
proliferation, these interactions are complex and each CD4 T cell subset is affected 
differently. Th1 cells appear to be highly stimulated by platelets via IL-1β (422), 
RANTES (423) and monocyte chemoattractant protein-1 (MCP-1) (424) whereas Th2 
are either stimulated, barely affected or inhibited by platelet contact depending on 
the environment (423). Interestingly, Tregs are also stimulated by platelets 
particularly through TGFβ (423, 425) and PF4 (426). Th17 are a relatively new subtype 
of CD4 T cells to be investigated and platelets act to promote differentiation and 
cytokine production through IL-1β and TGFβ (422). But as many of these studies that 
have investigated the effect of isolated mediators on T cell differentiation and 
function have been conducted in vitro, crucial in vivo information is lacking on how 
platelets act on CD4 T cells within the complex milieu of atherosclerosis. 
 
As this study looked at the overall CD4 T cell population and not the individual subsets, 
we cannot determine whether there were significant differences in binding between 
the subsets in a healthy state or atherosclerosis. As highlighted in section 1.2.2, Th1 
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cells are abundant in plaques and promote a pro-inflammatory environment. Whereas 
Tregs suppress inflammation and their absence is linked to progressive and unstable 
plaques. However, all CD4 T cell subsets are present in plaques with varying numbers. 
Therefore understanding how platelets interact with these cells, the consequences of 
these interactions on the immune system and how this is modified by existing 
antiplatelet agents is important as it will allow us to understand potential mechanisms 
of action of existing drugs and may allow us to identify additional targets for novel 
therapies. 
 
Unlike the CD4 T cell population there were few changes in the CD8 cytotoxic T cells 
between healthy donors and vascular patients. There was a 40% increase in effector 
CD8 T cells, but this activation phenotype did not predominate. There was no increase 
in platelet binding to CD8 T. CD8 T cells are present in atherosclerotic plaques and 
have been identified in early lesions in mouse models, yet their role in atherosclerosis 
remains unresolved. A recent study looking at CD8 T cells in a mouse model of 
atherosclerosis concluded CD8+ T lymphocytes promote the development of 
vulnerable atherosclerotic plaques by perforin- and granzyme B–mediated apoptosis 
of macrophages, smooth muscle cells, and endothelial cells that, in turn, leads to 
necrotic core formation and further augments inflammation by TNF-α secretion (427). 
However, there is limited evidence to confirm this finding in humans. The increase in 
CD8 effector T cells observed in the vascular group may represent more active CD8 T 
cells in atherosclerosis promoting inflammation. Platelets have been reported to 
interact with and enhance CD8 T activity; particularly in adenovirus infections, causing 
IFN-γ production and increasing the cytolytic capacity of CD8 T cells (407). Although 
our study would suggest that platelets are not influencing CD8 T cell function in 
vascular disease.  
 
Our study observed a 40% increase in Natural Killer T (NKT) cells in vascular disease 
however this trend was not statistically significant. NKT cells are a unique subset of T 
lymphocytes that share surface markers from both conventional T cells and NK cells. 
Although NKT cells are associated with decreasing inflammation and immune 
responses in autoimmune disease and cancer (430), their role in atherosclerosis has 
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been found to be pro-atherogenic especially in early lesional development. Unlike 
conventional T cells that only recognize peptide antigens, NKT cells can recognize 
glycolipid antigens as well and it is this ability that has been hypothesized to promote 
the pro-atherogenic response of NKT cells in a typically high ox-LDL environment 
(431). With the increase in NKT cells in our vascular cohort we also observed a trend 
to increased platelet binding. The potential for platelets and NKT to interact are 
practically unknown in either healthy donors or patients with atherosclerosis. Studies 
investigating Natural Killer (NK) function have shown platelets can inhibit NK cell’s 
anti-tumor cytolytic ability, thereby increasing tumor metastasis in mouse models 
(432) and as discussed previously platelets exert their influence on T cells in a host of 
different ways. Therefore, this finding could signify a novel interaction of platelets and 
NKT cells in atherosclerosis that warrants further investigation.  
7.5 Limitations 
As we designed this study to look specifically at platelet-T cell interactions, we did not 
include markers of platelet–monocyte or platelet–neutrophil conjugates which have 
been well documented and investigated in these two populations and could have 
acted as a positive control for the assay in our cohorts. However, as we were 
interested in the changes between the two populations using the same standardised 
procedure and not at platelet–T cell conjugates as a biomarker for disease, the need 
for this positive control is reduced. The study population was relatively small with 10 
people per group and a larger cohort would have allowed more statistical power for 
subgroup analysis. However we did find significant differences between the healthy 
donors and vascular group, which has highlighted areas of interest to pursue further. 
The average age of the healthy volunteer group was significantly lower than the 
vascular population, which may have impacted on our findings. However, to ensure 
the healthy group were free of risk factors and were unlikely to have occult 
atherosclerosis, this difference in age was necessary to investigate our aims. Similar 
to other vascular disease populations, several of the patients had other co-morbidities 
such as diabetes, hyperlipidaemia and hypertension and receiving treatments that we 
could not rule out as factors influencing platelet–T cell conjugates irrespective of 
atherosclerosis. But as this disease is complex and the interactions between platelets 
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and immune cells change dramatically depending on the physiological and 
pathological microenvironment, studying these interactions in a real world in vivo 
setting is imperative to advancing our understanding of atherosclerosis.  
7.6 Conclusion 
In this study we observed an increase in platelet–T cell conjugates in vascular patients 
compared to healthy donors. Platelets also preferentially bound to CD4 T and NKT 
cells in vascular disease, which was not observed in the CD8 T cell subgroup. The CD4 
T cell subgroup also exhibited changes in the activation phenotype, shifting from a 
predominantly memory phenotype in healthy patients to an effector response in 
vascular disease, which again was not observed in the CD8 cells. These changes in the 
CD4 T cell population coupled with our existing knowledge of the important role of 
CD4 T cells in atherosclerosis, raises questions on how platelets may be influencing 
the different subtypes of helper T cells to influence disease progression and what 
impact inhibiting these interactions has on the immune system. 
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8 Chapter 8 – The effect of platelets on 
CD4 T cell differentiation 
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8.1 Introduction 
As discussed in Chapter 7, CD4 T cells are major orchestrators of atherosclerotic lesion 
progression, and platelets may provide key interactions with CD4 T cells that influence 
their response. However, because different subsets of CD4 T cells may have either 
pro-inflammatory or regulatory functions in atherosclerosis, it is unknown how 
platelets may impact each of these different functional subsets. The inhibition of 
platelets with clopidogrel has been associated with reductions in CRP levels and 
decreased expression of CD40L and P-selectin in a variety of disease states, including 
cardiovascular disease, cerebrovascular disease, diabetes, and renal transplantation 
(433). This anti-inflammatory response may potentially be due to modulation of 
leukocyte responses by platelet inhibition, and in particular, could involve the 
inhibition of platelet interactions with pro-inflammatory T cells or possibly 
augmentation of the anti-inflammatory activity of Tregs. 
 
Antiplatelet therapy is a cornerstone treatment in patients with CAD and PVD due to 
their known ability to prevent platelet aggregation and reduce thrombotic risk. This 
has been our main focus in the first series of studies. However, antiplatelet therapy 
may be providing protection from adverse events through other mechanisms other 
than thrombosis.  
  
Therefore this chapter investigates the impact of platelet interactions on CD4 T cell 
differentiation and the effect of antiplatelet therapy on platelet-T cell interactions. 
This study was designed to investigate 1) how platelets could modify CD4 T cell subset 
differentiation and 2) if and how this differentiation was changed after antiplatelet 
therapy. Therefore, to exclude any variance in the immune response due to disease 
state, concurrent medication use and increasing age that is often present in patients 
with atherosclerosis, we decided to conduct the study in healthy volunteers.  
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The specific aims of the study were:  
1. To examine the impact of CD4 T cell-platelet interactions on IFN-γ 
production.  
2. To investigate the impact of CD4 T cell-platelet interactions on CD4 T 
cell differentiation, specifically Th1, Th17 and Treg subsets.   
3. To investigate the effect of inhibiting platelet-T cell interactions in-vivo 
on IFN-γ production and T cell differentiation using the P2Y12 
antagonist, prasugrel. 
8.2 Methods 
8.2.1 Study population 
Participants enrolled in the study were between the ages of 18 – 50 years with no 
known cardiovascular disease. Exclusion criteria included diabetes, smokers, an acute 
illness within the preceding six weeks and those who were treated with cardiovascular 
medication including antiplatelet therapies, non-steroidal anti-inflammatory drugs 
(NSAID) or immune modulating medications. All participants provided written 
informed consent and the study was reviewed and approved by the Central Regional 
Ethics Committee (12/CEN/59). The study was also registered with the Australian New 
Zealand Clinical Trials Registry (registration number ACTRN12612001157864).  
8.2.2 Study design and drug treatment  
This was a prospective, double-blind, placebo-controlled, randomized crossover trial. 
Subjects were randomized to receive either 60 mg of prasugrel (Group A) followed by 
10 mg/day prasugrel for 6 days or placebo (Group B) (Figure 8-1). After the first 
treatment there was a washout period of 21 days and participants were crossed over 
to the other study drug. An independent cardiology research nurse conducted 
randomization and drug administration.  
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Figure 8-1 Study cross over protocol 
8.2.3 Blood sampling and Multiplate testing 
Blood was drawn before and after each drug treatment from a peripheral arm vein as 
described previously in Chapter 2.2.2. Thirty-five ml of blood was drawn into sodium 
heparin tubes (158 USP unites, BD Biosciences, NJ, USA) for CD4 T cell isolation. A 
single hirudin tube (25 μg/ml, Dynabyte, Munich, Germany) was also obtained for 
isolation of autologous platelets and platelet function testing using the Multiplate, as 
described in Chapter 2.2.2 to assess adequate antiplatelet therapy was achieved.  
8.2.4 Peripheral blood mononuclear cell (PBMC) isolation 
All cell work was carried out in a class II purifier biological safety cabinet (LABCONCO, 
MO, USA) with HEPE air filters. Before use, sterilization with ultraviolet (UV) light 
(1390 mW/m2) for 15 min was carried out and all surfaces were wiped down with 70% 
ethanol. Blood was diluted 2.3 fold in sterile PBS and carefully layered on top of RT 
Histopaque-1077 Hybri Max (Sigma, MO, USA) in 15 ml Falcon tubes (BD Biosciences, 
NJ, USA) with a 1:1 ration of Histopaque to whole blood. The tubes were then spun at 
400 x g for 30 minutes at RT. The upper plasma layer was aspirated and discarded to 
within 0.5 cm of the opaque interface containing the peripheral blood mononuclear 
cells (PBMCs). The buffy coat layer was then carefully transferred to a separate tube 
and washed twice with 10 ml of dPBS, mixed with inversion and centrifuged at 250 x 
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g for 5 minutes. Cells were counted using a hemocytometer and 0.4% tryphan blue 
(Sigma, MO, USA) and resuspended at 5 x 107 cells/ml in isolation buffer (Appendix 1).  
8.2.5 CD4 T cell isolation 
CD4 T cells were isolated using the Dynabeads Untouched Human CD4 T cell kit (Life 
Technologies, CA, USA). Following the manufacturers instructions, 100 μL of FCS and 
100 μL of antibody mix was added to the aliquot of isolated PBMCs and incubated for 
20 minutes at 4°C. Cells were then washed with 4 ml of isolation buffer and mixed by 
inversion several times before being centrifuged at 350 x g for 8 minutes at 5°C. The 
washed pellet of cells was resuspended in 500 μL of IB. 500 μL of pre-washed 
Dynabeads (Life Technologies) were added to the cell suspension and the sample was 
incubated for 15 minutes at RT with gentle tilting and rotation. Following incubation, 
4 ml of isolation buffer was added to the bead-cell mix and the bead-bound cells were 
resuspended by pipetting the sample thoroughly with a 100 μL tipped pipette whilst 
avoiding foaming. The tube was then placed in the Dynamag magnet (Life 
Technologies) for 2 minutes and the supernatant containing the isolated CD4 T cells 
was transferred to a fresh tube. A further 4 ml of isolation buffer was added to the 
tube containing the bead-bound cells, repeating the resuspension and aspiration of 
remaining CD4 T cells. The CD4 T cells were counted and washed before resuspending 
in dPBS at 2 x 106 cells/ml.  
8.2.6 Isolation of autologous platelets 
Platelets were isolated from hirudin anticoagulated blood by centrifuging at 200 x g 
for 20 minutes at RT. The upper 2/3 of platelet-rich-plasma (PRP) was collected and a 
platelet count was determined using the XE-2100 hematology analyser (Sysmex, 
GmbH, Germany) operated and located in the Wellington Hospital Medical 
Laboratory. PRP was centrifuged at 1,000 x g for 15 minutes at RT and resuspended in 
CTCM at 2 x 108 cells/ml. 
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8.2.7 Cell culture 
T cells were resuspended in CTCM and plated in 96-well tissue culture U bottom plates 
(BD Biosciences, NJ, USA) with 2 x 106 T cells per well. For stimulated samples, the T 
cells were plated in 96 well anti-human CD3 T cell activation plates (BD Biosciences, 
NJ, USA) with the addition of 0.3 ug/ml of purified NA/LE mouse anti-human CD28, 
clone CD28.2 (BD Biosciences, NJ, USA). For platelet-T cell co-cultures, 1 x 107 platelets 
resuspended in CTCM were added to sample wells to give a final ratio of 1:250 of T 
cells to platelets. All samples were cultured in a Sanyo CO2 incubator (Global Science, 
PA, USA) for 48 hours in a humid environment at 37°C, supplemented with 5% CO2. 
For the last 5 hours of incubation BD GolgiStop (BD Biosciences, NJ, USA) was added 
to all samples and anti-CD3/CD28-stimulated CD4 T cells were challenged with PMA 
(50 ng/ml)/Ionomycin (1 μg/ml).  
8.2.8 CD4 T cell phenotyping 
Samples were transferred to eppendorf tubes after 48 hours of incubation and cells 
were spun out of media at 250 x g for 5 minutes. Supernatant from cell cultures was 
aspirated and frozen for IFN-γ quantification. Cells were washed in 500 μL of PBS, spun 
at 250 x g for 5 minutes and the supernatant removed to leave 50 μL of resuspended 
cells. Fixable viability dye eFlour 780 (eBioscience, CA, USA) was diluted 1:5000 and 
added to cells to give a final concentration of 1:10000, and used to gate out dead cells 
during analysis. Cells were incubated with the viability dye on ice in the dark for 30 
minutes followed by the addition of 500 μL FACS buffer (Appendix 1). Samples were 
spun at 250 x g for 5 minutes, the supernatant was removed, and an additional FACS 
wash was performed before staining with the extracellular CD4 antibody. Cells were 
stained with a final concentration of 500 ng/ml anti-human CD4 PE-Cy7 (clone OKT4, 
Biolegend, CA, USA) in 100 μL of FACS buffer for 20 minutes in the dark at RT.  
 
After staining, cells were washed twice with 500 μL of FACS buffer and centrifuged at 
250 x g for 5 minutes, leaving a cell suspension of 100 μL for intracellular staining. The 
intracellular staining of the CD4 T cells was performed using the Human Th17/Treg 
Phenotyping Kit (BD Biosciences, NJ, USA) following manufacturers guidelines. Cells 
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were fixed with 500 μL of Human FoxP3 Buffer A and incubated for 15 minutes in the 
dark at RT. The fixative was removed by spinning samples at 500 x g for 5 minutes and 
the supernatant aspirated carefully to not disturb the buoyant pellet. To permeablize 
cells, 400 μL of FoxP3 Buffer C was incubated with samples for 30 minutes in the dark 
at RT. Cells were washed twice with 500 μL of FACS buffer and centrifuged at 500 x g 
for 5 minutes, leaving a cell suspension of 100 μL for intracellular staining. FITC-
labelled anti-human IFN-γ (clone 25723.11, BD Biosciences, NJ, USA) at a final 
concentration of 7.5 μg/ml as well as 20 μL of antibody cocktail containing PE-labelled 
anti-human IL-17 and Alexa Flour 647-labelled anti-FoxP3 antibodies were added to 
the appropriate samples. Isotype controls (Appendix 2) and appropriate single stains 
were included along side phenotyping samples. All samples were stained for 40 
minutes in the dark at RT. At the end of staining, cells were washed twice with 500 μL 
of FACS buffer and spun at 500 x g for 5 minutes and resuspended in 200 μL of FACS 
buffer for sample acquisition. 
8.2.9  Flow cytometry  
Samples were collected on the FACS Canto II using Diva software (BD Biosciences, NJ, 
USA). At least 40,000 CD4 positive gated events were collected to allow for a minimum 
of 20,000 viable CD4 T cells to be analysed per sample. Anti–mouse Ig, 
κ/compensation beads (BD Biosciences, NJ, USA) were acquired at the same time as 
samples for compensation during analysis. Data was analysed using FlowJo software 
(Tree star, Ashland, OR, USA). CD4 T cell subgroup populations were determined by 
the gating strategies as outlined in Figures 8-2 to 8-6 
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Figure 8-2 Identification of CD4 T cells 
CD4 T cells were identified by excluding debris based on the Forward (FSC) and Side Scatter 
(SSC) properties (A) and including only single cells (B). With stimulation (E & F), the expression 
of CD4 was down regulated and as the majority of cells were CD4 positive in culture (C) as 
checked after isolation, the high and low CD4 population was included for analysis of 
proliferation and CD4 T cell sub groups. 
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Figure 8-3 Identification of T helper (Th)1 cells 
T helper 1 (Th1) cells were identified by the expression of IFN-γ compared to the isotype control (A). An example of the Th1 population in unstimulated CD4 T 
cells (B), anti-CD3/CD28 stimulated CD4 T cells (B) and anti-CD3/CD28 stimulated CD4 T cells + platelets (D) are shown. 
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Figure 8-4 Identification of T helper (Th)17 cells 
T helper 17 (Th17) cells were identified by the expression of IL-17A compared to isotype control (A). An example of the Th17 population in unstimulated CD4 
T cells (B), anti-CD3/CD28 stimulated CD4 T cells (C) and anti-CD3/CD28 stimulated CD4 T cells plus platelets (D) are shown. 
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Figure 8-5 Identification of T regulatory (Treg) cells 
T regulatory (Treg) cells were identified by the expression of FoxP3 compared to isotype control (A). An example of the Treg population in unstimulated CD4 T 
cells (B), anti-CD3/CD28 stimulated CD4 T cells (C) and anti-CD3/CD28 stimulated CD4 T cells plus platelets (D) are shown. 
CHAPTER 8 
 
198 
8.2.10  Quantification of IFN-γ production by ELISA 
The production of IFN-γ in the cell culture of unstimulated CD4 T cells, anti-CD3/CD28 
stimulated CD4 T cells and stimulated CD4 T cells + platelets was detected using the 
Legend Max™ Human IFN-γ ELISA kit (Biolegend, CA, USA) following the 
manufacturers guidelines. Briefly, all reagents were brought to room temperature and 
the lyophilized Human IFN-γ standard was reconstituted in Assay buffer A to give a 20 
ng/ml standard stock solution. The standard was serially diluted from 1000 pg/ml, to 
15.6 pg/ml. The plate was washed and 50 μL of sample or standard were added to 
wells. Unstimulated samples were added undiluted and stimulated and stimulated + 
platelet samples were diluted 100 fold first and all samples were tested in duplicate. 
The plate was sealed and incubated at RT for 2 hours while shaking at 200 rpm. The 
plate was washed and incubated in the IFN-γ detection antibody solution 1 hour while 
shaking. Avidin-HRP solution was then added to each well after washing and incubated 
for 30 minutes. Substrate solution F was added and incubated for 15 minutes in the 
dark at RT. The reaction was then stopped and the absorbance was read at 570 nm 
and 450 nm on a Versamax Microplate Reader (Molecular Devices, CA, USA). The OD 
value at 570 nm was subtracted from 450 nm and the level of IFN-γ in samples was 
determined from the standard curve. 
8.2.11 Statistics 
Due to the cross over design of the study, analysis of a potential period effect and 
treatment-period interaction were performed before comparisons could be done 
between treatment groups. This analysis was performed following the method 
outlined by Altman (434). For each parameter to be tested, the difference (di) and the 
average (ai) for each subject was calculated and averaged in Group A and B. The period 
effect was tested by a two-sample t test to compare the difference between the 
periods in the two groups of participants. This test determines whether a group 
benefits more from receiving the drug first or second. To investigate the treatment-
period interaction, a two-sample t test comparing the average responses between 
group A and B was performed. This analysis determines whether there is any carry-
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over of treatment effect from one period to the next and the effectiveness of the wash 
out period. 
 
Based on the variance of IFN– γ in the literature, we calculated a cohort size of 10 
patients would give us 80% power to observe a significant reduction in IFN-γ levels 
following prasugrel of more than 33%. We decided on a group size of 12 to slightly 
overpower the study 
 
Continuous variables were expressed in mean ± SEM. Comparisons between 
stimulation treatments and drug treatments were performed using 1-way ANOVA 
with post-hoc Bonferroni testing of selected pairs. Statistical analysis and graphs were 
generated using GraphPad Prism 5 (GraphPad Software Inc., CA, USA). 
8.3 Results 
8.3.1 Period effect and treatment-period interaction analysis 
To assess how platelet interactions with T cells could shape T cell phenotype and 
subset differentiation, a double blind, placebo controlled, cross over trial was 
performed on 12 healthy volunteers with a median age of 31 (21 – 45). Due to the 
cross over trial design, there was a possibility of period effects or treatment-period 
interactions. However, we found no statistically significant period effect or treatment-
period interaction between group A and group B. For example, the difference in T 
helper 1 cells for the drug and placebo period are calculated for each individual in 
group A  (Table 8-1) and group B (Table 8-2). There was no difference between đ1 and 
đ2 (p=0.34) and therefore no period effect. There was also no significant difference 
between ā1 and ā2 (p=0.25), which indicates the wash out period was sufficient and 
there was no treatment-period interaction. This analysis was repeated for every 
parameter and no period effect or treatment-period interaction was found. Therefore 
comparisons between baseline and treatments and between the two different 
treatments could be undertaken without adjustment.  
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Table 8-1 Group A: Drug (prasugrel) followed by placebo n=6 
 Period 1 
Drug 
Period 2 
Placebo 
(1) – (2) (1) + (2)/2 
1 -499% -42% -4.57 -2.71 
 -72% 27% -0.99 -0.23 
 -92% -96% 0.04 -0.94 
 -104% 43% -1.47 -0.30 
 -29% 23% -0.51 -0.03 
 -44% 22% -0.66 -0.11 
Mean -140% -4% -136% (đ1) -72% (ā1) 
SD 178% 54% 165% 103% 
 
Table 8-2 Group B: Placebo followed by drug (prasugrel) n=6  
 
                                                        
1 Difference in T helper 1 cells for the drug and placebo period are calculated for 
each individual and are expressed as % change between baseline and 
measurement following drug treatment.  
 Period 1 
Placebo 
Period 2 
Drug 
(1) – (2) (1) + (2)/2 
 84% -87% 1.72 -0.01 
 -110% -155% 0.44 -1.32 
 -40% -45% 0.05 -0.42 
 -67% -114% 1.81 -0.23 
 -15% -113% 0.98 -0.64 
 -3% -115% 1.12 -0.59 
Mean -3% -105% 102% (đ2) -54% (ā2) 
SD 71% 36% 69% 45% 
CHAPTER 8 
 
 201 
8.3.2 Platelet function following placebo and prasugrel therapy 
To assess whether the treatments were having the desired impact on platelet 
function, platelet reactivity was measured with the Multiplate before and after each 
therapy (Figure 8-6). Treatment with placebo resulted in no change in platelet function 
between baseline and placebo treatment. However, following prasugrel therapy, all 
participants had a marked reduction in platelet reactivity (86.8 AU ± 7.7 AU vs. 27.3 
AU ± 5.2 AU, p < 0.0001). This finding confirms that prasugrel was having a significant 
and expected antiplatelet effect in the study participants. 
 
Figure 8-6 Marked reduction in platelet function following prasugrel therapy  
Platelet function (AU) as measured by Multiplate in whole blood, before and after placebo 
therapy (A) and prasugrel therapy (B). Each bar represents a participant’s response before and 
after each treatment n = 12. *** p < 0.0001 by paired Student’s t test. 
8.3.3 IFN–γ production and CD4 T cell differentiation at baseline 
To investigate the impact of platelets on CD4 T cell IFN–γ production and T cell 
differentiation, IFN–γ production and the Th1, Th17 or Treg phenotype was assessed 
on purified, anti-CD3/CD28 stimulated CD4 T cells (isolated at baseline) co-cultured 
with or without platelets. As expected, unstimulated cultures exhibited a low level of 
IFN–γ production and only a small proportion of CD4 T cells expressing the Th1, Th17 
or Treg phenotype (Figure 8-7). With the addition of anti-CD3/CD28 T cell stimulation 
there was a significant increase in all measured parameters. IFN-γ production 
significantly increased to an average production of 258 ng/ml ± 60 ng/ml from 
undetectable in unstimulated cultures (p < 0.01, Figure 8-7A). The proportion of CD4 
T cells positive for the Th1 phenotype (i.e. IFN-γ production) significantly increased to 
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7.8% ± 0.8% with stimulation of T cells compared to 0.5% ± 0.05% in unstimulated 
controls (p <0.001, Figure 8-7B). The proportion of CD4 T cells positive for the Th17 
phenotype (i.e. IL-17 production) significantly increased stimulation of T cells to 3.4% 
± 0.4% of CD4 T cells compared to 0.8% ± 0.2% in unstimulated (p <0.001, Figure 8-7C). 
The proportion of CD4 T cells positive for the Treg phenotype (i.e. FoxP3 expression) 
significantly increased with stimulation of T cells, accounting for 11.2% ± 1.3% of CD4 
T cells compared to 1.4% ± 0.4% in unstimulated cultures (p <0.01, Figure 8-7D).  
 
In co-cultures of anti-CD3/CD28 stimulated T cells and autologous platelets there was 
further increase in the IFN-γ production and Th1 and Th17 subgroups. Co-culture 
resulted in a significant enhancement of IFN-γ production with an average production 
of 454 ng/ml ± 78 ng/ml (p = 0.019, Figure 8-7A). The addition of platelets further 
enhanced the Th1 population at baseline to 10.8% ± 0.8% (p = 0.01, Figure 8-7B). 
Similarly, co-culture resulted in the increase of the Th17 population to 5.4% ± 0.7% (p 
= 0.01, Figure 8-7C). In contrast, the addition of platelets did not significantly alter the 
Treg subpopulation compared to stimulated alone (p = 0.07, Figure 8-7D). These 
results indicate that stimulation with anti-CD3/CD28 drives the production of IFN-γ 
and promotes the differentiation of Th1, Th17 and Treg phenotypes and that the 
presence of platelets further enhances IFN-γ as well as Th1 and Th17 differentiation.  
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Figure 8-7 The addition of platelets to anti-CD3/CD28 stimulated CD4 T cells 
enhances the production of IFN- and Th1 and Th17 differentiation.  
Isolated CD4 T cells at baseline were cultured without stimulation (U), with anti-CD3/CD28 
stimulation (S) and stimulation plus autologous platelets (S + P). IFN-γ production was 
measured in the supernatant of cultures with ELISA and the CD4 T cell subsets were measured 
by intracellular cytokine staining for IFN-γ (Th1), IL-17A (Th17) and FoxP3 (Treg) using flow 
cytometry. IFN-γ production is expressed in ng/ml (A) and the subsets are expressed as the 
proportion of CD4 T cells expressing the Th1 phenotype (B), Th17 phenotype (C) and Treg 
phenotype (D) in each culture condition. Data is displayed as mean ± SEM for every 
measurement. The data represents all 12 patients. One way ANOVA was performed for each 
parameter and was found to be significant (p < 0.05) allowing paired Student’s t tests to be 
performed (*p <0.05, ** p < 0.01).  
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8.3.4 The effect of prasugrel on IFN-γ production and CD4 T cell 
differentiation  
To determine if treatment with a placebo alone altered IFN-γ production and the CD4 
T cell subset differentiation from baseline measurements, these parameters were 
measured following placebo treatment in all participants and compared to the 
baseline values. No significant change was seen in IFN-γ production (Figure 8-8) or the 
CD4 T cell subset differentiation (see Appendix 3) compared to baseline. Additionally, 
there was no significant change for any of the parameters in unstimulated cultures 
from the prasugrel group compared to placebo or baseline. Therefore, given that 
baseline and placebo responses were the same and the unstimulated cultures were 
not affected by any treatment, the stimulated CD4 T cell responses following prasugrel 
treatment were directly compared to the placebo treatment to more specifically 
assess the effect of prasugrel treatment on platelet-T cell interactions.  
 
Figure 8-8 No difference in isolated CD4 T cell IFN-γ production following 
placebo therapy compared to baseline in all culture conditions 
Isolated CD4 T cells at baseline and after placebo therapy were cultured without stimulation 
(U), with anti-CD3/CD28 stimulation (S) and stimulation plus autologous platelets (S + P). IFN-
γ production was measured in the supernatant of cultures with ELISA and expressed in ng/ml. 
Data is displayed as mean ± SEM for every measurement. The data represents all 12 patients. 
One way ANOVA was performed for each parameter and was found to be significant (p < 0.05) 
allowing paired T tests to be performed of culture conditions. 
Focusing on this comparison, there were several significant changes in the co-culture 
effects following prasugrel treatment. The level of IFN-γ in stimulated T cell–platelet 
cultures was significantly lower at 89 ng/ml ± 17 ng/ml compared to co-culture 
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samples following placebo treatment (p <0.01, Figure 8-9A) and the stimulatory effect 
of platelets on T cells was abolished. This change was also evident in the Th1 subgroup 
with a significant decrease in the proportion of CD4 T cells that was Th1 positive 
compared to co-cultures in the placebo group (5.9% ± 0.8% vs 10.2% ± 1.1%, p < 0.01, 
Figure 8-9B). Furthermore, the Th17 response was not enhanced with the addition of 
platelets to stimulated T cell cultures following prasugrel therapy resulting in 
comparable levels to when T cells were stimulated alone (2.7% ± 0.4% vs. 2.7% ±0.2%, 
Figure 8-9C). As seen in the placebo group, the addition of platelets to stimulated T 
cells did not alter the proportion of Tregs following prasugrel therapy (Figure 8-9D). 
Taken together these findings suggest that following prasugrel treatment, the 
enhancement of the pro-inflammatory CD4 T cell phenotype by platelets following 
anti-CD3/CD28 stimulation is abolished.  
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Figure 8-9 Prasugrel therapy abolishes the enhancement of isolated CD4 T cell 
IFN-γ production and Th1 and Th17 differentiation by platelets 
Isolated CD4 T cells following placebo and prasugrel treatment were cultured with anti-
CD3/CD28 stimulation (S) and stimulation plus autologous platelets (S + P). IFN-γ production 
was measured in the supernatant of cultures with ELISA and the CD4 T cell subsets were 
measured by intracellular cytokine staining for IFN-γ (Th1), IL-17A (Th17) and FoxP3 (Treg) 
using flow cytometry. IFN-γ production is expressed in ng/ml (A) and the subsets are expressed 
as the proportion of CD4 T cells expressing the Th1 phenotype (B), Th17 phenotype (C) and 
Treg phenotype (D) in each culture condition. Data is displayed as mean ± SEM for every 
measurement. The data represents all 12 patients. One way ANOVA was performed for each 
parameter and was found to be significant (p < 0.05) allowing paired Student’s t tests to be 
performed (*p <0.05, ** p < 0.01).  
 
S S + P S S + P
0
100
200
300
400
500
600
700
800
IF
N
-g
 n
g
/m
L
**
*
Placebo Prasugrel
S S + P S S + P
0
1
2
3
4
5
6
%
 o
f 
C
D
4
 T
h
1
7
* **
Placebo Prasugrel
S S + P S S + P
0
2
4
6
8
10
12
Placebo Prasugrel
**
%
 o
f 
C
D
4
 T
h
1
S S + P S S + P
0
2
4
6
8
10
12
14
%
 o
f C
D
4
 T
re
g
Placebo Prasugrel
A B
C D
CHAPTER 8 
 
 207 
8.4 Discussion 
This study investigated the impact of platelet-T cell interactions on CD4 T cell IFN-γ 
production and Th subset differentiation. Stimulation of T cells with the known T cell 
stimulant, anti-CD3/CD28, induced a significant production of IFN-γ and an increase in 
Th1, Th17 and Treg subsets confirming that our experimental model was functional. 
The addition of platelets to stimulated T cells caused a further enhancement of IFN-γ 
production and greater proportion of Th1 and Th17 subsets. However, Tregs were less 
affected by platelet co-culture. The effect of inhibiting platelet activation in vivo with 
prasugrel on T cell responses was also determined and indicated that prasugrel 
treatment abolished the platelets’ ability to augment IFN-γ production and Th1 and 
Th17 differentiation.  
 
Platelet function testing confirmed prasugrel induced a marked inhibition in platelet 
activity in all subjects. However, prasugrel administration did not affect IFN-γ 
production or T cell differentiation in unstimulated or anti-CD3/CD28 stimulated T cell 
cultures in the absence of platelets. These two observations along with our findings 
from co-culture stimulations, suggest that platelets are potent regulators of CD4 T cell 
differentiation and cytokine production and that the impact of prasugrel on cytokine 
production and differentiation is due to the drug’s effects on platelet function. 
 
The addition of platelets to stimulated T cells resulted in a 340% increase in IFN-γ 
levels in the supernatant of cell cultures and a 40% increase in Th1 cell populations 
compared to stimulated alone. Th1 cells are the primary subset of CD4 T cells found 
in atherosclerotic lesions and secrete the pro-inflammatory cytokines, IFN-γ, IL-2 and 
TNF-α, which can activate other lesional cells to promote inflammation and augment 
lesion development (433). From various in vitro experimental settings, platelets and 
their derived mediators have shown to regulate Th1 differentiation and function. The 
platelet chemokines RANTES and MCP-1 have been demonstrated to enhance the 
production of IL-2, an important cytokine for T cell survival, from Th1 cells stimulated 
with anti-CD3/CD28, (424), and the neutralization of RANTES inhibited IL-2 and TNF-α 
production in CD4 T cell-platelet co-culture (434). Another platelet derived 
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chemokine, PF4 has demonstrated regulatory effects on CD4 T cells, although not 
always stimulatory depending on the environment. With cultured total T cells, PF4 
inhibited IL-2 and IFN-γ production in response to both antigenic and polyclonal 
stimulation (435). However, a recent study demonstrated PF4 enhanced Th1 
differentiation and cytokine production when CD4 T cells were cultured with 
autologous platelets, which the authors attributed to Th1 effector and memory cell 
stimulation (434).  
 
Other platelet-related inflammatory mediators, such as thromboxane A2, and platelet-
activating factor (PAF) also display Th1 cell-regulatory effects. Activated platelets 
produce a significant amount of TxA2, which inhibits Th1 proliferation and cytokine 
production (436). Activated T cells express PAF receptor (437), and PAF can enhance 
Th1 IFN-γ production of cultured T cells (437, 438). Finally, IL-1β a known potent 
promoter of Th1 differentiation from naïve CD4 T cells and this cytokine can be 
synthesized in platelets upon activation and deposited into fibrin nests of thrombi 
(439). Hence, a thrombus may serve as a reservoir of highly concentrated platelet-
derived cytokines and mediators that enhance platelet-dependent regulation of T cells 
in thrombi. Many of the studies have investigated Th1 differentiation and cytokine 
production with the addition of an isolated platelet derived mediator, but this study 
is the first to investigate the impact of platelets on Th1 differentiation and IFN-γ 
production ex vivo with the involvement of all platelet-derived mediators. Our findings 
suggest that overall platelets have a stimulatory effect on cytokine production and 
Th1 differentiation. 
 
Furthermore, this is the first study to ascertain the impact of inhibiting platelet-T cell 
interactions with a P2Y12 inhibitor in vivo, on T cell differentiation, cytokine 
production and proliferation. After prasugrel administration in participants, the 
addition of platelets to T cell cultures dramatically reduced the production of IFN-γ 
and Th1 differentiation to levels comparable to stimulated alone. Prasugrel eliminated 
the platelets’ stimulatory affects on Th1 cells. In animal models, it has been 
consistently demonstrated that the inhibition of Th1 cell differentiation or deficiency 
of Th1 cytokine receptors markedly reduces lesion formation (440, 441). As IFN-γ is an 
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important activator of monocytes and macrophages to become highly inflammatory, 
which are key inflammatory cells in atherosclerotic lesions, inhibiting this cytokine can 
reduce inflammation. Therefore, antiplatelet therapy may be providing therapeutic 
benefits by indirectly modulating Th1 activity and reducing pro-inflammatory cytokine 
production.  
 
Co-cultures of stimulated CD4 T cells and platelets also promoted a significant 
enhancement in Th17 differentiation. Th17 cells are a recently recognized CD4 T cell 
lineage in atherosclerotic lesions and previously have been acknowledged for their 
critical role in host defense and autoimmunity. Th17 cells secrete its signature 
cytokine IL-17, which acts on other cells to produce pro-inflammatory cytokines and 
chemokines and is the clear pro-inflammatory role of Th17 cells in autoimmune 
disease (444). The impact of Th17 cells in atherosclerosis however remains 
controversial. Patients with ACS have more circulating Th17 cells and higher plasma 
levels of IL-17, IL-6 and IL-23 (20) and mouse models of IL-17 deficiency show a 
reduction in atherosclerotic lesions (443). In contrast to these studies, which suggest 
the Th17 phenotype is pathogenic, other studies have found increased Th17 
differentiation and IL-17 in human atherosclerotic plaques are associated with a stable 
plaque phenotype (22).  
 
Despite this controversy, several platelet-derived mediators are thought to regulate 
Th17 differentiation and cytokine production. Platelets have abundant stores of TGFβ, 
which is released and acts with IL-6 and IL-21 to promote Th17 differentiation. TGFβ 
promotes Th17 differentiation in the presence of IL-6 whereas TGFβ alone drives Treg 
differentiation (425). As already mentioned, platelets can synthesise IL-1β and the 
release of this causes Th17 polarisation through inducing RORγt expression, a key 
transcription factor in Th17 differentiation (444). This cytokine is also critical in 
maintaining the steady status of Th17 cells and IL-6 acts to enhance IL-1β activity 
(444). Moreover, platelet activation leads to PAF synthesis and release, which can 
promote Th17 differentiation and cytokine production (445).  
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Prasugrel administration abolished the enhancement of Th17 differentiation by 
platelets in co-culture with T cells and produced similar Th17 levels to stimulated 
alone. Our results would suggest that platelets have a potent affect on Th17 
differentiation and antiplatelet treatment can inhibit this stimulus. However, it is 
unknown what affect and to what extent this inhibition would impact on 
atherosclerosis as the role of Th17 cells in atherogenesis remains controversial. 
 
CD4 T regulatory (Treg) cells are key anti-inflammatory cells in the immune system 
and operate to govern immunological tolerance and the terminate immune 
responses. With anti-CD3/CD28 stimulation, a significant increase in Treg 
differentiation was achieved at all time points. However, the addition of platelets did 
not significantly enhance the Treg response compared to stimulated alone. Other 
studies have found platelets can have a marked effect on Treg differentiation via 
platelets abundant stores of TGFβ (434). TGFβ is essential for Treg differentiation and 
high local concentrations selectively promote this CD4 phenotype (425). However, 
neutralization of this growth factor did not prevent platelet-enhanced Treg 
differentiation, indicating there are other platelet-derived factors that may be 
impacting on Treg differentiation. Platelet factor 4 (PF4) and IL-1β have both been 
indicated in in vitro models to enhance anti-CD3/CD28-stimulated Treg differentiation 
(446). However, the influence of these mediators on Treg development can be 
augmented by the presence of IL-2 and by the level of TGFβ, indicating the regulation 
of Treg in vivo is likely complex. In our present study, the net impact of platelets on 
Treg differentiation appears to be small and variable between healthy individuals. 
 
Not surprisingly, platelet inhibition with prasugrel did not reduce Treg differentiation 
significantly. The presence of Treg at atherosclerotic lesions can act to suppress 
immune responses in vulnerable plaques. Many strategies have been investigated to 
increase Treg activity in atherosclerosis with little success. Potentially the inhibition of 
platelets through the P2Y12 pathway can impact on Th1 and Th17 cells without 
altering Treg differentiation significantly, although further investigation would be 
needed to confirm this.  
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Overall, as this study has demonstrated, platelets are not solely anucleate aggregating 
bodies driving thrombosis but can also communicate with cells including CD4 T cells 
to influence differentiation and cytokine production. While this study has primarily 
considered the role of platelet-T cell interactions in atherosclerosis, our findings have 
implications that extend beyond atherosclerosis and which may suggest a role for 
platelet-lymphocyte interactions in other diseases such as but not limited to; sepsis, 
rheumatoid arthritis, cancer, asthma and cystic fibrosis to (75, 449). Thus the novel 
finding that prasugrel can abolish the ability of the platelet to augment CD4 T cell 
stimulation highlights the potential use of antiplatelet therapy in other inflammatory 
conditions.  
8.5 Limitations 
One of the limitations of this study was the size of the study population and therefore 
the statistical power to detect subtle changes in the various parameters. As originally 
anticipated, with 12 participants we had the power to detect a >30% reduction in IFN-
γ levels following prasugrel therapy compared to placebo. However, with higher 
numbers of participants, we would have had the power to detect more subtle 
changes, such as the change in Treg differentiation and the interesting decrease in 
IFN-γ levels in stimulated samples following prasugrel treatment. Nevertheless, with 
12 participants we were able to detect significant and interesting effects of platelets 
on IFN-γ production and Th1 and Th17 subsets.  
 
Additionally, we looked at a limited number of CD4 T cell subsets and markers of cell 
function. It would have been interesting to look at Th2 subsets and other important 
populations of T cell such as natural killer T cells (i.e. NKT). However, from the 
literature it has been shown that Th1, Th17 and Treg subsets have a significant 
influence in atherosclerosis and therefore the impact of platelets on these cells was 
more likely to offer the most relevant results for this thesis. Finally, IFN-γ was the only 
cytokine to be quantified in culture supernatants due to the cost of ELISA kits, but in 
the future, it would be vaulable to measure other cytokines, both inflammatory and 
regulatory, to provide a fuller picture of the effect of platelets on CD4 T cell effector 
functions.  
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8.6 Conclusion  
Our findings suggest that platelets are potent regulators of CD4 T cell differentiation 
and IFN-γ production. The addition of platelets to stimulated T cells enhanced the 
production of IFN-γ and the differentiation of Th1 and Th17 subsets compared to 
single cultures of anti-CD3/CD28 stimulated T cells in healthy individuals. The 
administration of prasugrel abolished the platelets ability to boost Th1 and Th17 
differentiation and the production of IFN-γ suggesting that antiplatelet therapy may 
provide therapeutic benefits through the inhibition of the platelets’ thrombotic ability 
and an indirect modulation of the immune response.  
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9 Chapter 9 – Summary and future 
directions 
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9.1 Summary 
In this thesis, the first aim of investigation was to understand the reproducibility and 
methodological factors that influenced the Multiplate’s measurement of residual 
platelet reactivity. The Multiplate system had a moderate CV at 10-11% and the pre-
analytical factors of time delay to testing and anticoagulant blood tubes, affect the 
assessment of platelet aggregation and need to be standardised for all measurements. 
Using the Multiplate to measure residual platelet reactivity in a NZ ACS population 
treated with aspirin and clopidogrel, the study found HOTPR was common and 
occurred more frequently in Maori and Pacific Islanders. Patients with diabetes or 
receiving low clopidogrel doses also had higher rates of HOTPR. The use of prasugrel 
in patients with HOTPR resulted in a marked reduction in residual platelet reactivity 
for all patients. 
 
Further investigation of the relationship between genetic and clinical factors with 
residual platelet reactivity was conducted to identify independent predictors of this 
phenotype. This study revealed that diabetes, low clopidogrel dose and high platelet 
count were all strong independent predictors of high residual platelet reactivity. 
Genetic variation in the CYP2C19 gene only moderately contributed to the observed 
variation in the clopidogrel response. In this study there were no clinical or genetic 
factors that were driving a low residual platelet reactivity response to clopidogrel.  
 
In addition to understanding the drivers of the on treatment phenotype, the 
relationship between phenotype, genotype and predictors of phenotype with MACE 
and bleeding events were also examined following an ACS. It was demonstrated that 
both phenotype and diabetes were independent predictors of MACE and genotype 
was not a significant driver of risk. Bleeding was low in the cohort and was not 
predicted by phenotype, genotype or clinical factors. 
  
Another population at high risk of thrombotic complications are patients undergoing 
major vascular surgery. The aim was to investigate whether biomarkers including 
platelet reactivity and other established cardiac risk markers had utility at predicting 
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thrombotic and bleeding outcomes in this population. Baseline elevated hs-TnT was 
the most predictive biomarker and was significantly associated with an increased risk 
of ischaemia following surgery. Residual platelet reactivity did not predict ischaemia 
or bleeding in this population.  
 
The interactions of platelets with T lymphocytes in patients with atherosclerotic 
disease and healthy volunteers were also investigated. The first exploratory study 
revealed a higher level of platelet-T cell conjugates in vascular patients compared to 
healthy controls. An interesting observation was found in the CD4 T cell population 
with a switch in the activation phenotype to predominantly an effector phenotype in 
vascular patients, which were not observed in healthy controls. Further examination 
of platelet interactions with CD4 T cells in healthy volunteers; suggest platelets are 
potent regulators of the CD4 T cell differentiation and cytokine production and this 
stimulation can be abolished with the administration of prasugrel. 
 
9.2 Limitations 
Across the thesis there have been certain limitations that may have influenced our 
findings. A large majority of the studies were observational in nature. Although we 
wanted to look at residual platelet reactivity and biomarkers in a real world setting so 
our results had wider clinical applicability, this limited our ability to control for 
differences in medication and patient management, which may have introduced 
unknown variance. We were limited to one measure of platelet function using only 
the Multiplate assay and the use of another assay such as VerifyNow may have 
allowed for interesting comparisons in the ability for an assay to identify patients at 
risk of MACE. However, the VerifyNow has a high test cost of $70/ patient and the 
addition of this test in all patients was not feasible. As discussed in chapter 2, we felt 
the low consumable cost and moderate coefficient of variance achieved with the 
Multiplate was the best option to measure residual platelet reactivity. Finally, our 
study populations were of a moderate size and in some instances, reduced our power 
to investigate relationships between clinical factors, platelet reactivity and outcome. 
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However, with the time constraints of the thesis and factoring in the time for follow 
up for two of our cohorts, recruiting larger patient cohorts were not possible.  
 
9.3 Clinical implications and future directions 
The findings from this thesis have several clinical implications and raise further 
avenues of investigation. Some of the observations in our studies may further explain 
the failure of clinical trials to demonstrate a benefit from personalised antiplatelet 
therapy based on platelet function testing. As we have shown in this study, the 
method used to measure residual platelet reactivity needs to be standardised to 
reduce variance in the test. Reported platelet function trials have primarily used the 
VerifyNow assay to tailor therapy and a protocol of 10 minutes to 4 hours time delay 
from blood sampling to measurement is recommended (454). Although we have not 
specifically tested the effect of time delay on the VerifyNow assay, our results suggest 
that time has a significant impact on the precision of an assay and this added variance 
may have reduced the ability to discern which patients would benefit from tailored 
therapy from a single cut point. 
 
There is sufficient evidence from multiple studies including ours, that high residual 
platelet reactivity is a powerful independent predictor of MACE in ACS patients. With 
the increasing use of new potent P2Y12 inhibitors and the availability of generic 
clopidogrel, it will be left to the decision of the attending physician which drug to 
choose for the individual patient by balancing the risk of thrombotic and bleeding 
events. The potential clinical benefit and cost difference from personalised therapy 
suggest further evaluation of platelet reactivity testing is attractive. However, our 
study highlighted that platelet reactivity alone does not predict a patient’s thrombotic 
risk. We also identified diabetes as a significant predictor of MACE, and it is likely that 
other clinical factors will also influence risk. With a combined risk factor strategy 
including platelet function testing and clinical factors, the ability to identify patients 
at high risk of thrombotic events may be improved beyond a single biomarker 
strategy. Using a risk model such as this to personalise antiplatelet therapy has not 
been investigated and larger outcome studies in ACS patients are needed to ascertain 
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the key clinical factors that predict risk and whether such a strategy would improve 
patient outcomes. 
 
Our study also supports the notion that the loss of function CYP2C19*2 allele is only 
having a minor impact on an individual’s response to clopidogrel (228, 309). 
Moreover, the LOF allele was not predictive of MACE at 1 year in ACS patients, which 
has been the centre of much debate in the literature (228, 455-457). We hypothesised 
that the variability in platelet reactivity due to the acute inflammation and oxidative 
stress following an ACS may be overshadowing the impact of the LOF allele on residual 
platelet reactivity and measuring the phenotype at a different time point would result 
in a stronger relationship. However, as genotype is a constant entity and the LOF 
genotype was not found to be a significant predictor of MACE at 1 year, even if the 
relationship between HOTPR and CYP2C19*2 was significant at another time point, 
knowing the genotype of an individual would not aid in risk stratifying a patient. The 
use of new generation P2Y12 inhibitors may also make the role of bedside genotyping 
in ACS patients redundant. Ticagrelor is an active drug and does not require hepatic 
bioactiviation (213). Although the metabolism of prasugrel is via various CYP 
isoenzymes, the common genetic variants in the CYP2C19 gene do not affect 
formation of the active metabolite, inhibition of platelet aggregation, or the clinical 
outcome of prasugrel-treated patients (458). Therefore, genotyping may offer little 
prognostic information to help clinicians tailor clopidogrel or new antiplatelet 
therapies to high risk individuals.   
 
In contrast to the ACS population, our study investigating the use of biomarkers to 
predict risk in patients undergoing major vascular surgery did not find a significant 
relationship between residual platelet reactivity and outcome. As discussed, this may 
be due to the stable diseased population that we measured the biomarker in. In CAD 
patients, platelet function testing is more predictive in patients at a higher risk of stent 
thrombosis and other thrombotic complications (455) which mainly includes the ACS 
population undergoing PCI. Our study suggests that platelet function testing does not 
provide any additional information regarding risk in a stable vascular population. 
Whether, platelet function testing may be of value in a higher risk acute vascular 
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population is unknown. Patients with critical limb ischaemia undergoing femoral 
bypass surgery and endovascular procedures are at high risks of graft occlusion and 
limb amputation (122). The risk of limb amputation and death, also increases 
significantly with every revascularisation procedure (123). Furthermore, studies have 
demonstrated patients with active limb ischaemia have the highest levels of platelet 
and monocyte activation before and during surgery compared to those with 
intermittent claudication (460). High residual platelet reactivity in this population may 
be more predictive of thrombotic complications and could be used to identify patients 
who would benefit from more aggressive antiplatelet therapy and prevent further 
graft complications. 
 
A biomarker that was found to be a significant predictor of ischaemia in the vascular 
population was an elevated baseline hs-TnT. This is the first study to demonstrate that 
preoperative measurements of hs-TnT can predict risk in vascular patients. Many 
studies have found both troponin elevations perioperatively and peak troponin levels 
post-surgery significantly correlate with an increased risk of mortality following major 
noncardiac surgery (461, 462). However, the clinical utility of measuring this 
biomarker during surgery is limited to only informing post-operative management. 
Having a pre-operative biomarker that predicts both short and long-term risk allows 
clinicians to alter several aspects of patient management to reduce risk. Before 
surgery, having this information may allow clinicians to carry out further cardiac 
investigations to optimise medical therapy or change a clinician’s strategy regarding 
surgery and the risk-benefit balance. This information is also valuable for 
perioperative management as surgical teams can control blood pressure within a 
stricter range, have blood products available and more aggressive fluid management 
in patients who are at an increased risk of ischaemia. Whether this approach results 
in the reduction of ischaemia is unknown and warrants further investigation. 
 
We also demonstrated that platelets have a significant influence on CD4 T cells and 
this stimulation can be eliminated with prasugrel administration. This stimulatory 
communication between platelets and T cells may be one of the mechanisms driving 
risk in patients with HOTPR, resulting in more inflammation and plaque instability. To 
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investigate this hypothesis we would first need to look at platelet-CD4 T cell 
interactions in patients with atherosclerotic disease to see if platelets are having the 
same effect on the CD4 subsets. It would also be interesting to identify how the 
activation phenotype of isolated CD4 T cells from patients with atherosclerotic disease 
effected cytokine production and proliferation compared to healthy volunteers. As we 
demonstrated in chapter 7, the activation phenotype of CD4 T cells switched from a 
predominantly memory phenotype in healthy individuals to an effector response in 
patients with vascular disease. Our finding that platelets enhanced CD4 T cell 
differentiation and cytokine production but had little impact on proliferation, may 
suggest platelets are more prone to enhance CD4 T effector-cell responses. Effector 
cells are primed to make cytokines (463) and platelet interactions in vascular patients 
may result in even higher levels of cytokine production and CD4 T cell differentiation 
contributing to the pro-inflammatory environment. The administration of prasugrel in 
these patients could provide powerful anti-inflammatory actions, which could benefit 
a patient’s long-term outcome and is an important focus of future studies.   
 
We focused our investigation on the interactions between CD4 T cells and platelets. 
However, it would also be important to understand what effects platelets were having 
on the activation and function of other T cells including CD8 and NK T cells and B cells 
in both healthy volunteers and patients with atherosclerosis.  
 
The clinical implications of our study on platelet-CD4 T cell interactions not only relate 
to atherosclerosis and high on treatment platelet reactivity but may also have 
important implications in other disease states. Platelets are thought to promote 
neutrophil and lymphocyte recruitment and cause tissue damage in diseases such as 
asthma, cystic fibrosis, inflammatory bowel disease, glomerulonephritis and arthritis, 
from studies conducted in animal and human in vitro models (449). But little is known 
about how platelets influence lymphocyte function in these diseases from human 
models and if antiplatelet therapy could provide immunomodulatory benefits. Studies 
looking at the role of platelets in cancer have primarily focused at their ability to cause 
thrombotic complications and the release of growth factors supporting tumour 
growth, angiogenesis and metastasis (464). The dysfunction of the immune system 
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and the imbalance between cytotoxic T-cell and regulatory T cell responses can allow 
cancer tumours to grow unchecked. Platelets may have important effects on T cell 
responses in cancer and warrant investigation.  
 
Platelets play a key role in sepsis pathophysiology and are one of the drivers of 
multiple organ failure during systemic infection and inflammation (461).  There is 
substantial evidence that platelets create a pro-coagulant environment in sepsis and 
aid in the recruitment of leukocytes. However, their direct influence on the activation 
and phenotype of leukocytes, including T cells have not been investigated (462). There 
is considerable interest around the use of antiplatelet therapy in sepsis to reduce 
multiple organ failure. Retrospective studies have investigated the impact of 
antiplatelet agents on outcomes following critical systemic infections in populations 
receiving antiplatelet therapy for other indications. These studies have found a trend 
to shorter ICU stays following infection, reduced rates of acute lung injury and in some 
cases, reduced mortality in patients receiving antiplatelet therapy (462). Antiplatelet 
therapy is undoubtedly lowering the thrombotic ability of platelets and reducing their 
propensity to cause pro-coagulant environments in sepsis. Another potential benefit 
of antiplatelet therapy in sepsis, which merits further investigation, may come from 
inhibiting platelet’s communication with immune cells and reducing the pro-
inflammatory environment.  
 
Platelets may have important roles in a number of other diseases not mentioned here. 
Their high frequency, ability to bind and communicate with an array of cells and 
abundant stores of cytokines, chemokines and growth factors mean platelets are 
positioned to significantly influence the immune system in a wide range of diseases. 
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11.1 Appendix 1 – Buffers and Solutions 
PBS 
NaCl      145 mM 
Na2HPO4     8.7 mM 
NaH2PO4     1.3 mM 
In ddH2O, autoclaved strilised 
 
FACS buffer (v/v) 
Fetal Calf Serum (FCS)    2% 
Sodium azide     0.1% 
PBS      97.9% 
 
Complete T cell media (CTCM) (v/v) 
Dulbecco’s Modified Eagle Medium  85.9% 
FCS      10% 
L-glutamate (200 mM)   1% 
Penicillin/Streptomycin   1% (100 U/ml/10 mg/ml) 
HEPES buffer (1 M)    1% 
Β-Mecaptoethanol    0.1% 
Non-essential amino acids (10nM)  0.1% 
 
Filter sterilized using 0.22μm syringe filter. 
 
Isolation Buffer (IB) (v/v) 
PBS      97.8% 
FCS      2% 
EDTA (0.5M)     0.2% 
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11.2 Appendix 2 – Antibody information 
Cell Surface 
Markers 
Flurophore Clone Isotype  Manufacturer 
CD3 FITC HIT3a Mouse IgG2a Biolegend 
CD8 PE 
PECy7 
HIT8a 
RPA-T8 
Mouse IgG1 
Mouse IgG1 
Biolegend 
BD Bioscience 
CD42a PerCP Beb-1 Mouse IgG1 BD Bioscience 
CD4 PECy7 OKT4 Mouse IgG2a Biolegend 
CD25 APC BC96 Mouse IgG1 Biolegend 
CD44 PE BJ18 Mouse IgG1 Biolegend 
CD62L APC DREG-56 Mouse IgG1 Biolegend 
CD56 PE HCD56 Mouse IgG1 Biolegend 
Isotype control FITC MOPC-173 Mouse IgG2a Biolegend 
PE MOPC-21 Mouse IgG1 Biolegend 
PerCP MOPC-21 Mouse IgG1 BD Bioscience 
PECy7 MPC-11 Mouse IgG2b Biolegend 
APC MOPC-21 Mouse IgG1 Biolegend 
Intracellular 
marker 
Flurophore Clone Isotype  Manufacturer 
IFNγ FITC 25723.11 Mouse IgG2a BD Bioscience 
IL-17A PE N49-653 Mouse IgG1 BD Bioscience 
FoxP3 Alexa Fluor 647 259D/C7 Mouse IgG1 BD Bioscience 
Isotype control FITC MOPC-173 Mouse IgG2a Biolegend 
PE MOPC-21 Mouse IgG1 BD Bioscience 
Alexa Fluor 647 MOPC-21 Mouse IgG1 BD Bioscience 
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11.3 Appendix 3 – Supplementary graphs for chapter 8 
 
 
 
Figure 11-1 No difference in isolated CD4 T cell differentiation following 
placebo therapy compared to baseline in all culture conditions 
Isolated CD4 T cells at baseline and after placebo therapy were cultured without stimulation 
(U), with anti-CD3/CD28 stimulation (S) and stimulation plus autologous platelets (S + P). CD4 
T cell subsets were measured by intracellular cytokine staining for IFN-γ (Th1), IL-17A (Th17) 
and FoxP3 (Treg) using flow cytometry. Data is displayed as mean ± SEM for the proportion of 
Th1 (A), Th17 (B) and Treg subsets (C). The data represents all 12 patients. Paired T tests of 
culture conditions were found to be not significant.  
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